Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.7 - plasmin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
[Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
Abortion, Spontaneous
Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.
Abscess
Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems.
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Stimulation of plasmin activity in cultured human fibroblast cells by Porphyromonas endodontalis.
The treatment of acute abscesses with human plasmin (fibrinolysin).
Acantholysis
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis.
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Plasmin induces acantholysis in skin organ cultures.
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
Acidosis
Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by ph and metals.
Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Acquired Immunodeficiency Syndrome
Dysregulated proteolysis in AIDS.
Enolase of Mycobacterium tuberculosis is a surface exposed plasminogen binding protein.
Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
Atherosclerosis in women with endometriosis.
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis.
Haemocoagulative modifications correlated with pregnancy.
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis.
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis.
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome.
Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial.
Prothrombotic disorders in children with moyamoya syndrome.
Prothrombotic disorders in infants and children with cerebral thromboembolism.
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis.
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
[Primary thrombophilia in México. VI: lack of statistical association among the inherited thrombophilic conditions]
[Screening methods in genetic diagnosis of hereditary protein C deficiency]
[Type I protein C deficiency caused by a novel protein C gene mutation]
Acute Coronary Syndrome
Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease.
Inflammation, the endothelium, and the acute coronary syndromes.
Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxin-alpha genes and acute coronary syndrome in Czech Caucasians.
Relationship between myocardial injury and soluble P-selectin in non-ST elevation acute coronary syndromes.
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Acute Kidney Injury
Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure.
The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome.
[Fibrinolysin (uroplasmin) therapy of initial manifestations of acute renal insufficiency transfusion]
Acute Lung Injury
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Acute-On-Chronic Liver Failure
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
adamts13 endopeptidase deficiency
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Adenocarcinoma
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Appearance of plasminogen activator activity during a synchronous cycle of a rat adenocarcinoma cell line, PA-III.
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Identification of the plasminogen activator(s) produced by the transformed liver cell line, SK-HEP-1.
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Localization of plasminogen activator(s) in primary and secondary rat adenocarcinoma cells.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activators and inhibitors in ovarian adenocarcinomas.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1.
Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells.
Proteases in human tumors.
Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells.
Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells.
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head.
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma.
Adenocarcinoma of Lung
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells.
Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours.
Adenocarcinoma, Follicular
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Adenoma
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Role of urokinase in colorectal neoplasia.
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
[Blood coagulation disorder in islet cell adenoma]
[Protease activities in gastric and colon cancer tissues]
Adenoma, Islet Cell
[Blood coagulation disorder in islet cell adenoma]
Adenoma, Villous
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
Adenomatous Polyposis Coli
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Adenomatous Polyps
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in human colorectal neoplasia.
Afibrinogenemia
Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Plasminogen interacts with human platelets through two distinct mechanisms.
[Plasmin and congenital afibrinogenemia]
Agammaglobulinemia
Intravenous administration of plasmin treated immunoglobulins in 10 patients with agammaglobulinemia.
Aggressive Periodontitis
A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis.
Periodontitis associated with plasminogen deficiency: a case report.
AIDS-Associated Nephropathy
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Airway Obstruction
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene.
Albinism, Ocular
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Albuminuria
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
[Urinary excretion of extracellular matrix proteins in insulin dependent diabetes mellitus]
Alopecia
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Alopecia Areata
The role of plasminogen activators in alopecia areata.
Alveolar Bone Loss
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Ligneous periodontitis and Ehlers-Danlos syndrome.
Alzheimer Disease
Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.
Activators and inhibitors of the plasminogen system in Alzheimer's disease.
Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications.
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors.
Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid.
Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2.
Association studies between the plasmin genes and late-onset Alzheimer's disease.
Beta-amyloidolysis and glutathione in Alzheimer's disease.
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.
Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
Plasmin deficiency in Alzheimer's disease brains: causal or casual?
Plasmin system of Alzheimer's disease patients: CSF analysis.
Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.
Plasminogen and plasmin in Alzheimer's disease.
Proteolysis in Alzheimer's disease. Can plasmin tip the balance?
Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains.
Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease.
The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system.
The plasminogen activating system in the pathogenesis of Alzheimer's disease.
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Ameloblastoma
Fibrinolytic activity in cystic lesions of jaw bones.
Amyloidosis
Amyloidosis associated bleeding diatheses in the surgical patient.
Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis.
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]
[The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Anaphylaxis
Anaphylactic shock in dogs. Role of fibrinolysin and vasoactive polypeptide systems.
Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock.
Fibrinolysis and anaphylaxis. I. Activation of blood fibrinolysin during anaphylactic shock in guinea pigs.
Study of fibrinogen and plasminogen concentrations in rabbits during anaphylactic shock.
Anemia
Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture.
Lonomia genus caterpillar toxins: biochemical aspects.
Anemia, Sickle Cell
Coagulopathies and arterial stroke.
Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture.
Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms.
Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall.
Clearance of plasmin-PN-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta.
Elastase-induced experimental aneurysms in rats.
Fibrinolytic activity of human brain.
Genes predisposing to rapid aneurysm growth.
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Molecular analysis of blood vessel formation and disease.
Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans.
Plasmin and matrix metalloproteinases in vascular remodeling.
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
Role of matrix metalloproteinases (MMPs) and MMP inhibitors on intracranial aneurysms: a review article.
Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.
Thrombus versus Wall Biological Activities in Experimental Aortic Aneurysms.
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.
Vascular aneurysms: a perspective.
Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Vascular extracellular matrix remodeling in cerebral aneurysms.
Aneurysm, Dissecting
Thrombolytic therapy and acute aortic dissection.
Angina Pectoris
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis.
[Newly developed stenocardia: effect of intensive physical training on the indicators of the blood coagulation system and fibrinolysis]
Angina, Stable
Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.
Angina, Unstable
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction.
Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina.
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators.
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.
[Unstable angina: tissue plasminogen activator, tissue plasminogen activator inhibitors, protein C and other factors of the blood fibrinolytic system]
Angioedema
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angioedema in Stroke Patients With Thrombolysis.
Assessing Plasmin Generation in Health and Disease.
Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.
Pathophysiology and underlying mechanisms in hereditary angioedema.
Plasminflammation-An Emerging Pathway to Bradykinin Production.
Protease inhibitors in the treatment of hereditary angioedema.
The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis.
Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation.
Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant.
Angioedemas, Hereditary
A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor.
A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan.
Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.
Angioedema without urticaria: novel findings which must be measured in clinical setting.
Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation.
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Definition and classification of hereditary angioedema.
Generation of plasmin during acute attacks of hereditary angioedema.
Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes.
Hereditary angioedema with a mutation in the plasminogen gene.
Hereditary angioedema.
Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema.
Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.
On the pathogenicity of the plasminogen K330E mutation for hereditary angioedema.
Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
Plasminogen activation in hereditary angioneurotic edema.
Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families.
Proteomic Analysis of the Acid-Insoluble Fraction of Whole Saliva from Patients Affected by Different Forms of Non-histaminergic Angioedema.
Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma.
Screening for Plasminogen Mutations in Hereditary Angioedema Patients.
sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor.
Specific functional and immunologic assay of plasma plasminogen in hereditary angioedema, in hereditary angioedema treated with tranexamic acid, and in normal subjects.
Study of angiopoietin and plasminogen genes in hereditary angioedema.
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene.
Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
Anovulation
Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Anthracosilicosis
[Effect of fibrinolysin and heparin on the formation of fibrosis in experimental anthracosilicosis]
Anthrax
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Antiphospholipid Syndrome
Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.
Coagulopathies and arterial stroke.
Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin.
Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice.
Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients.
Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship.
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen.
The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen.
[Diagnosis and treatment of coagulation disorders]
[Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
[The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome].
Antithrombin III Deficiency
Coagulopathies and arterial stroke.
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria.
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
[Molecular basis of thrombosis]
Aortic Aneurysm
Doxycycline treatment in a model of early abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Activators of plasminogen and the progression of small abdominal aortic aneurysms.
Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm.
Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping.
Increased PAI-1 in Females Compared to Males is Protective for Abdominal Aortic Aneurysm Formation in a Rodent Model.
Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes.
Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms.
Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm.
Aortic Diseases
Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease.
Aortic Valve Stenosis
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves.
[A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement]
Arrhythmias, Cardiac
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Arterial Occlusive Diseases
[Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs]
Arteriosclerosis
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta.
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds.
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
Treatment of experimental pulmonary arteriosclerosis with cortisone, heparin and fibrinolysin.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
[Effect of fibrinolysin on the development of experimental cholesterol arteriosclerosis in rabbits]
[Lipoprotein (a)--a further risk factor in arteriosclerosis?]
[Lypolytic activity of aorta and liver under the effect of fibrinolysin in rabbits with experimental cholesterol arteriosclerosis]
[Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.]
Arteriosclerosis Obliterans
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans.
Arteriovenous Fistula
Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients.
[The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis]
Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Arthritis
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.
Fibrin dissolution in synovial fluid.
Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis.
Mini-plasminogen-like fragments of plasminogen in synovial fluid in acute inflammatory arthritis.
Novel aspects and new roles for the serine protease plasmin.
Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Plasminogen activator/plasmin system in arthritis and inflammation: friend or foe?
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis.
Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.
Role of plasminogen activator inhibitor - 1 (PAI-1) in regulating the pathogenesis of S. aureus arthritis via plasminogen pathway.
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation.
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
[Experimental plasmin arthritis]
Arthritis, Experimental
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
Arthritis, Infectious
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis.
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Arthritis, Juvenile
[Disorders of the system of hemostasis in patients with juvenile rheumatoid arthritis and rheumatic fever]
Arthritis, Rheumatoid
Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis.
Are plasminogen antibodies in rheumatoid arthritis of pathogenic significance?
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis.
Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis.
Lack of effect of tranexamic acid on rheumatoid arthritis.
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study.
Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts.
Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.
Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.
Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Regulation of plasminogen receptors.
Serum antiplasmin and plasmin in rheumatoid arthritis.
Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis.
The primary plasmin inhibitor in rheumatoid synovial fluid.
The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis.
[Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)]
[Experimental plasmin arthritis]
Arthus Reaction
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Aspergillosis
Plasminogen alleles influence susceptibility to invasive aspergillosis.
Asthma
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Cyclic adenosine monophosphate induces plasminogen activator inhibitor-1 expression in human mast cells.
Genetic susceptibility to severe asthma with fungal sensitization.
PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model.
Plasmin system regulation in an ovalbumin-induced rat model of asthma.
Plasminogen Activation by Airway Smooth Muscle is Regulated by Type I Collagen.
Plasminogen is an important regulator in the pathogenesis of a murine model of asthma.
Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
The plasminogen activation system: new targets in lung inflammation and remodeling.
Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study.
Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.
[Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma]
Astrocytoma
Cytokines regulate plasminogen activation system in astrocytoma cells.
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.
Atherosclerosis
A basic study on theglobal coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients.2. Plasminogen activator, plasminogen, a2-macroglobulin in atherosclerosis and endogenous hypertriglyceridaemia.
A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis.
A new hypothesis: possible mechanisms in the involvement of the increased plasminogen activator activity in branching regions of the aorta in the initiation of atherosclerosis.
A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
A role of plasminogen in atherosclerosis and restenosis models in mice.
Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency.
Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton.
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Assembly of plasmin-generating proteins on the surface of human endothelial cells.
Atherogenesis and fibrinogen: historical perspective and current status.
Atherogenesis and vascular calcification in mice expressing the human LPA gene.
Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Changes in arterial expression of fibrinolytic system proteins in atherogenesis.
Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease.
Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques.
Current understanding of pathogenesis of coronary artery disease and its future implications.
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Effects of lipids on thrombotic mechanisms in atherosclerosis.
Endothelial cell fibrinolytic assembly.
Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.
Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis.
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis.
Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.
Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway.
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties.
Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes.
Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial.
Level of Macrophage uPA Expression Is an Important Determinant of Atherosclerotic Lesion Growth in Apoe-/- Mice.
Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
Lipoprotein(a) and coronary heart disease risk.
Lipoprotein(a) and ischemic heart disease-A causal association? A review.
Lipoprotein(a) as a cardiovascular risk factor: current status.
Lipoprotein(a) as a risk factor for coronary artery disease.
Lipoprotein(a), atherosclerosis and thrombosis.
Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism.
Lipoprotein(a), plasmin modulation, and atherogenesis.
Lipoprotein(a): an emerging cardiovascular risk factor.
Lipoprotein(a): Current Perspectives.
Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.
Molecular analysis of blood vessel formation and disease.
Novel aspects and new roles for the serine protease plasmin.
Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression.
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis.
Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?
Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells.
Plasmin and matrix metalloproteinases in vascular remodeling.
Plasmin induces intercellular adhesion molecule 1 expression in human endothelial cells via nuclear factor-?B/mitogen-activated protein kinases-dependent pathways.
Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response.
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Plasminogen activators in vascular remodeling and angiogenesis.
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.
Plasminogen inhibits TNFalpha-induced apoptosis in monocytes.
Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.
Plasminogen-induced foam cell formation by macrophages occurs through a histone 2B (H2B)-PAR1 pathway and requires integrity of clathrin-coated pits.
Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study.
Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Studies in experimental atherosclerosis. IV. Serum fibrinolysin activity in cholesterol atherosclerosis.
The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels.
The role of the fibrinolytic system in corneal angiogenesis.
Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells.
Vascular accumulation of Lp(a): in vivo analysis of the role of lysine-binding sites using recombinant adenovirus.
[A study of problems of the diagnosis and pathogenesis of atherosclerosis using fibrinolysin labeled with I-131]
[Experimental cholesterin atherosclerosis in the rabbit: action of a duodenal heparinoid. III. Modifications in the factors of hemocoagulation, plasmin and plasminogen, and in the thromboplastin and fibrinolytic activity of the aortic wall.]
[Experimental substantiation of the diagnosis of atherosclerosis by the use of fibrinolysin labeled with I-131]
[Expression of tissue-type plasminogen activator (t-PA) in smooth muscle cells of injured iliac arteries in rabbits]
[Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta]
[Lipids and atherosclerosis]
[Lipoprotein (a) and plasminogen in atherosclerosis]
[Lipoprotein (a). An additional marker of atherosclerosis]
[Lipoprotein(a). Its importance as an additional atherosclerosis marker]
[Lipoprotein(a): a link between thrombogenesis and atherogenesis]
[New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?]
[Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy]
[Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis]
[Protective effect of combined injection of fibrinolysin and heparin against thrombogenesis in animals during the pre-thrombotic state and in experimental atherosclerosis]
[Relations between fibrinolysis and human atherosclerosis. Tissue activator of plasminogen of the arterial wall]
[Some biochemical indices of the blood under the effect of fibrinolysin in rabbits with experimental cholesterol atherosclerosis]
[The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Atrial Fibrillation
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Autoimmune Diseases
A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.
alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci.
Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis.
Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Plasmin as a proinflammatory cell activator.
Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
Autoimmune Pancreatitis
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Babesiosis
Blood markers of fibrinolysis and endothelial activation in canine babesiosis.
Bacteremia
Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).
Elevated concentrations of cross-linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia.
Immobilization of plasminogen on Escherichia coli flagella.
Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks.
Bacterial Infections
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.
Procalcitonin and Other Biomarkers of Sepsis in Newborns in the Intensive Care Unit.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure.
The interaction of two novel putative proteins of Leptospira interrogans with E-cadherin, plasminogen and complement components with potential role in bacterial infection.
Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.
Behcet Syndrome
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
beta-Thalassemia
Impact of ?-thalassemia trait carrier state on inflammatory status in patients with newly diagnosed hypertension.
Blister
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis?
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Collagen XVII Processing and Blistering Skin Diseases.
Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes.
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Fibrinolysis inhibition in human burn blister fluid.
Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
The extra-articular deposition of fibrinogen antigenic material in patients with rheumatoid arthritis.
[Coagulation factors in human born blisters (author's transl)]
Bone Diseases
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.
Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.
Bone Resorption
Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Effects of plasminogen and interleukin-1 beta on bone resorption in vitro.
Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency.
Modulation of plasminogen activators and plasminogen activator inhibitors by TGF-beta, IL-1 alpha and EGF in fetal rat calvaria cells at different times of culture.
Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones.
The role of the plasminogen system in bone resorption in vitro.
Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane.
Brain Diseases
Cellular mechanisms regulating non-haemostatic plasmin generation.
[Change in the concentration of plasmin and its inhibitors in the blood of patients with dyscirculatory encephalopathy before and after treatment]
Brain Edema
Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model.
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.
Plasminogen activators potentiate thrombin-induced brain injury.
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat.
Brain Infarction
[Revising the principles and improving the methods of differential therapy of ischemic stroke]
Brain Injuries
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury.
Plasminogen activators potentiate thrombin-induced brain injury.
Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
[The permeability of the hemato-encephalic barrier and the proteolytic potential of the cerebrospinal fluid in severe craniocerebral trauma]
Brain Injuries, Traumatic
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Fibrinolysis: from blood to the brain.
Genotype and Injury Effect on the Expression of a Novel Hypothalamic Protein Sushi Repeat-Containing Protein X-Linked 2 (SRPX2).
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
Traumatic brain injury: Tissue-type plasminogen activator-harmful or beneficial?
Using antifibrinolytics to tackle neuroinflammation.
Brain Ischemia
Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity.
Cerebral ischemia and neuroregeneration.
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia.
GSK-3? as a target for protection against transient cerebral ischemia.
Intracerebral transplantation of bone marrow stromal cells ameliorates tissue plasminogen activator-induced brain damage after cerebral ischemia in mice detected by in vivo and ex vivo optical imaging.
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.
Neuroendocrine Targeting of Tissue Plasminogen Activator (t-PA).
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples.
Plasminogen activation in experimental permanent focal cerebral ischemia.
Plasminogen activation in focal cerebral ischemia and reperfusion.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
The effect of age on expression of endogenous plasminogen activators after focal cerebral ischemia in mice.
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
Brain Neoplasms
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Brain tumors and plasmin inhibitors.
Genes Encoding Mammalian Oviductal Proteins Involved in Fertilization are Subjected to Gene Death and Positive Selection.
Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes.
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Plasma fibrinolytic profile in patients with brain tumors.
Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
[A plasminogen regulation system in brain tumors].
Brain Stem Infarctions
[Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction]
Breast Cyst
Breast cyst fluid plasmin activity and its effect on TGF-beta2 activation.
Urokinase and tissue-type plasminogen activators are present in breast cyst fluids.
Breast Diseases
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Breast Neoplasms
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Association of plasminogen activator activity and steroid receptors in human breast cancer.
Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator.
Characteristics of fibrinolysin secreted by cultured rat breast carcinoma cells.
Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Correlation of tissue and blood plasminogen activation system in breast cancer.
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol.
Evidence for the clinical use of tumour markers.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Factors involved in the plasminogen activation system in human breast tumours.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.
Functional evaluation of plasmin formation in primary breast cancer.
Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen.
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling.
Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.
Pathway-Based Biomarker Search by High-Throughput Proteomics Profiling of Secretomes.
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer.
Plasmin induces the formation of multicellular spheroids of breast cancer cells.
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Prognosis and prediction of response in breast cancer: the current role of the main biological markers.
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
Proteases as prognostic markers in cancer.
Proteolysis of CCN1 by plasmin: functional implications.
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Sanguisorba minor extract suppresses plasmin-mediated mechanisms of cancer cell migration.
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Sialylated Lewis x Antigen Bearing Glycoproteins in Human Plasma.
Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion.
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
Synthetic substrates specific to activated plasmin can monitor the enzymatic functional status in situ in breast cancer cells.
Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer.
Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer.
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Tissue plasminogen activators in breast cancer.
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
[A plasminogen regulation system in brain tumors].
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
[The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue]
[The immunoenzyme determination of plasminogen activators and their inhibitor in breast tumors: the connection to clinico-morphological prognostic factors]
Bronchiectasis
Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in bronchiectasis in vivo.
Bronchiolitis
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Bronchitis
[Plasminogen activators in assessing the reaction of patients with chronic obstructive bronchitis to physical loading]
Budd-Chiari Syndrome
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
Bundle-Branch Block
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
[Fibrinolysis or angioplasty in acute myocardial infarction?]
Carcinogenesis
Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype.
Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer.
Helicobacter pylori interactions with plasminogen.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis.
The interplay between hemostasis and malignancy: the oral cancer paradigm.
The molecular biology of colorectal cancer development and the associated genetic events.
The plasminogen activator inhibitor "paradox" in cancer.
The role of plasmin in the pathogenesis of murine multiple myeloma.
Three are better than one: plasminogen receptors as cancer theranostic targets.
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
[Endothelial cell proteases and their modulation by platelets]
Carcinoma
A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas.
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
A receptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity.
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Alterations in fibrinogen, plasminogen, and inhibitors of plasmin with the growth of V2 carcinoma in rabbits.
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Androgen-dependent fibrinolytic activity in a murine mammary carcinoma (Shionogi SC-115 cells) in vitro.
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells.
Angiostatin generation by human pancreatic cancer.
Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis.
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.
Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas.
Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells.
Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases.
Circulating fibrinolysin in carcinoma of the prostate.
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats.
Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Expression and activation of proteases in co-cultures.
Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Expression of plasminogen activators in basal cell carcinoma.
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Fibrinolytic activity of in vitro cultivated human bladder cell lines.
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.
Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.
Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN.
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice.
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Invasive neoplastic uroepithelial cells express high-levels of urokinase receptor and plasminogen receptor, alpha-enolase.
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Isolation and spontaneous transformation of cloned lines of hamster tracheal epithelial cells.
Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators.
Localization of blood coagulation factors in situ in pancreatic carcinoma.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Plasminogen activators in oesophageal carcinoma.
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Plasminogen receptors on rat colon carcinoma cells.
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Proteolytic patterns of head and neck squamous cell carcinoma.
Receptor for plasmin on human carcinoma cells.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Relationship between plasminogen activators and stomach carcinoma stage.
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells.
Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
The accumulation of angiostatin-like fragments in human prostate carcinoma.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines.
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Visualization of the plasmin receptor on carcinoma cells.
Visualization of the plasmin receptor on sections of human mammary carcinoma cells.
Vitronectin in human breast carcinomas.
[Behavior of plasminogen in prostatic carcinoma treated with cytonal]
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Carcinoma in Situ
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Carcinoma, Basal Cell
Expression of plasminogen activators in basal cell carcinoma.
Carcinoma, Bronchogenic
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Carcinoma, Brown-Pearce
Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit.
Carcinoma, Ehrlich Tumor
Action of antibodies and plasmin on Ehrlich ascites tumour cells.
Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Plasmin regulating system from embryonal carcinoma F9 cells: plasminases A, B and embrinogen.
Carcinoma, Hepatocellular
Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1.
Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence.
Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells.
Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma bearing male mice.
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.
Kringle 5 of Human Plasminogen Suppresses Hepatocellular Carcinoma Growth Both in Grafted and Xenografted Mice by Anti-Angiogenic Activity.
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.
Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a).
Regulation of plasminogen gene expression by interleukin-6.
Suppression of Plasminogen Activators and the MMP-2/-9 Pathway by a Zanthoxylum avicennae Extract to Inhibit the HA22T Human Hepatocellular Carcinoma Cell Migration and Invasion Effects in Vitro and in Vivo via Phosphatase 2A Activation.
The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation.
Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
[Clinical studies of serum protease inhibitors in hepatoma]
[Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma]
Carcinoma, Lewis Lung
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice.
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Carcinoma, Non-Small-Cell Lung
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer.
Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Carcinoma, Papillary
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Carcinoma, Renal Cell
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Carcinoma, Squamous Cell
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro.
Proteolytic patterns of head and neck squamous cell carcinoma.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Carcinoma, Transitional Cell
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Carcinosarcoma
The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.
The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood.
Cardiomyopathies
Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Exercise-induced hemostatic activation in patients with dilated cardiomyopathy in sinus rhythm.
Cardiovascular Diseases
A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and Validation.
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.
Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?
Alcohol, heart disease, and mortality: a review.
Biochemistry of protein tyrosine nitration in cardiovascular pathology.
Cardiovascular diseases (CVD) risk factors, physical activity (PA) and plasma plasminogen (Plg) in a random sample of community-dwelling elderly.
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up.
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
Molecular analysis of blood vessel formation and disease.
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
New developments in thrombolytic therapy.
Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus.
Plasminogen activator system and vascular disease.
Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.
Recent developments in depsipeptide research.
Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease.
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
The functions of plasminogen in cardiovascular disease.
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
[Biochemical markers of endothelial dysfunction and cardiovascular system state in patients with occupationai bronchopulmonary diseases].
Caroli Disease
Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease.
Carotid Artery Diseases
Hemostatic function and carotid artery disease.
Carotid Artery Injuries
Endoluminal arterial injury in plasminogen-deficient mice.
Carotid Artery Thrombosis
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis.
Catalepsy
Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
Cataract
Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract.
Tissue plasminogen activator-assisted vitrectomy in the early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery.
[Densitometric analysis of changes in the vitreous body after cataract extraction]
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation]
[Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery]
Celiac Disease
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Central Nervous System Diseases
Interventional use of plasminogen activators in central nervous system diseases.
Cerebral Amyloid Angiopathy
An Enzyme from Aristolochia indica Destabilizes Fibrin-? Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases.
Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target?
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.
Cerebral Hemorrhage
An emerging role of mast cells in cerebral ischemia and hemorrhage.
Antithrombotic treatments in acute ischemic stroke.
Blood-brain barrier disruption by low-frequency ultrasound.
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Comparative safety of thrombolytic agents.
Coronary artery disease, myocardial infarction, and brain embolism.
Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage.
Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke.
Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats.
Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
Role of tissue-type plasminogen activator in ischemic stroke.
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
The Effects of the Contact Activation System on Hemorrhage.
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis.
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Thrombolytic therapies: the current state of affairs.
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Cerebral Infarction
Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke.
Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Early fibrinogen degradation coagulopathy: a predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis.
Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes: Analysis From the SELECT Study.
Hematologic abnormalities occur in both cortical and lacunar infarction.
Hemorrhagic complications of thrombolytic therapy in experimental stroke.
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Polymorphism of plasminogen in healthy individuals and patients with cerebral infarction.
Prothrombotic risk factors in childhood stroke and venous thrombosis.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.
The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis.
[Frequency and clinical significance of congenital plasminogen abnormality in cerebral infarction]
Cerebrovascular Disorders
A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.
Congenitally abnormal plasminogen in juvenile ischemic cerebrovascular disease.
Fibrinolysin in cerebrovascular diseases.
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Therapeutic problems in cerebrovascular disease. The experimental use of plasmin in dogs.
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Chagas Disease
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Charcot-Marie-Tooth Disease
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Cholangiocarcinoma
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholelithiasis
[Hemostatic indices of oncological patients with different forms of jaundice]
Cholera
Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells.
Cholestasis
Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis.
Cholesteatoma
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Cholesteatoma, Middle Ear
Plasminogen activators in tissue extract of aural cholesteatoma.
Chondrosarcoma
Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Choriocarcinoma
Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells.
Choroidal Neovascularization
Anti-inflammatory and anti-angiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.
Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
[Intravitreal injection. Drugs to treat subretinal hemorrhage].
Chronic Limb-Threatening Ischemia
tPA-MMP-9 Axis Plays a Pivotal Role in Mobilization of Endothelial Progenitor Cells from Bone Marrow to Circulation and Ischemic Region for Angiogenesis.
Chronic Periodontitis
Neutrophil elastase is involved in the initial destruction of human periodontal ligament.
Plasmin is essential in preventing periodontitis in mice.
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
coagulation factor xia deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Coinfection
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
Colic
Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
Colitis
Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells.
Colitis, Ulcerative
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Colonic Diseases
Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases.
Colonic Neoplasms
Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway.
Butyrate regulates gene expression of the plasminogen activating system in colon cancer cells.
Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential.
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer.
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells.
Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer.
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway.
[Protease activities in gastric and colon cancer tissues]
Colorectal Neoplasms
Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin.
Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Differences in the activation mechanism between the alpha and beta subunits of human meprin.
Evidence for the clinical use of tumour markers.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Plasminogen activation system and colorectal cancer biology.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Prognostic role of tumor-associated proteases in colorectal cancer.
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
Role of urokinase in colorectal neoplasia.
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Tumor associated proteases -- prognostic markers of colorectal cancer.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Coma
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Communicable Diseases
Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Use of Intraoperative Tranexamic Acid and Wound Complications in Spine Surgery: A Retrospective Cohort Study.
Congenital Abnormalities
Clinical application of fibrinolysis laboratory tests: a review.
Clinical disorders of fibrinolysis: a critical review.
Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.
[Congenital abnormality of plasminogen]
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Conjunctivitis
A large deletion in the Plasminogen gene is associated with ligneous membranitis in a Maltese dog.
Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature.
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis.
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis.
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Difficulties in mutation screening of the plasminogen (PLG) gene in patients with ligneous conjunctivitis and severe hypoplasminogenemia.
Difficulties in the mutation analysis of plasminogen gene: a study in two patients with ligneous conjunctivitis.
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog.
Fresh frozen plasma (Octaplas) and topical heparin in the management of ligneous conjunctivitis.
Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous Conjunctivitis.
Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature.
Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis.
Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.
Human homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity.
Letter Regarding "Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature" by Y. Tu et al.
Ligneous conjunctivitis associated with type I plasminogen deficiency: A rare case.
Ligneous conjunctivitis due to plasminogen deficit: Diagnostic and therapeutic approach. With literature review.
Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report.
Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency.
Ligneous conjunctivitis in a Mexican patient with a mutation in the plasminogen (PLG) gene.
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
Ligneous conjunctivitis in a young patient with homozygous K19E plasminogen gene mutation: a diagnostic and therapeutic challenge.
Ligneous conjunctivitis in plasminogen-deficient mice.
Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog.
Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level.
Ligneous conjunctivitis with plasminogen deficiency.
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Ligneous conjunctivitis.
Ligneous conjunctivitis: a clinicopathological, immunohistochemical, and genetic study including the treatment of two sisters with multiorgan involvement.
Ligneous conjunctivitis: a local manifestation of a systemic disorder?
Ligneous periodontitis in a child with plasminogen deficiency.
Long-term efficacy of surgical removal of pseudomembranes in a child with ligneous conjunctivitis treated with plasminogen eyedrops.
Management of hydrocephalus in children with plasminogen deficiency.
Management of ligneous conjunctivitis in a child with plasminogen deficiency.
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review.
Novel plasminogen and hyaluronate sodium eye drop formulation for a patient with ligneous conjunctivitis.
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Otolaryngological manifestations of ligneous conjunctivitis.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
Plasminogen deficiency.
Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency.
Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics.
Retraction: Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in An 8-Week-Old Female Infant.
Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis.
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency.
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
Topical Plasminogen as Adjunctive Treatment in Recurrent Ligneous Conjunctivitis.
Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant.
Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen.
[Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature]
[Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)]
[Pharmaceutical supply of human plasminogen replacement therapy for the treatment of ligneous conjunctivitis: Logistics for a university hospital].
Conjunctivitis, Allergic
Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Conjunctivitis, Bacterial
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Connective Tissue Diseases
Decrease in matrix metalloproteinase?3 activity in systemic sclerosis fibroblasts causes ?2?antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Corneal Diseases
Elevation of tear fluid plasmin in corneal disease.
Corneal Dystrophies, Hereditary
[Secretion of plasminogen activators and their inhibitors in corneal fibroblasts. Modification of this secretion in Schnyder's lens corneal dystrophy]
Corneal Injuries
Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair.
Enzyme histochemistry of corneal wound healing.
The histochemical pattern of mechanically or chemically injured rabbit cornea after aprotinin treatment: relationships with the plasmin concentration of the tear fluid.
Corneal Neovascularization
Acidic/Neutral Amino Acid Residues Substitution in NH2 Terminal of Plasminogen Kringle 5 Exerts Enhanced Effects on Corneal Neovascularization.
Anti-angiogenic role of angiostatin during corneal wound healing.
Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization.
Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas.
Plasmin and epidermal growth factor in the tear fluid of contact-lens wearers: effect of wearing different types of contact lenses and association with clinical findings.
Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin.
The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF.
The role of the fibrinolytic system in corneal angiogenesis.
Towards a closed eye model of the pre-ocular tear layer.
[Fibrinolysis components and angiogenesis regulation by example of burn-induced corneal neovascularization in rabbits].
Corneal Opacity
[Etiology of corneal opacities after plasminogen activator-induced fibrinolysis of the anterior chamber]
Corneal Ulcer
Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy.
Coronary Aneurysm
Decreased plasminogen activator inhibitor-1 levels in coronary artery aneurysmatic patients.
Coronary Artery Disease
Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.
Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.
Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis.
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia.
Inflammation, the endothelium, and the acute coronary syndromes.
Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group.
Plasminogen and fibrinogen plasma levels in coronary artery disease.
Plasminogen and plasmin activity in patients with coronary artery disease.
Plasminogen levels and risk of coronary artery disease.
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Severity of coronary artery disease and basal fibrinolysis.
The interactions between hemostasis and resistance training: a review.
The peculiar evolution of apolipoprotein(a) in human and rhesus macaque.
Thrombin and plasmin activity in coronary artery disease.
Urokinase plasminogen activator system in humans with stable coronary artery disease.
[The use of heparin and fibrinolysin in patients with coronary arteriosclerosis]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Disease
Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.
Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease.
Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene.
Lipid-thrombosis interface.
The effect of exercise on thrombin and plasmin generation in middle-aged men.
[A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease]
[Effect of puerarin on fibrinolytic activity and lipid peroxide in patients with coronary heart disease]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Occlusion
Intracoronary thrombolysis in evolving myocardial infarction.
[Blood coagulation shifts in patients with myocardial infarction treated with streptokinase]
Coronary Stenosis
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.
Coronary Thrombosis
Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR.
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
FIBRINOLYSIN AND ITS RELATION TO THE MANAGEMENT OF CORONARY THROMBOSIS.
Novel antithrombotic approaches to coronary artery disease.
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Role of nitrates in acute myocardial infarction.
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
COVID-19
A Matter of Caution: Coagulation Parameters in COVID-19 Do Not Differ from Patients with Ruled-Out SARS-CoV-2 Infection in the Emergency Department.
Assessing Plasmin Generation in Health and Disease.
Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study.
Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19).
Comparison of the coagulopathies associated with COVID-19 and sepsis.
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Fibrinolysis and COVID-19: A plasmin paradox.
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
Low level of plasminogen increases risk for mortality in COVID-19 patients.
Lung Epithelial Cell Transcriptional Regulation as a Factor in COVID-19-associated Coagulopathies.
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.
Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant.
The multifaceted role of plasminogen in inflammation.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies.
Cowpox
The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Craniocerebral Trauma
[The possible mechanisms of a fibrinolytic disorder in patients with severe craniocerebral trauma]
Creutzfeldt-Jakob Syndrome
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease.
Crohn Disease
Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
Cushing Syndrome
Further studies on the hypercoagulable state of patients with Cushing's syndrome.
Cystic Fibrosis
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Cysts
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs.
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Cytomegalovirus Infections
Human cytomegalovirus infection induces mRNA expression and secretion of plasminogen inhibitor type-1 in endothelial cells.
Darier Disease
Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis?
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies.
Darier's disease: an immunohistochemical study using antibodies to proteases.
Death, Sudden, Cardiac
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene.
Dehydration
Expression, purification, and biological characterization of Anaplasma phagocytophilum enolase.
Stress down regulates milk yield in cows by plasmin induced beta-casein product that blocks K+ channels on the apical membranes.
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease.
Dementia, Vascular
Plasminogen and plasmin in Alzheimer's disease.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Demyelinating Diseases
Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination.
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Plasminogen activator activity and plasmin inhibition in nerves.
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
Tissue plasminogen activator gene expression in multiple sclerosis brain tissue.
Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.
Dengue
Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity.
Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities.
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Current Understanding of the Pathogenesis of Dengue Virus Infection.
Dengue Virus Nonstructural Protein 1-Induced Antibodies Cross-React with Human Plasminogen and Enhance Its Activation.
Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation.
Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection.
GRP78: a multifunctional receptor on the cell surface.
Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor.
Modulation of ?-enolase post-translational modifications by dengue virus: increased secretion of the basic isoforms in infected hepatic cells.
Participation of the Dengue virus in the fibrinolytic process.
Peptide Bbeta(15-42) preserves endothelial barrier function in shock.
Dental Plaque
Cellular source, activation and inhibition of dental plaque collagenase.
Plasminogen binding by oral streptococci from dental plaque and inflammatory lesions.
Relationship between fibrinolytic activity and gingival inflammatory reaction in young individuals.
Dermatitis
The effect of tamol on human mast cell chymase and plasmin.
Dermatitis, Atopic
Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis.
Plasminogen activators and antiplasmin activity in atopic dermatitis.
Dermatomyositis
Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS).
Diabetes Complications
Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry.
Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Diabetes Mellitus
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors.
Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen.
Plasminogen activation in diabetes mellitus: kinetics of plasmin formation with plasminogen and tissue plasminogen activator from diabetic donors.
Plasminogen activation in diabetes mellitus: normalization of blood sugar levels improves impaired enzyme kinetics in vitro.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells.
Risk Factors for Thrombosis Development in Mexican Patients.
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients.
Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control.
[Effect of venous stasis on plasminogen activation and plasma alpha 2-antiplasmin levels in type II diabetes mellitus]
[Lipoprotein and plasminogen serum levels in patients with diabetes mellitus type 2: risk factors for macroangiopathy? Preliminary study]
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
[Plasma fibrinopeptide A, fibrinopeptide B beta 15-42 and 4 other coagulation factors levels in patients with diabetic retinopathy]
[Plasminogen activation and erythrocyte aggregation in diabetic patients]
Diabetes Mellitus, Type 1
Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Hemostatic variables in Arab diabetics.
Diabetes Mellitus, Type 2
Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Blood coagulation and fibrinolysis in obese NIDDM patients.
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria.
Hemobiological properties of gliclazide.
Hemostatic variables in Arab diabetics.
Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.
Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
[Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)]
Diabetic Foot
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
Diabetic Nephropathies
Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.
Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy.
Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
[Effects of shear stress on expression of plasminogen activator (tPA and uPA) in cultured kidney proximal tubular epithelial cells and its significance]
[Lipid metabolism and fibrinolysis in diabetic nephropathy in the course of diabetes type II]
[Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC]
[The vascular wall and fibrinolysis--pathologic aspects]
[Urinary-plasmin alpha 2 plasmin inhibitor complex (PIC) in patients with diabetic nephropathy]
Diabetic Retinopathy
Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT).
Autologous plasmin enzyme in the surgical management of diabetic retinopathy.
Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema.
Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice.
Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose.
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Pharmacologic Vitreolysis in Diabetic Retinopathy.
Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
The metabolism of fibrinogen and plasminogen related to diabetic retinopathy in man.
uPA, tPA and PAI-1 mRNA expression in periretinal membranes.
Utilizing network pharmacology to explore the underlying mechanism of Radix Salviae in diabetic retinopathy.
[Studies on diabetic retinopathy and plasmin activity in the blood (with reference to duration and blood sugar)]
Diphtheria
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Disseminated Intravascular Coagulation
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Acute generalized, widespread bleeding. Diagnosis and management.
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.
Coagulation and fibrinolysis study after local thrombolysis of a cerebral artery with urokinase.
Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin.
Consumption coagulopathy associated with shock in acute African swine fever.
Depressed plasma activity of plasminogen or alpha2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation.
Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated intravascular coagulation: antithrombin, plasminogen, and coagulation abnormalities in 41 dogs.
DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma.
Effect of urokinase on disseminated intravascular coagulation.
Effects of intravenous infusion of human prostate tissue substances in dogs.
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Experimental study of rabbit fibrinogen degradation products. Influence of plasminogen level for the interpretation of serum concentration of fibrinogen degradation products in consumption coagulopathies.
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation.
Fibrinolysis in disseminated intravascular coagulation.
Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis.
Hematin: unique effects of hemostasis.
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
New rapid assay for factor XIa-alpha 1 antitrypsin complex--application to DIC.
Pathways of coagulation/fibrinolysis activation in malignancy.
Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation.
Postoperative bleeding in a patient with normal screening coagulation tests.
Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine.
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.
Treatment of severe acute respiratory distress syndrome: a final report on a phase I study.
Vitamin K reduces bleeding in left ventricular assist device recipients.
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
[Protease inhibitors and plasminogen in leukemia--with special reference to disseminated intravascular coagulation (author's transl)]
[Serial changes in protein C, antithrombin III, alpha 2-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC)]
Down Syndrome
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Nerve growth factor metabolic dysfunction in Down's syndrome brains.
Dry Eye Syndromes
Tear fluid plasmin activity of dry eye patients with Sjögren's syndrome.
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Dry Socket
Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Duodenal Ulcer
Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
[Vascular component of the fibrinolytic system of blood (plasminogen activator of vascular wall) in patients with duodenal ulcer with a history of hemorrhagic complications]
Dysentery
[Activity of the plasmin enzymatic system and of serum hyaluronidase in dysentery]
[Correlations of the level of plasmin system and blood serum hyaluronidase activity with pathology of the large intestine in dysentery]
Dyslipidemias
Dyslipidemia and the risk of Alzheimer's disease.
Impaired fibrinolytic activity is present in children with dyslipidemias.
Metabolic abnormalities in hypertension.
Ehlers-Danlos Syndrome
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Embolic Stroke
Alterations of haemostatic markers in various subtypes and phases of stroke.
Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke.
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study.
[Changes of haemostatic parameters in patients with acute cardioembolic stroke].
Embolism
Fibrinolysin (Actase) in the treatment of peripheral embolism.
Fibrinolytic effect of tissue plasminogen activator on cerebral embolism in stroke-prone spontaneously hypertensive rats.
LYSIS OF THE EXPERIMENTAL RADIOACTIVE PULMONARY EMBOLUS INDUCED BY STREPTOKINASE AND SK-ACTIVATED PLASMIN.
Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
Thrombolytic effect of tissue plasminogen activator in a cerebral embolic model.
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
[Lipoprotein(a): structure, metabolism and atherosclerotic disease]
[Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs]
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
[Treatment of thrombosis and embolisms with human fibrinolysin.]
Embolism and Thrombosis
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Embolism, Cholesterol
Cholesterol embolism after intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Empyema
Management of Pleural Infection.
Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study.
Encephalitis
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Encephalitis, Herpes Simplex
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Encephalomyelitis
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Encephalomyelitis, Autoimmune, Experimental
Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
End Stage Liver Disease
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Endarteritis
Can the activation of plasminogen/plasmin system of the host by metabolic products of Dirofilaria immitis participate in heartworm disease endarteritis?
Fibrinolysis and proliferative endarteritis: two related processes in chronic infections? The model of the blood-borne pathogen Dirofilaria immitis.
Glyceraldehyde 3-phosphate dehydrogenase and galectin from Dirofilaria immitis participate in heartworm disease endarteritis via plasminogen/plasmin system.
Endemic Diseases
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
Endocarditis
Activation of plasminogen by Streptococcus mutans.
Antibiotic modulation of the plasminogen binding ability of viridans group streptococci.
The role of streptococcal plasmin(ogen) binding in infective endocarditis.
Endocarditis, Non-Infective
The role of streptococcal plasmin(ogen) binding in infective endocarditis.
Endometrial Hyperplasia
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometrial Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma.
High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma.
Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometriosis
A role for the fibrinolytic system in postsurgical adhesion formation.
Fibrinolysis in the peritoneal fluid during adhesions, endometriosis and ongoing pelvic inflammatory disease.
Fibrinolytic properties of peritoneal fluid in endometriosis.
Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation.
Local activation of TGF-beta1 at endometriosis sites.
Plasminogen activators and plasminogen activator inhibitors in endometriosis.
Plasminogen activators in endometriosis.
Endometritis
Involvement of the plasminogen activation system in cow endometritis.
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
Endotoxemia
Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture.
Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia.
Interaction of leukocytes and endotoxin with the plasmin and kinin systems.
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
Eosinophilia
Plasminogen levels in subjects with eosinophilia.
Epidermolysis Bullosa Dystrophica
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Epilepsy, Rolandic
Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR.
Epiretinal Membrane
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Plasminogen activation in epiretinal membranes.
Plasminogen in proliferative vitreoretinal disorders.
SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM.
[Enzymatic vitrectomy by intravitreal autologous plasmin injection as initial treatment for macular epiretinal membranes and vitreomacular traction syndrome.]
[Thrombospondin and its importance in proliferative retinal diseases]
Esophageal Neoplasms
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Serine proteinase activation in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Essential Hypertension
Abnormalities of fibrinolysis in essential hypertension.
Fibrinolytic system in normotensive subjects and hypertensive patients.
Haemostatic variables in arterial hypertension.
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
[Changes in the fibrinolytic activity in hypertension and acute cerebral infarction]
[Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension: the effect of atenolol (author's transl)]
[The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension].
Exostoses
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Eye Diseases
A study of plasmin in eye disease.
Eye Hemorrhage
[Mechanism of action of fibrinolysin and a verification of the efficacy of its use in traumatic hemophthalmos]
[Phonophoresis of fibrinolysin and potassium iodide in complex treatment of hemophthalmos]
Eye Infections
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
Fabry Disease
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.
Factor V Deficiency
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Factor XI Deficiency
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Factor XII Deficiency
Chloroform-induced fibrinolysis. Its dependence on Hageman factor, plasma prekallikrein, and high molecular weight kininogen.
Factor XIII Deficiency
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Familial Mediterranean Fever
Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis.
Familial Primary Pulmonary Hypertension
A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension.
Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences.
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension.
Fatty Liver
ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.
Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.
Febrile Neutropenia
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Fetal Alcohol Spectrum Disorders
Plasminogen activator system homeostasis and its dysregulation by ethanol in astrocyte cultures and the developing brain.
Fetal Death
Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
Fetal Growth Retardation
Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies.
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Fibroadenoma
Factors involved in the plasminogen activation system in human breast tumours.
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Fibrocystic Breast Disease
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Fibrosarcoma
Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin.
Cumulative influence of elastin peptides and plasminogen on matrix metalloproteinase activation and type I collagen invasion by HT-1080 fibrosarcoma cells.
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells.
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2.
Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor.
Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin.
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Follicular Cyst
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Foot Ulcer
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
Fuchs' Endothelial Dystrophy
Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract.
Galactosemias
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Gastritis
Glycoproteomic analysis of serum from patients with gastric precancerous lesions.
Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874.
Gastrointestinal Diseases
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface.
Gastrointestinal Neoplasms
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
gelatinase b deficiency
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Genetic Diseases, Inborn
Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation.
Giant Cell Arteritis
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Giardiasis
Insights into the Giardia intestinalis enolase and human plasminogen interaction.
Gingival Hyperplasia
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Periodontitis associated with plasminogen deficiency: a case report.
Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report.
Gingival Overgrowth
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Gingivitis
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
Ligneous alveolar gingivitis in the absence of plasminogen deficiency.
Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis.
Ligneous gingivitis secondary to plasminogen deficiency: a multidisciplinary diagnostic challenge.
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Successful treatment of ligneous gingivitis with warfarin.
Glaucoma
Glaucoma is associated with plasmin proteolytic activation mediated through oxidative inactivation of neuroserpin.
Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
[Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy].
[Use of fibrinolysin after microsurgical operations for glaucoma]
Glaucoma, Open-Angle
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma.
Glioblastoma
Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Antifibrinolytic therapy of experimentally grown malignant brain tumors.
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Plasmin Activation of Glial Cells through Protease-Activated Receptor 1.
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody.
Plasminogen-dependent internalization of soluble melanotransferrin involves the low-density lipoprotein receptor-related protein and annexin II.
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
[A plasminogen regulation system in brain tumors].
Glioma
Annexin A2 promotes glioma cell invasion and tumor progression.
Binding of bovine, ovine, porcine, canine, and rat plasminogen to rat hepatocytes and rat C6 glioma cells in vitro.
CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Endothelial cell-derived plasmin promotes human glioma cell proliferation.
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Expression of plasminogen receptors on C6 glioma cells.
High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Human glioma cell BT325 expresses a proteinase that converts human plasminogen to kringle 1-5-containing fragments.
Hyaluronic acid facilitates glioma cell invasion in vitro.
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin.
Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3.
Investigation of serum proteome alterations in human glioblastoma multiforme.
Lithium chloride inhibits thrombin-induced intracellular calcium mobilization in C6 rat glioma cells.
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Plasmin modulates the thrombin-evoked calcium response in C6 glioma cells.
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes.
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
Protease nexin 1 is expressed in the human placenta.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
The role of the plasminogen activation cascade in glioma cell invasion: a review.
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
[Biological profiles of malignant gliomas]
[Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture]
Glomerulonephritis
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Attributes of antiangiogenic factor plasminogen kringle 5 in glomerulonephritis.
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis.
Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat.
Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease.
Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis: A case report.
Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis.
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis.
Nephritis-associated plasmin receptor (NAPlr)-positive glomerulonephritis in a case of ANCA-negative small vessel vasculitis.
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.
Relationship between elevation in the plasma concentration of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and haemostatic parameters during haemodialysis.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
Urinary plasminogen and chronic glomerulonephritis.
Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases.
[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]
[The effect of membrane-stabilizing therapy on the status of the hemostatic system in patients with glomerulonephritis with a hematuric component]
[The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis]
[Urinary excretion of plasmin and fibrin-fibrinogen degradation products in various types of glomerulonephritis (author's transl)]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis, IGA
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Role of tubulointerstitial plasmin in the progression of IgA nephropathy.
Glomerulonephritis, Membranous
A novel autoantibody to plasminogen and its characterization in Heymann nephritis.
Analysis of a 45-kDa protein that binds to the Heymann nephritis autoantigen GP330.
Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330.
Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells.
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen.
Glomerulosclerosis, Focal Segmental
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.
Glucose Intolerance
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Goiter
[Thyroid tissue link of hemostasis in diffuse toxic and euthyroid goiter]
Gout
Fibrin dissolution in synovial fluid.
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
Graft vs Host Disease
Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking.
Granuloma
An immunoperoxidase study of immunological factors in high immune and low resistance granulomas in leprosy.
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
The monocyte-macrophage system in granulomatous inflammation.
Granulomatosis with Polyangiitis
Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients.
Gray Platelet Syndrome
Plasminogen interacts with human platelets through two distinct mechanisms.
Guillain-Barre Syndrome
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Hamartoma
SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM.
Healthcare-Associated Pneumonia
Klebsiella pneumoniae enolase-like membrane protein interacts with human plasminogen.
Hearing Loss
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
[A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy]
Hearing Loss, Sensorineural
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
Asymmetric sudden sensorineural hearing loss: is all this testing necessary?
Heart Arrest
Pediatric In-Hospital Cardiac Arrest Secondary to Acute Pulmonary Embolism.
Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model.
Pulmonary thromboembolism after carbon monoxide poisoning.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Heart Block
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-? and potentiates fibrosis.
Heart Defects, Congenital
Pre- and post-operative studies of fibrinolysis and prothrombin in cyanotic congenital heart disease.
Heart Diseases
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Apolipoproteins(a): a puzzling evolutionary story.
Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels.
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease.
Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease.
Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]
Heart Failure
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart.
Prevention of incipient diabetic cardiomyopathy by high-dose thiamine.
Heart Rupture
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Hemangioma
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Hemarthrosis
Does Tranexamic Acid Reduce Knee Swelling and Improve Early Function Following Arthroscopic Meniscectomy? A Double-Blind Randomized Controlled Trial.
Hematocolpos
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Hematologic Diseases
[Study of hemostasis in patients with a recent thromboembolic complication]
Hematologic Neoplasms
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases.
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].
Hematoma, Subdural
Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
Hematoma, Subdural, Chronic
Degradation of fibrinogen and fibrin by plasmin and nonplasmin proteases in the chronic subdural hematoma: evaluation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot.
Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections.
Fibrinolytic enzyme in the lining walls of chronic subdural hematoma.
Tissue-type plasminogen activator in the chronic subdural hematoma.
Hemoglobinuria
Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemoglobinuria, Paroxysmal
Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system.
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemolytic-Uremic Syndrome
Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells.
Hemophilia A
Assessing Plasmin Generation in Health and Disease.
Development and application of global assays of hyper- and hypofibrinolysis.
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Fibrinolysin studies in hemophilia.
Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation.
THE ROLE OF FIBRINOLYSIN AND PROFIBRINOLYSIN ACTIVATOR IN HEMOPHILIA.
Therapies for the treatment of abnormal uterine bleeding.
[Evaluation of the results of studying fibrinase in patients with hemophilia A]
Hemorrhagic Disorders
A single thymine nucleotide deletion responsible for congenital deficiency of plasmin inhibitor.
Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Studies on the plasminogen proactivator of plasma in children with hemorrhagic disorders.
Hemorrhagic Fever with Renal Syndrome
Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis.
[A dynamic study of plasminogen, antithrombin III, fibrinogen and DIC in epidemic hemorrhagic fever]
[Detection of plasma AT-III and plasminogen in patients with epidemic hemorrhagic fever and its clinical significance]
Hemorrhagic Stroke
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.
Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-d-aspartate glutamate receptors improves hemorrhagic stroke outcome.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
Hemothorax
STUDY OF FIBRINOLYSIN ON CLOTTED HEMOTHORAX.
Treatment of clotted hemothorax with fibrinolysin.
[Coagulative and fibrinolytic properties of blood effused into the pleural cavity after lung surgery]
Hepatic Encephalopathy
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Hepatic Insufficiency
Plasminogen abnormalities in patients with Argentine hemorrhagic fever.
[The disorders of hemostasis system and thrombotic complications in oncologic patients having liver operation.]
Hepatic Veno-Occlusive Disease
Hepatic Veno-Occlusive Disease: A Role for Tissue Plasminogen Activator?
Hepatitis
Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
Bilirubin or plasminogen--which is better in the assessment of the severity of viral hepatitis?
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Potency of fragmented IgG: two studies of postexposure prophylaxis in type A hepatitis.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis.
[Diagnostic value of plasminogen in viral hepatitis]
[Reduced fibrinolysin activity in fatal epidemic hepatitis.]
Hepatitis A
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis.
Robustness of nanofiltration for increasing the viral safety margin of biological products.
Hepatitis B
Contributions to the optimal use of human blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives.
Immunohistological investigations of PAS-negative globular intracisternal hyalin in human liver biopsy specimens.
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Hepatitis C
Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers.
Monitor.
Hepatitis E
Hepatitis E virus open reading frame 3 protein interacts with porcine liver-specific plasminogen and ?2-antiplasmin.
Hepatitis, Chronic
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
[The activity of fibrinase in cirrhosis of the liver and chronic hepatitis]
Hepatolenticular Degeneration
[Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction]
Herpes Simplex
Herpesviruses enhance fibrin clot lysis.
Herpes Zoster
Changes in the bovine zona pellucida induced by plasmin or embryonic plasminogen activator.
Effects of plasmin on sperm-oocyte interactions during in vitro fertilization in the pig.
How Is Plasminogen/Plasmin System Contributing to Regulate Sperm Entry Into the Oocyte?
Localization of plasminogen in the extracellular matrix of hamster eggs: exogenous activation by streptokinase.
nompA encodes a PNS-specific, ZP domain protein required to connect mechanosensory dendrites to sensory structures.
Plasminogen detection in oocytes and plasminogen activator activities in the porcine oviduct during the estrous cycle.
The effects of plasminogen on in vitro ovine embryo development.
Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of invitro but not of invivo fertilisation in the mouse.
Histiocytosis, Langerhans-Cell
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
Hodgkin Disease
PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE.
Homocystinuria
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
Huntington Disease
Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington's disease caudate nucleus.
Hyaline Membrane Disease
Ontogeny of fibrinolysin system and its role in pathogenesis of hyaline membrane disease of infants.
Plasminogen in the prevention of hyaline membrane disease.
Prevention of hyaline membrane disease with plasminogen. A cooperative study.
Prevention of hyaline membrane disease with plasminogen. Preliminary report of a cooperative study.
Studies on hyaline membrane disease. I. The fibrinolysin system in pathogenesis and therapy.
STUDIES ON HYALINE MEMBRANE DISEASE. II. THE ONTOGENY OF THE FIBRINOLYSIN SYSTEM.
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen.
[Treatment of hyaline membrane disease with the plasminogen urokinase combination]
Hydatidiform Mole
Coagulation and fibrinolysis in intact hydatidiform molar pregnancy.
Hydrocephalus
Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus.
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
Management of hydrocephalus in children with plasminogen deficiency.
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
The ventriculocholecystic shunt: two case reports and a review of the literature.
[Fibrinolytic treatment of cerebral intraventricular hemorrhage]
Hydronephrosis
Causes of venous thrombosis in fifty Chinese patients.
Hydronephrosis is associated with elevated plasmin in urine in pediatric patients and rats and changes in NCC and ?-ENaC abundance in rat kidney.
Hyperalgesia
The p75 receptor is associated with inflammatory thermal hypersensitivity.
Hypercholesterolemia
Cardiovascular issues in hypogonadism and testosterone therapy.
Hyperemia
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
Hyperglycemia
Biochemical pharmacology of the fibrinolysin system of the rat. I. The effect of alloxan-induced hyperglycemia.
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.
Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.
The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
Hyperhomocysteinemia
Coagulopathies and arterial stroke.
Prothrombotic disorders and ischemic stroke in children.
Thrombophilic screening in retinal artery occlusion patients.
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
Hyperinsulinism
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia.
Metabolic abnormalities in cardiac ischemia.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Hyperkalemia
Deterioration of Kidney Function by the (Pro)renin Receptor Blocker Handle Region Peptide in Aliskiren-treated Diabetic Transgenic (mRen2)27 Rats.
Hyperlipidemias
Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease.
Hyperlipemia, fibrinolysis and arteriosclerosis.
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
[Hemostasis profiles in thrombotic disease]
[Hemostatic changes during pregnancy in reference to hyperlipidemia]
Hyperlipoproteinemias
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
[Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb]
Hyperpigmentation
Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.
Hypersensitivity
Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites.
Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries.
Rapid appearance of plasmin in tear fluid after ocular allergen exposure.
Review and application of serine protease inhibition in coronary artery bypass graft surgery.
Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease.
[Allergic reactions to fibrinolysin]
[On the role of plasmin in the mechanism of allergy.]
[Round table conference. V. Plasmin and allergy]
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation]
Hypersensitivity, Delayed
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Hypertension
A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and Validation.
Abnormalities of fibrinolysis in essential hypertension.
Advances in diabetes for the millennium: the heart and diabetes.
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection.
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Comparison of plasma total plasmin activities in male and female hypertensive rats.
Correlation between family history of hypertension and haemostatic disorders.
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity.
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
Haemostatic parameters in patients with primitive venous hypertension.
Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.
Is urinary excretion of plasminogen associated with development of pre-eclampsia? An observational, explorative case-control study.
Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease.
Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10?years of follow-up.
Mechanisms of renal NaCl retention in proteinuric disease.
Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers.
Risk Factors for Thrombosis Development in Mexican Patients.
The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition.
The endocrine function of adipose tissue: an update.
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients.
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
[Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension]
[Effect of heparin on the fibrinase activity of the blood in patients with hypertension]
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients]
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
[Neurology in the 21st century--the era of preventive neurology utilizing new diagnostic and therapeutic techniques]
[Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis]
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
[The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome]
Hypertension, Pregnancy-Induced
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
Hypertension, Pulmonary
Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension.
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
High Fibrinogen Plus Low Plasminogen Levels Predict Poor Post-Surgical Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension.
Neutrophil extracellular traps (NETs): the role of inflammation and coagulation in COVID-19.
Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia.
[High-altitude pulmonary hypertension and fibrinolysis]
Hyperthyroidism
Coagulation and fibrinolysis in thyroid disease.
Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment.
[Disorders of hemostasis in dysthyroidism]
Hypertriglyceridemia
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Hypertrophy, Left Ventricular
Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy.
[The indices of the fibrinolysis, blood coagulation and lipid transport systems in hypertension patients]
Hypertrophy, Right Ventricular
Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload.
Hyphema
Fibrinolysin irrigation in traumatic secondary hyphema.
Fibrinolysis and hyphema. The effect of thrombolysin and Kabikinas on clotted blood in camera anterior of the eye in rabbits.
Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Treatment of total hyphema with fibrinolysin.
[Thrombolytic effect of plasmin, miniplasmin and fibrinolysin in simulated intraocular hemorrhage]
[Treatment of experimental hyphema in rabbits by Sevac plasmin]
[TREATMENT OF TOTAL HYPHEMAS OF THE ANTERIOR CHAMBER WITH FIBRINOLYSIN.]
Hypoglycemia
Biochemical pharmacology of the fibrinolysin system of the rat. II. The effect of insulin induced hypoglycemia.
Hypogonadism
Cardiovascular issues in hypogonadism and testosterone therapy.
Hypotension
A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis.
Acute blood pressure effects of selected serine proteases in normotensive rats and dogs.
Acute haemodilution and prostaglandin E1-induced hypotension: effects on the coagulation-fibrinolysis system.
[ROLE OF PLASMIN IN PEPTONE-INDUCED ARTERIAL HYPOTENSION IN RATS.]
Hypothyroidism
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasma.
Hypoxia-Ischemia, Brain
Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia.
[Changes and significance of endogenous tissue plasminogen activators in cerebral hypoxia-ischemia in neonatal rats]
Idiopathic Pulmonary Fibrosis
Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces.
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.
Immunoglobulin G4-Related Disease
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Infant, Newborn, Diseases
Studies on the ontogeny and significance in neonatal disease of the fibrinolysin system and of fibrin stabilizing factor.
Infarction, Middle Cerebral Artery
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Mechanistic insight into Neurotoxicity of Tissue Plasminogen Activator-Induced Thrombolysis Products in a Rat Intraluminal Middle Cerebral Artery Occlusion Model.
Plasminogen activation in focal cerebral ischemia and reperfusion.
Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
Protective Effect of ApoA1 (Apolipoprotein A1)-Milano in a Rat Model of Large Vessel Occlusion Stroke.
Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
The Effects of the Contact Activation System on Hemorrhage.
Thrombolysis with plasmin: implications for stroke treatment.
[Evaluation for antithrombotic agents by a thrombotic model in animals].
Infections
A rapid fluorometric assay for tear fluid plasmin activity.
A study of cutaneous lesions caused by Leishmania mexicana in plasminogen-deficient mice.
Acquisition of the Sda1-encoding bacteriophage does not enhance virulence of the M1 Streptococcus pyogenes strain SF370.
Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection.
Analysis of plasminogen-binding M proteins of Streptococcus pyogenes.
Babesia bovis (= argentina): changes in erythrophylic and associated proteins during acute infection of splenectomized and intact calves.
Bacille Calmette-Guérin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen.
Bacterial metastasis: the host plasminogen system in bacterial invasion.
Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Binding of plasminogen to Escherichia coli adhesion proteins.
Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection.
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Contribution of plasminogen activation towards the pathogenic potential of oral streptococci.
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Current Understanding of the Pathogenesis of Dengue Virus Infection.
Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice.
Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague.
Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury.
Effect of ions and inhibitors on the catalytic activity and structural stability of S. aureus enolase.
Elevation of tear fluid plasmin in corneal disease.
Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells.
Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies.
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
Expression, genetic localization and phylogenic analysis of NAPlr in piscine Streptococcus dysgalactiae subspecies dysgalactiae isolates and their patterns of adherence.
Fibrin and fibrinolysis in infection and host defense.
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study.
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Herpesviruses enhance fibrin clot lysis.
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface.
Humanized Plasminogen Mouse Model to Study Group A Streptococcus Invasive Disease.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor.
Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Influence of plasma protease activation on electroimmunoassay and nephelometry of plasma fibronectin in sepsis.
Interaction of Trypanosoma evansi with the plasminogen-plasmin system.
Interleukin-6-induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta).
Intracellular/surface moonlighting proteins that aid in the attachment of gut microbiota to the host.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients.
Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.
Low level of plasminogen increases risk for mortality in COVID-19 patients.
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate.
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Molecular characterization of a Trichinella spiralis enolase and its interaction with the host's plasminogen.
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Molecular cloning and expression analysis of coagulation factor VIII and plasminogen involved in immune response to GCRV, and immunity activity comparison of grass carp Ctenopharyngodon idella with different viral resistance.
Molecular mechanisms underlying group A streptococcal pathogenesis.
Moonlighting glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH): an evolutionarily conserved plasminogen receptor on mammalian cells.
Myxomavirus serpin alters macrophage function and prevents diffuse alveolar hemorrhage in pristane-induced lupus.
Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen.
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort.
Nonfibrinolytic functions of plasminogen.
Oligosaccharide processing in the expression of human plasminogen cDNA by lepidopteran insect (Spodoptera frugiperda) cells.
Parasitism in optima forma: Exploiting the host fibrinolytic system for invasion.
Plasmin activity in the porcine airways is enhanced during experimental infection with Mycoplasma hyopneumoniae, is positively correlated with proinflammatory cytokine levels and is ameliorated by vaccination.
Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated Neutrophil Killing.
Plasmin, Immunity, and Surgical Site Infection.
Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.
Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection.
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Plasmodium berghei: pulmonary oedema and changes in clotting and fibrinolysis during infection in mice.
Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments.
Preventing Candida albicans from subverting host plasminogen for invasive infection treatment.
Production of outer membrane vesicles by the plague pathogen Yersinia pestis.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality.
Role of plasminogen in propagation of scrapie.
Role of secreted glyceraldehyde-3-phosphate dehydrogenase in the infection mechanism of enterohemorrhagic and enteropathogenic Escherichia coli: interaction of the extracellular enzyme with human plasminogen and fibrinogen.
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
Secretion of the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase by the LEE-encoded type III secretion system in enteropathogenic Escherichia coli.
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis.
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms.
Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation.
Structural diversity of streptokinase and activation of human plasminogen.
Subunits of the Pyruvate Dehydrogenase Cluster of Mycoplasma pneumoniae Are Surface-Displayed Proteins that Bind and Activate Human Plasminogen.
Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime.
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke.
Targeting host cell proteases to prevent SARS-CoV-2 invasion.
The Bfp60 surface adhesin is an extracellular matrix and plasminogen protein interacting in Bacteroides fragilis.
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.
The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells.
The interaction between pathogens and the host coagulation system.
The interaction of Streptococcus dysgalactiae with plasmin and plasminogen.
The novel Leptospira interrogans protein Lsa32 is expressed during infection and binds laminin and plasminogen.
The novel leptospiral surface adhesin, Lsa20, binds laminin, human plasminogen and is probably expressed during infection.
The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.
The procoagulant envelope virus surface: contribution to enhanced infection.
The recombinant LIC10508 is a plasma fibronectin, plasminogen, fibrinogen and C4BP-binding protein of Leptospira interrogans.
The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase.
Tranexamic acid modulates the immune response and reduces postsurgical infection rates.
Trigger for group A streptococcal M1T1 invasive disease.
Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice.
[Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo]
[Enolase and parasitic infection].
[Hemostasis in burn patients and treatment with heparin. Relation to prognosis and infection. Pattern of blood levels of prekallikrein, alpha-2-macroglobulin, antithrombin III, plasminogen and alpha-2-antiplasmin]
[Hemostasis in patients with acute leukemia treated with high doses of cytosine-arabinoside: the effect of chemotherapy and infectious complications on hemostasis]
[The results of the measured oral infection of white mice with strains of the causative agent of plague differing in their plasmid profile]
Infertility
Possible role of the plasminogen activation system in human subfertility.
Tissue-type plasminogen activator level is decreased in human seminal plasma with abnormal liquefaction.
[Consequences for labile blood products of leukocyte depletion by whole blood filtration using the Leucoflex LST1 in-line filter. Evaluation of the Leucoflex LST1 filter]
Infertility, Female
[Serum plasminogen levels and timing of ovulation]
Inflammatory Bowel Diseases
Coagulation parameters in inflammatory bowel disease.
D-dimer tests detect both plasmin and neutrophil elastase derived split products.
Inflammatory Bowel Disease: A Gastrointestinal Presentation of Congenital Plasminogen Deficiency.
Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.
Influenza in Birds
Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus.
Neuraminidase-associated plasminogen recruitment enables systemic spread of natural avian Influenza viruses H3N1.
Influenza, Human
Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin.
Assays for functional binding of plasminogen to viral proteins.
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus.
Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.
Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin independent of the viral neuraminidase.
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Proteolytic activation of the 1918 influenza virus hemagglutinin.
Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen.
Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies.
[Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo]
[Role of neuraminidase in pathogenesis of influenza]
Insulin Resistance
Adiponectin levels may help assess the clinical repercussions of obesity irrespective of body mass index.
Cardiovascular issues in hypogonadism and testosterone therapy.
Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Differential gene expression between visceral and subcutaneous fat depots.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women.
[Adipocitokines, adipose tissue and its relationship with immune system cells]
Intervertebral Disc Displacement
[A Japanese family with congenital abnormal plasminogen]
Intestinal Neoplasms
[Clinical study of hemostatic molecular markers expression in patients with cancer.]
Intestinal Obstruction
[Intraperitoneal administration of a solution of fibrinolysin, hydrocortisone and novocaine and its effect on blood coagulability in acute adhesive intestinal obstruction]
Intestinal Volvulus
Molecular cloning of an alpha-enolase from the human filarial parasite Onchocerca volvulus that binds human plasminogen.
Intra-Abdominal Hypertension
Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm.
Intracranial Aneurysm
Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Effect of dietary ? carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E(-/-) mice.
Intracranial Embolism
Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism.
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
[Cerebral embolism after electric depolarization of a patient with cardiac fibrillation treated with fibrinolysin]
Intracranial Hemorrhages
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial.
Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Gender differences in the outcome of interventional cardiac procedures.
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system.
Outcomes in acute ischemic strokes presenting with disabling neurologic deficits without intracranial vascular occlusion.
Pharmacologic and clinical characteristics of thrombolytic agents.
PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Relationship between abnormalities of coagulation and fibrinolysis and postoperative intracranial hemorrhage in head injury.
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Utilization of lysis percentage via thromboelastography for tissue plasminogen activator-induced symptomatic intracranial hemorrhage.
Intracranial Thrombosis
Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism.
Lysis of a Cerebral Thrombus with Fibrinolysin: A Case Report.
Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
[Preliminary study on the effects of coagulation factor XII on fibrinolysis]
[The use of fibrinolysin with heparin in developing cerebral thrombosis]
Invasive Fungal Infections
Plasminogen alleles influence susceptibility to invasive aspergillosis.
Preventing Candida albicans from subverting host plasminogen for invasive infection treatment.
Iridocyclitis
[Use of fibrinolysin in plastic iridocyclitis]
Iron Overload
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Ischemic Stroke
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
?2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.
A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.
A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke.
Advances in ischemic stroke treatment: neuroprotective and combination therapies.
Alpha 1-Antitrypsin Therapy Mitigated Ischemic Stroke Damage in Rats.
An emerging role of mast cells in cerebral ischemia and hemorrhage.
Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency.
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angioedema in Stroke Patients With Thrombolysis.
Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.
Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke.
Benefits of stroke treatment delivered using a mobile stroke unit trial.
Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions.
Clinical neuroprotective drugs for treatment and prevention of stroke.
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
Comparison of Partial (.6 mg/kg) versus Full-Dose (.9 mg/kg) Intravenous Recombinant Tissue Plasminogen Activator Followed by Endovascular Treatment for Acute Ischemic Stroke: A Meta-Analysis.
Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.
Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.
Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Desmoteplase in the treatment of acute ischemic stroke.
Detection of prothrombotic state in ischemic stroke by monitoring plasma molecular markers.
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke: A Matched-Pairs Analysis.
Disparities and Trends in Door-to-Needle Time: The FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities).
Does "time is brain" also mean "time is clot"? Time dependency of tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
Effects of alteplase in the treatment of acute ischemic stroke.
Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment.
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Efficacy of telemedicine for thrombolytic therapy in acute ischemic stroke: a meta-analysis.
Emergency department nurses' perceived barriers and facilitators to caring for stroke patients.
Engineered Micro- and Nanoparticles for Fibrinolysis.
Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis.
Evolution of a US County System for Acute Comprehensive Stroke Care.
Factors and outcomes associated with recanalization timing after thrombolysis.
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
Fibrinolysis: from blood to the brain.
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Hemostatic markers in ischemic stroke of undetermined etiology.
Histopathological Characteristics of IV Recombinant Tissue Plasminogen -Resistant Thrombi in Patients with Acute Ischemic Stroke.
HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator.
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial.
Impact of Participation in a Telestroke Network on Clinical Outcomes.
Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.
Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis.
Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator.
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients.
LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.
LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase.
Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke.
Looking for Our Ten Years Results for Coronary Heart Disease and Ischemic Stroke Group for the Standpoint of Haemostasis.
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Magnetic Resonance Imaging or Computed Tomography Before Treatment in Acute Ischemic Stroke.
Medicine. Stroke--tPA and the clinic.
Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review.
Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice.
Menstrual blood transplantation for ischemic stroke: Therapeutic mechanisms and practical issues.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Neuroprotection by urokinase plasminogen activator in the hippocampus.
Neuroserpin, a neuroprotective factor in focal ischemic stroke.
Neurovascular intervention in the acute phase of cerebral infarction.
Noncoding RNAs in ischemic stroke: time to translate.
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator.
NXY-059: a neuroprotective agent in acute stroke.
Optimized gene synthesis, expression and purification of active salivary plasminogen activator alpha2 (DSPAalpha2) of Desmodus rotundus in Pichia pastoris.
Outcomes Among Patients With Ischemic Stroke Treated With Intravenous tPA (Tissue-Type Plasminogen Activator) via Telemedicine.
Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.
Pharmacologic management of ischemic stroke: relevance to stem cell therapy.
Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples.
Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?
Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis.
Plasminogen activation and thrombolysis for ischemic stroke.
Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches.
Plasminogen activator inhibitor-1 promotes synaptogenesis and protects against A?(1-42)-induced neurotoxicity in primary cultured hippocampal neurons.
Plasminogen Activators and Ischemic Stroke: Conditions for Acute Delivery.
Plasminogen activators in ischemic stroke: introduction.
Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children.
Relationships Between Imaging Assessments and Outcomes in Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke.
Releasable tissue plasminogen activators in ischemic stroke.
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2).
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Role of tissue-type plasminogen activator in ischemic stroke.
Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.
Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
Sex and Race-Ethnic Disparities in Door-to-CT Time in Acute Ischemic Stroke: The Florida Stroke Registry.
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
t-PA, but not desmoteplase, induces a plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions which can be reversed within a limited time frame.
The -7351C/T polymorphism in the TPA Gene and ischemic stroke risk: a meta-analysis.
The Belgian experience with intravenous thrombolysis for acute ischemic stroke.
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015.
The Nrf2 Pathway in Ischemic Stroke: A Review.
The Plasminogen Activation System Promotes Dendritic Spine Recovery and Improvement in Neurological Function After an Ischemic Stroke.
The role of plasminogen activators in stroke treatment: fibrinolysis and beyond.
Therapeutic spectrum of interferon-? in ischemic stroke.
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Thrombolysis with plasmin: implications for stroke treatment.
Thrombolytic therapy for patients who wake-up with stroke.
Thrombolytic therapy of acute ischemic stroke during pregnancy.
Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial.
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Tissue-type plasminogen activator: a historical perspective and personal account.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
Translational initiatives in thrombolytic therapy.
Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.
Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review.
Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant.
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?
[Development and response to intravenous treatment with tissue plasminogen activator with regard to referral hospitals. The experience of a stroke referral unit].
[Evaluation for antithrombotic agents by a thrombotic model in animals].
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
[Intravenous thrombolysis for acute ischemic stroke. A four years? experience in a Chilean public hospital].
[Thrombolytic therapy of ischemic stroke].
Jaw Cysts
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Joint Diseases
Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases.
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.
Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis.
Keloid
Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype.
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts.
Keratitis
A rapid fluorometric assay for tear fluid plasmin activity.
Keratoderma, Palmoplantar
Identification of novel homozygous SLURP1 mutation in a Javanese family with Mal de Meleda.
Kidney Diseases
A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.
Physiology and pathophysiology of the plasminogen system in the kidney.
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Kidney Failure, Chronic
Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis.
Coagulation and fibrinolysis in chronic renal failure. Change in tissue-type plasminogen activator activity.
Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
Factor VIII complex in chronic renal failure: influence of protein C, fibrinolysis and diabetes mellitus.
Increased thrombin and plasmin generation in chronic renal failure.
Kidney Neoplasms
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Laryngeal Neoplasms
[Fibrinase and antifibrinolytic activity of the blood in patients with laryngeal cancer]
[Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Laryngitis
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Leg Ulcer
Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts.
Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration.
Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review).
Local ambulatory treatment of chronic leg ulcers with hyaluronidase, plasminogen, and antibiotics.
Plasminogen activation in venous leg ulcers.
Plasminogen activators, venous leg ulcers and reepithelialization.
The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity.
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes.
[Treatment of leg ulcers with plasmin and antibiotics]
Leishmaniasis
Enolase as a plasminogen binding protein in Leishmania mexicana.
Lens Subluxation
Lens subluxation after plasmin and SF6 injections in rabbit eyes.
Leprosy
Changes in the activity of blood plasmin after administration of 3-pyridyl acetic acid in leprosy patients. Correlation of activity changes with the Mitsuda reaction.
Leukemia
A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface.
Annexin II: a plasminogen-plasminogen activator co-receptor.
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Blood plasminogen (profibrinolysin) levels in patients with leukemia and lymphoma.
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
Fribrinolysis kinetics and its application.
Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V.
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood.
Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro.
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Plasminogen activation on tumor cell surface and its involvement in human leukemia.
Plasminogen activator activity in differentiating leukemia cells.
Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.
Regulation of S100A10 by the PML-RAR-{alpha} oncoprotein.
Sudden death due to undiagnosed acute promyelocytic leukemia: a case report.
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity.
The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF.
[Bleeding complications in acute myeloblastic leukemia (author's transl)]
[Plasminogen activator in leukemic cell homogenate]
Leukemia, Lymphoid
[Proteolytic enzymes in human lymphocytic leukemia cells. I. Activity of dipeptidylaminopeptidase IV, plasminogen activator and cathepsins B and L in cells with different immunologic phenotype]
[T-PA and PAI-1 in lymphocytes of patients with chronic lymphoid leukemia]
Leukemia, Monocytic, Acute
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The secretion of plasminogen activators by human myeloid leukemic cells in vitro.
Leukemia, Myeloid, Acute
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
Changes in plasma levels of protease and fibrinolytic inhibitors induced by treatment in acute myeloid leukemia.
Fribrinolysis kinetics and its application.
Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation.
Leukemia, Promyelocytic, Acute
An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface.
Annexin II: a plasminogen-plasminogen activator co-receptor.
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood.
Sudden death due to undiagnosed acute promyelocytic leukemia: a case report.
Leukocytosis
A mouse model to study the alterations in haemostatic and inflammatory parameters induced by Lonomia achelous caterpillar haemolymph.
Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism.
Linear IgA Bullous Dermatosis
Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97.
Liver Abscess
Hepatic artery thrombosis after adult liver transplantation.
Liver Cirrhosis
Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
Catabolism of human fibrinogen fragment D in normal subjects and patients with liver cirrhosis.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Fibrinolytic Factors in Liver Fibrosis.
Fibrinopeptide A and B beta 15-42 in liver cirrhosis.
Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S.
Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis.
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease.
Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis.
Plasminogen in patients with liver cirrhosis.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Retinoids in liver fibrosis and cancer.
The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
The plasminogen-activating system in hepatic stellate cells.
[Alterations of hemostasis in liver cirrhosis of the dog]
[Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma]
[Description of a new method of plasminogen determination. Its application to the study of liver cirrhosis]
[Plasma serine protease inhibitors in patients with liver cirrhosis]
[The mechanism of plasmin activation in the blood of cases with liver cirrhosis.]
Liver Cirrhosis, Alcoholic
Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage.
Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Plasminogen in patients with liver cirrhosis.
Liver Cirrhosis, Biliary
Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease.
Liver Diseases
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.
Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis.
Circadian rhythms of fibrinogen antithrombin III and plasminogen in chronic liver diseases of increasing severity.
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-beta 1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-beta 1.
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence.
Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis.
Low plasminogen levels and liver disease.
Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group.
Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases.
Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease.
Plasminogen and plasminogen proactivator in liver diseases.
Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.
Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
The alpha2-plasmin inhibitor levels in liver diseases.
The fibrinolytic system in human ascites.
The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo.
The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis.
Thrombin and plasmin generation in patients with liver disease.
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
[Clinical evaluation of measurement of plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen in various liver disease]
[Clinical significance of thrombin-antithrombin III complex and plasmin-alpha 2 plasmin inhibitor complex in chronic liver diseases]
[Potential fibrinolytic activity of the blood in jaundice of parenchymal and mechanical origin]
[Research on the influence of vasculo-tissue factors on coagulation and on fibrinolysis. IX. Liberation of anticoagulants and plasminogen activators induced by venous stasis in subjects with chronic liver diseases]
Liver Diseases, Alcoholic
The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine.
Liver Failure, Acute
Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure.
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure.
Treatment of severe coagulation disturbances as a condition of improved prognosis in fulminant liver failure.
Lung Diseases
Apoprotein-based synthetic surfactants inhibit plasmic cleavage of fibrinogen in vitro.
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells.
Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces.
Plasmin improves oedematous blood-gas barrier by cleaving epithelial sodium channels.
Serum plasminogen and lung surfactant in the respiratory distress syndrome.
The plasminogen activation system in lung disease.
[Evaluation of serum thrombomodulin in patients with interstitial pneumonia]
Lung Diseases, Interstitial
The plasminogen activation system: new targets in lung inflammation and remodeling.
Lung Injury
Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36.
Characterization of low-dose ozone-induced murine acute lung injury.
Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.
Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury.
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung.
Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models.
Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase.
Suppression of superantigen-induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor.
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
Tranexamic acid attenuates oleic-acid-induced pulmonary extravasation.
Lung Neoplasms
Abnormal haemostasis in small cell lung cancer.
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Autoantibodies to plasminogen and their role in tumor diseases.
Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer.
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Modulation of tumor cell motility by plasmin.
Nitrated and oxidized plasma proteins in smokers and lung cancer patients.
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Plasminogen activators and plasmin in lung cancer.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Prognostic significance of blood coagulation tests in lung cancer.
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Serum levels of alpha1-antitrypsin and alpha2-macroglobulin in lung cancer.
Surface ?-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.
The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
The plasminogen activation system and its role in lung cancer. A review.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Urokinase-like plasminogen activators of unusually high molecular weight secreted by a cell line derived from a human lung cancer case.
Lupus Erythematosus, Systemic
Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
Plasminogen activation in plasma of patients with systemic lupus erythematosus.
Risk factors for thrombosis in lupus patients.
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
[Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus]
Lupus Nephritis
?2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses.
Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis.
[The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis]
Lyme Disease
Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi.
Binding of human plasminogen to Borrelia burgdorferi.
Borrelia spirochetes upregulate release and activation of matrix metalloproteinase gelatinase B (MMP-9) and collagenase 1 (MMP-1) in human cells.
Endogenous and Borrowed Proteolytic Activity in the Borrelia.
Plasmin-coated borrelia Burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix.
Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice.
Lymphadenopathy
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
Lymphangioleiomyomatosis
Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor.
Lymphangioma, Cystic
Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections.
[The pathogenesis of chronic subdural hematomas and hydromas in children]
Lymphatic Metastasis
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Plasminogen Activation System in Rectal Adenocarcinoma.
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Lymphoma
A T-cell-related proteinase expressed by T-lymphoma cells activates their endogenous pro-urokinase.
Blood plasminogen (profibrinolysin) levels in patients with leukemia and lymphoma.
Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
Lymphoma, Non-Hodgkin
Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity.
Macrophage Activation Syndrome
Pharmacological targeting of plasmin prevents lethality in a murine model of macrophage activation syndrome.
The multifaceted role of plasminogen in inflammation.
Macular Degeneration
Hemorrhagic age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, gas tamponade, and upright positioning.
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.
Intravitreal Bevacizumab, Plasminogen, and Pneumatic Retinopexy for Subfoveal Hemorrhage in Age-Related Macular Degeneration.
OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND SURGICAL OUTCOMES OF TISSUE PLASMINOGEN ACTIVATOR-ASSISTED VITRECTOMY FOR SUBMACULAR HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Subretinal hemorrhage removal with multiple retinotomy sites in age-related macular degeneration.
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration.
Use of autologous plasmin during vitrectomy for diabetic maculopathy.
Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.
[The intravitreal application of the tissue plasminogen activator in the treatment of submacular hemorrhage--a case report]
[Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)].
Macular Edema
Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema.
Intrasurgical plasmin enzyme in diabetic macular edema.
Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema.
Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated with Branch Retinal Vein Occlusion.
Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion.
Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema.
Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.
Pharmacologic Vitreolysis in Diabetic Retinopathy.
Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.
Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema.
Use of autologous plasmin during vitrectomy for diabetic maculopathy.
[Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema.]
Malaria
Acquisition of human plasminogen facilitates complement evasion by the malaria parasite Plasmodium falciparum.
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Plasminogen activators are not required in the erythrocytic life cycle of malaria parasites.
Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments.
Mastitis
Acute mastitis induces upregulation of expression of plasminogen activator-related genes by blood monocytes and neutrophils in dairy ewes.
Changes in milk protein fraction as affected by subclinical mastitis.
Characterization of hemolytic activity of Staphylococcus aureus strains isolated from bovine mastitic milk.
Development of magnetic nanoparticle based calorimetric assay for the detection of bovine mastitis in cow milk.
E. coli proteolytic activity in milk and casein breakdown.
Effect of frequent milkings on milk NAGase, plasmin, trypsin inhibitory capacity and the quality of whey as the growth medium for mastitis pathogens.
Effect of subclinical mastitis on milk plasminogen and plasmin compared with that on sodium, antitrypsin and N-acetyl-beta-D-glucosaminidase.
Effects of added plasmin on the formation and rheological properties of rennet-induced skim milk gels.
Plasmin and plasminogen in bovine milk: a relationship with involution?
Polymorphonuclear neutrophils and Escherichia coli proteases involved in proteolysis of casein during experimental E. coli mastitis
Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality.
Tailor made plasmin substrates as potential diagnostic tool to test for mastitis.
Mastocytoma
Plasminogen activator production from murine mastocytoma cells. Dissociation of plasminogen activator and histamine production by sodium butyrate.
Measles
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases.
Melanoma
A potential role for the plasmin(ogen) system in the posttranslational cleavage of the neural cell adhesion molecule L1.
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Active transforming growth factor-beta in human melanoma cell lines: no evidence for plasmin-related activation of latent TGF-beta.
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo.
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Binding of tissue-type plasminogen activator to human melanoma cells.
Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators.
Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein.
Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.
Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.
Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix.
Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin.
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.
Immunological characterization of plasminogen activators in human mixed saliva.
In vivo inhibition of angiogenesis by a soluble form of melanotransferrin.
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors.
Kinetic studies of plasminogen activation by epithelial tissue plasminogen activator.
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.
Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model.
Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator.
Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo.
Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain.
Modulation of tumor cell motility by plasmin.
Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Partial purification and characterization of epidermal plasminogen activator and their inhibitor.
Plasmin in pericellular proteolysis and cellular invasion.
Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activators in human malignant melanoma.
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Proteolytic enzymes and plasminogen activator in melanoma.
Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.
Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration.
Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Serine enzymes released by cultured neoplastic cells.
Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface.
Spitz naevi may express components of the plasminogen activation system.
Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion.
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Synthesis and refolding of human tissue-type plasminogen activator in Bacillus subtilis.
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system.
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
The tissue-type plasminogen activator story.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
Melanoma, Experimental
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Melanosis
Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
Laser-assisted delivery of tranexamic acid for melasma: Pilot study using a novel 1927 nm fractional thulium fiber laser.
Meningioma
[A plasminogen regulation system in brain tumors].
Meningitis
Angiostrongylus cantonensis: efficacy of albendazole-dexamethasone co-therapy against infection-induced plasminogen activators and eosinophilic meningitis.
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Enhancement of tissue plasminogen activator-catalyzed plasminogen activation by Escherichia coli S fimbriae associated with neonatal septicaemia and meningitis.
Meningitis, Bacterial
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Meningococcal Infections
Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
Menorrhagia
Antifibrinolytics for heavy menstrual bleeding.
Browplasminin, a condensed tannin with anti-plasmin activity isolated from an aqueous extract of Brownea grandiceps Jacq. flowers.
Induction of endometrial plasminogen activator-inhibitor 1: a possible mechanism contributing to the effect of intrauterine levonorgestrel in the treatment of menorrhagia.
The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid.
Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas.
Tranexamic acid: a review of its use in the management of menorrhagia.
[Changes of peroxidase, plasminogen and fibrinolytic activity on menorrhagia induced by IUDS and the effect of treatment with vitamin E]
Mesenteric Ischemia
Diagnostic value of plasminogen activity level in acute mesenteric ischemia.
Mesothelioma
Expression of plasminogen activator and plasminogen activator inhibitor by rat mesothelioma induced by asbestos.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Metabolic Syndrome
Association of Metabolic Syndrome with Serum Adipokines in Community-Living Elderly Japanese Women: Independent Association with Plasminogen Activator-Inhibitor-1.
Controlled Exposure of Humans with Metabolic Syndrome to Concentrated Ultrafine Ambient Particulate Matter Causes Cardiovascular Effects.
Sex-differences in the impact of metabolic syndrome on tissue plasminogen activator-induced recanalization.
[The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome]
[The markers of dysfunction of endothelium and cytokine profile in patients with metabolic syndrome and abdominal obesity.]
Metabolism, Inborn Errors
Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study.
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Mouth Neoplasms
A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review).
Moyamoya Disease
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Mucocele
Proteolytic enzymes in salivary extravasation mucoceles.
Mucocutaneous Lymph Node Syndrome
Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease.
Mucositis
A controlled, cross-sectional exploratory study on markers for the plasminogen system and inflammation in crevicular fluid samples from healthy, mucositis and peri-implantitis sites.
Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.
Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.
Multiple Myeloma
Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.
The role of plasmin in the pathogenesis of murine multiple myeloma.
Multiple Sclerosis
Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.
Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro.
Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis.
Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice.
Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases.
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Plasminogen in cerebrospinal fluid originates from circulating blood.
Validation of semaphorin 7A and ala-?-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.
[The kinin and plasmin systems of the blood serum and cerebro- spinal fluid in patients with multiple sclerosis and schizophrenia]
Mumps
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Muscular Diseases
The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1).
Muscular Dystrophies
Plasma plasmin inhibitors in Duchenne-type progressive muscular dystrophy.
Muscular Dystrophy, Duchenne
Alpha-enolase plasminogen receptor in myogenesis.
Plasma plasmin inhibitors in Duchenne-type progressive muscular dystrophy.
Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis.
Musculoskeletal Diseases
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Myocardial Infarction
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
A placebo-controlled patency study of intravenous anisoylated plasminogen streptokinase activator complex 30U in acute myocardial infarction.
A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.
A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis.
A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase.
Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease.
Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading.
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries.
Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Acute myocardial infarction: is streptokinase really as effective as tissue plasminogen activator?
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.
AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
An evaluation of fibrinolysin therapy in acute myocardial infarction.
An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma.
Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study.
Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Anti-clotting drugs best in afternoon.
Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome.
Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction.
Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model.
Antiplatelet and anticoagulant therapy during coronary thrombolysis.
Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction.
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Biotechnological production of recombinant tissue plasminogen activator protein (reteplase) from transplastomic tobacco cell cultures.
Cardiac tamponade early after thrombolysis for acute myocardial infarction: a rare but not reported hemorrhagic complication.
Characterization of plasmin-induced platelet aggregation.
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.
Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).
Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction.
Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Comparison in acute myocardial infarction of anisoylated plasminogen streptokinase activator complex versus heparin evaluated by simultaneous thallium-201/technetium-99m pyrophosphate tomography.
Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
Comparison of results of intravenous infusion of anistreplase versus streptokinase in acute myocardial infarction.
Comparison of the safety and tolerance of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction.
Coronary artery disease, myocardial infarction, and brain embolism.
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction.
Current issues concerning thrombolytic therapy for acute myocardial infarction.
Dependence of assessment of coronary artery reperfusion during acute myocardial infarction on angiographic criteria and interobserver variability.
Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction.
Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI).
Design of novel thrombolytic agents via domain modifications.
Discrepant changes in plasminogen by two different assays in patients receiving streptokinase.
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group.
Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group.
Effect of post-solubilization conditions on the yield and efficiency of recombinant streptokinase purification at large-scale.
Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction.
Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/non-ST-segment elevation myocardial infarction patients.
Effects of intravenous SM-9527 (double-chain tissue plasminogen activator) on left ventricular function in the chronic stage of acute myocardial infarction.
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.
Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators.
Electrocardiogram during experimental coronary thrombolysis.
Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results.
Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties.
Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
Fibrinolytic and plasmin inhibitor activities in patients with acute myocardial infarction.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries.
Histidine-rich glycoprotein in thrombolytic therapy: has it clinical relevance?
Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs.
Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)
Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke.
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene.
Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
Intracoronary thrombolysis in acute myocardial infarction.
Intracoronary thrombolysis in evolving myocardial infarction.
Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings.
Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?
Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.
Intravenous thrombolytic treatment for acute myocardial infarction. Effects of early intervention and early examination.
Left ventricular function after anisoylated plasminogen streptokinase activator complex.
Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction.
Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction.
Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase: no prediction of efficacy but inverse correlation with plasminogen activation in non-patency.
Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group.
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Monitoring of Functional Plasminogen in Blood of Patients Receiving Fibrinolytics.
Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase.
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
New developments in thrombolytic therapy.
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Overview: rationale of thrombolysis in treating acute myocardial infarction.
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.
Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
Pharmacology of thrombolytic drugs.
Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII.
Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart.
Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
Prehospital administration of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Production and purification of urokinase: a comprehensive review.
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Prolonged low-dose thrombolytic therapy: a novel adjunctive strategy in the management of an infected right atrial thrombus.
Properties of molecular variants of tissue-type plasminogen activator.
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.
Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction.
Rash after treatment with anistreplase.
Recombinant tissue plasminogen activator: a brief review.
Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition.
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Regulation of nonproteolytic active site formation in plasminogen.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex.
Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction.
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator.
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction.
ST-segment analysis: a useful marker for reperfusion after thrombolysis with APSAC? The Belgian EMS Study Group.
Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.
Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
Tenecteplase (TNK tissue plasminogen activator): A new fibrinolytic for the acute treatment of myocardial infarction.
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model.
The APSAC interventional mortality study (AIMS) trial: mortality data.
The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage.
The fibrinolytic system and use of fibrinolysin in myocardial infarction; preliminary report.
The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.
The safety of anistreplase from the placebo-controlled AIMS study (anistreplase Intervention Mortality Study). The AIMS Study Group.
The safety of automatic versus manual blood pressure cuffs for patients receiving thrombolytic therapy.
The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
The thrombolytic paradox.
The tissue-type plasminogen activator story.
Thermal stability of the three domains of streptokinase studied by circular dichroism and nuclear magnetic resonance.
Third generation plasminogen activators in the treatment of acute myocardial infarction.
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thrombolysin therapy in myocardial infarction.
Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators.
Thrombolytic agents--an overview.
Thrombolytic therapy and acute aortic dissection.
Thrombolytic therapy in acute coronary thrombosis.
Thrombolytic therapy in acute myocardial infarction in the elderly.
Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.
Tissue-type plasminogen activator: a historical perspective and personal account.
Tissue-type plasminogen activator: characteristics, applications and production technology.
Translational initiatives in thrombolytic therapy.
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Efficacy data.
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Tolerance data.
Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
Use of thrombolytic drugs in non-coronary disorders.
Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction.
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Value of electrocardiographic scoring systems for the assessment of thrombolytic therapy in acute myocardial infarction. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator.
Value of fibrinolysin in management of myocardial infarction. A preliminary report.
Value of myocardial defect size measured by thallium-201 SPECT: results of a multicenter trial comparing heparin and a new fibrinolytic agent.
Variability of thrombolytic coronary reperfusion: an angiographic study of streptokinase and anistreplase.
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
[A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study]
[A trial of the use of a new thrombolytic preparation--recombinant tissue-type plasminogen activator--in myocardial infarct patients]
[Actilyse (a recombinant tissue-type plasminogen activator] in the treatment of acute myocardial infarct. Comparison of the effects of Actilyse and streptokinase]
[Alterations of plasma plasminogen and fibrinogen, serum fibrin degradation products and degree of ADP induced platelet aggregation in acute myocardial infarction (author's transl)]
[An echographic study of left ventricular function in acute myocardial infarct undergoing thrombolysis]
[An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context]
[Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin]
[Antithrombogenic properties of the vascular walls and intravascular platelet activation in ischemic heart disease]
[Behavior of tissue plasminogen activators and plasmin inhibitors in experimental myocardial infarct with and without trasylol]
[Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct]
[Changes in fibrinolysis system in patients with acute myocardial infarction in intracoronary administration of fibrinolysin with heparin]
[Changes in the coagulation and anticoagulation systems of blood in myocardial infarct during the process of treatment with anticoagulants and fibrinolysin]
[Clinical features in 65 patients with acute myocardial infarction underwent successful thrombolytic therapy post cardiopulmonary resuscitation]
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]
[Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct]
[Effect of fibrinolysin and heparin on the kinetic properties of the thrombocytes and the oxidation-reduction processes in myocardial infarct]
[Effectiveness of early use of fibrinolysin in acute myocardial infarct under conditions of emergency aid]
[Effects of intravenous administration of nasaruplase, a plasminogen pro-activator, on left ventricular function and systemic hemodynamics in a canine model of acute myocardial infarction]
[Electro-mechanical dissociation concomitant with myocardial reperfusion in the acute phase of myocardial infarction]
[Fibrinolysis or angioplasty in acute myocardial infarction?]
[Fibrinolytic and plasmin inhibitor activities in normal subjects and patients with acute myocardial infarction (author's transl)]
[Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis].
[Formation of left ventricular thrombus in acute myocardial infarction: significance of the determination of fibrinogen, of products of fibrinogen degradation, and of plasminogen]
[Functional disorders of thrombocytes and fibrinase activity in patients with myocardial infarct and chronic coronary insufficiency in the stage of exacerbation]
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
[Interrelation of the blood kallikrein-kinin and anticoagulation systems in experimental myocardial infarct]
[Intracoronary administration of fibrinolysin in acute myocardial infarct]
[Intravenous thrombolytic therapy in acute infarct of the myocardium]
[Ischemic cardiopathy (VIII). Thrombolysis with plasminogen activator in myocardial infarct]
[Plasmin and streptokinase in the treatment of myocardial infarction]
[Plasminogen activators as thrombolytic agents in myocardial infarction]
[Results and limits of fibrin-unspecific thrombolysis in acute myocardial infarct]
[State of the blood coagulation system in patients with myocardial infarct and chest pain and the changes in it during the use of anticoagulants and fibrinolysin]
[Study of new thrombolytic agents in myocardial infarction: a multicenter randomized trial (APSAC versus rt-PA)]
[STUDY OF THE EFFECTIVENESS OF THE USE OF FIBRINOLYSIN IN MYOCARDIAL INFARCT.]
[Study on the influence of vasculo-tissular factors on coagulation and fibrinolysis. X. Release of anticoagulants and plasminogen activators after induced venous stasis and behavior of the coagulative-fibrinolytic system in subjects with recent myocardial infarct]
[The effect of fibrinolysin and streptokinase preparations on the course and prognosis of acute myocardial infarction]
[The effect of fibrinolysin with heparin and thrombolytin on blood coagulation indices in myocardial infarct patients with thromboembolic complications]
[The fibrinolysis system in recurrent myocardial infarction]
[Various problems in the therapy of myocardial infarcts with fibrinolysin and heparin]
Myocardial Ischemia
Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency.
The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair Urokinase attenuates ventricular remodeling.
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
[Effect of agents used in the therapy of acute ischemic heart disease on the histomorphological changes in the myocardium in acute dystrophy]
[Gender differences in the state of the system of hemostasis in patients with ischemic heart disease]
[Lipoprotein (a) and plasminogen in atherosclerosis]
Myocarditis
[Fermental (plasmin) blood system in patients with acute viral myocarditis]
Myoma
The relationship between urokinase plasminogen activator/plasminogen activator inhibitor type-1 expression in myoma/myometrium and mechanism of uterine artery occlusion by laparoscopy for uterine myoma treatment.
Myopia
The plasminogen protein is associated with high myopia as revealed by the iTRAQ-based proteomic analysis of the aqueous humor.
Myotonic Dystrophy
Assay of pig growth hormone preparations for metabolic activities in the rat and in man.
Myxoma
Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.
Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis.
Nasal Polyps
Plasminogen activators in human nasal polyps and mucosa.
Neoplasm Metastasis
4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.
A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin.
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.
Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target.
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase.
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
Annexin A2 expression during cellular differentiation in myeloid cell lines.
Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells.
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Anticoagulants and cancer. A review.
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Bacterial metastasis: the host plasminogen system in bacterial invasion.
Bacterial plasminogen activators and receptors.
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Cancer invasion and metastasis: changing views.
Cancer metastasis: biological and clinical aspects.
Cancer therapy targeting the fibrinolytic system.
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Cellular mechanisms regulating non-haemostatic plasmin generation.
Characterization of the cellular binding site for the urinary trypsin inhibitor.
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases.
Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck.
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.
Correlation of fibrinolytic activity with invasion and metastasis of R3230 AC rat mammary carcinoma cell lines.
Correlation of tissue and blood plasminogen activation system in breast cancer.
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Decrease in pulmonary metastases: potentiation of nitrogen mustard effect by heparin and fibrinolysin.
Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells.
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies.
Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats.
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Exploitation of plasmin(ogen) by bacterial pathogens of veterinary significance.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.
Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation.
Expression of Tissue Factor Pathway Inhibitor 2 in Human Pancreatic Carcinoma and its Effect on Tumor Growth, Invasion, and Migration in vitro and in vivo.
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer.
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Gender affects skin wound healing in plasminogen deficient mice.
Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Global secretome analysis identifies novel mediators of bone metastasis.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Guanidinobenzoatase and UPA in high-grade human astrocytomas and after xenografting cell suspensions into the rat cerebral cortex: proteases for metastasis and disease progression.
HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN.
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation.
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.
Hormonal regulation of plasminogen activator in rat hepatoma cells.
Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Influence of urokinase on cell proliferation and invasion.
Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis.
Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Limited proteolysis of angiogenin by elastase is regulated by plasminogen.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo.
Met-HGF/SF: tumorigenesis, invasion and metastasis.
Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation.
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Modulation of Ion Channels and Receptors by p11 (S100A10).
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Molecular mechanisms of protease-mediated tumor invasiveness.
Molecular pattern of ductal pancreatic cancer.
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
New Insight on the Role of Plasminogen Receptor in Cancer Progression.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activation: biochemistry, physiology, and therapeutics.
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Plasminogen binding and cancer: promises and pitfalls.
Plasminogen receptors: the sine qua non of cell surface plasminogen activation.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Posttranscriptional regulation of PAI-1 gene expression.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking.
Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders.
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis.
Regulation of plasminogen receptors.
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor.
Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Serpins shield tumor cells from antimetastatic brain defenses.
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Spitz naevi may express components of the plasminogen activation system.
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
The accumulation of angiostatin-like fragments in human prostate carcinoma.
The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.
The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
The elastase-mediated pathway of fibrinolysis.
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
The mechanism of action of angiostatin: can you teach an old dog new tricks?
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
The Multifaceted Role of Plasminogen in Cancer.
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
The plasminogen activation system in tumor growth, invasion, and metastasis.
The plasminogen activation system in tumour invasion and metastasis.
The plasminogen activator inhibitor "paradox" in cancer.
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
The role of plasminogen activators in metastasis.
The role of the plasminogen activation system in angiogenesis and metastasis.
The role of the plasminogen activation system in cancer.
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
The urokinase plasminogen activator system: a target for anti-cancer therapy.
The urokinase receptor as an entertainer of signal transduction.
The urokinase-type plasminogen activator system in cancer metastasis: a review.
The urokinase-type plasminogen activator system in prostate cancer metastasis.
Three are better than one: plasminogen receptors as cancer theranostic targets.
Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.
TRAUMA AS A CAUSE OF LOCALIZATION OF BLOOD-BORNE METASTASES: PREVENTIVE EFFECT OF HEPARIN AND FIBRINOLYSIN.
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Type-1 plasminogen activator inhibitor in human breast carcinomas.
u-PA expression in benign, borderline and malignant ovarian tumors.
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Urokinase-dependent cell surface proteolysis and cancer.
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis.
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
[Determination of plasminogen activator of the head and neck tumor tissue]
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]
[Role of PAI-1 in gynaecological malignancies]
[Role of plasminogen activators in the development of tumors and the process of their metastasis]
[Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases]
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
Neoplasm Micrometastasis
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Neoplasm, Residual
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Neoplasms
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.
A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
A clinical study on the use of a fluorogenic substrate assay of plasminogen.
A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas.
A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin.
A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines.
A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
A mediator of cell surface-specific plasmin generation.
A Multiscale Mathematical Model of Tumour Invasive Growth.
A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors.
A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice.
A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells.
A novel mode of intervention with serine protease activity: targeting zymogen activation.
A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number.
A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer.
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
A plasmin-derived hexapeptide from the carboxyl end of osteocalcin counteracts oxytocin-mediated growth inhibition [corrected] of osteosarcoma cells.
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.
A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.
A site for direct integrin ?v?6·uPAR interaction from structural modelling and docking.
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Acetylcholine receptor: effects of proteolysis on receptor metabolism.
Action of antibodies and plasmin on Ehrlich ascites tumour cells.
Action of heparin and plasminogen inhibitor (EACA) on metastatic tumour spread in an isologous system.
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.
Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth.
Alpha 2-macroglobulin in the regulation of pericellular plasminogen activation of human tumor cells.
Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ?133p53? mimic.
Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target.
Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer.
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology.
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, suppresses tumor growth in mice via impeding both angiogenesis and vascular permeability.
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Angiostatic activity of human plasminogen fragments is highly dependent on glycosylation.
Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.
Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
Angiostatin fragments in urine from patients with malignant disease.
Angiostatin generation by human tumor cell lines: involvement of plasminogen activators.
Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase.
Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease.
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo.
Annexin A2 promotes glioma cell invasion and tumor progression.
Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells.
Annexin II: a plasminogen-plasminogen activator co-receptor.
Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model.
Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro.
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action.
Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.
Anticoagulants and cancer. A review.
Antifibrinolytic therapy of experimentally grown malignant brain tumors.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.
ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer.
Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study.
Assessment of plasminogen synthesis in vitro by mouse tumor cells using a competition radioimmunoassay for mouse plasminogen.
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
Autoantibodies to plasminogen and their role in tumor diseases.
Baculovirus vector-mediated transfer of sodium iodide symporter and plasminogen kringle 5 genes for tumor radioiodide therapy.
Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases.
Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Biological regulation through protein disulfide bond cleavage.
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87).
Bradykinin and nitric oxide in infectious disease and cancer.
Brain tumors and plasmin inhibitors.
Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential.
Cancer invasion and metastasis: changing views.
Cancer metastasis: biological and clinical aspects.
Cancer therapy targeting the fibrinolytic system.
Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.
Cancer-associated stroke: Pathophysiology, detection and management (Review).
Causes of venous thrombosis in fifty Chinese patients.
Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.
Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.
Cell surface remodeling by plasmin: a new function for an old enzyme.
Cell surface-dependent generation of angiostatin4.5.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Cellular mechanisms regulating non-haemostatic plasmin generation.
Cellular receptors in the regulation of plasmin generation.
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli.
Characterization of a family of high-molecular-weight plasminogen activators secreted by a lung tumor cell line.
Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation.
Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators.
Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18.
Characterization of the cellular binding site for the urinary trypsin inhibitor.
Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin: implications for the inhibition of plasmin in extracellular matrix microenvironments.
Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Circulating plasminogen activator inhibitor-1 activity: a biomarker for resectable non-small cell lung cancer?
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck.
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Clinical trials with anticoagulant and antiplatelet therapies.
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy.
Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.
Combined effects of angiostatin and ionizing radiation in antitumour therapy.
Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Combined use of haemostatic system indices for evaluation of upper respiratory tract cancer progression.
Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
Comparative localization of receptors for plasmin and for urokinase on MCF 7 cells.
Comparative proteomic analysis reveals cytotoxicity induced by graphene oxide exposure in A549 cells.
Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1 beta through similar signal transduction pathways.
Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model.
Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth?
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression.
Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.
Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Correlation of tissue and blood plasminogen activation system in breast cancer.
Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases.
Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture.
Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein.
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
Decreased expression of the low-density lipoprotein receptor-related protein-1 (LRP-1) in rats with prostate cancer.
Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells.
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Demonstration of fibrin in early stages of experimental metastases.
Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Development of Recombinant Adeno-Associated Virus Serotype 2/8 Carrying Kringle Domains of Human Plasminogen for Sustained Expression and Cancer Therapy.
Diagnosis of primary hyperfibrinolysis and in vitro investigation of the inhibitory effects of tranexamic acid in a group of dogs with sarcomas - A pilot study.
Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis.
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence.
Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.
Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1.
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Differential protease expression by cutaneous squamous and basal cell carcinomas.
Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Differential regulation of collagen degradation by rabbit keratocytes and polymorphonuclear leukocytes.
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium.
Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells.
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Directed migration of murine and human tumor cells to collagenases and other proteases.
DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia.
Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.
Effect of earthworm (G-90) extract on formation and lysis of clots originated from venous blood of dogs with cardiopathies and with malignant tumors.
Effect of fibrinolysin on spread of cancer.
Effect of heparin and plasminogen inhibitor (EACA) in brief and prolonged treatment on intravenously injected tumour cells.
Effect of heparin and plasminogen inhibitor (EACA) on intravenously injected ascites tumour cells.
Effect of human Angiostatin protein on human angiogenesis in vitro.
EFFECT OF PLASMIN THERAPY ON BLOOD COAGULATION AND ON PLASMA PROTEINS IN PATIENTS WITH CANCER.
Effect of retinoic acid on plasminogen activator expression in human melanoma cells.
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium.
Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Effects of the ethyl acetate fraction of Spatholobi caulis on tumour cell aggregation and migration.
Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells.
Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization.
Elevated plasminogen receptor expression occurs as a degradative phase event in cellular apoptosis.
Endogenous peptides from biophysical and biochemical fractionation of serum analyzed by matrix-assisted laser desorption/ionization and electrospray ionization hybrid quadrupole time-of-flight.
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Endothelial cell fibrinolytic assembly.
Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis.
Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity.
ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells.
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol.
Evidence for the clinical use of tumour markers.
Evidence for the functional similarity between tumour cell surface guanidinobenzoatase and tissue type plasminogen activator.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells.
Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Expression of plasminogen activators in basal cell carcinoma.
Expression of the catalytic activity of plasminogen activator under physiologic conditions.
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
Expression of Tissue Factor Pathway Inhibitor 2 in Human Pancreatic Carcinoma and its Effect on Tumor Growth, Invasion, and Migration in vitro and in vivo.
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size.
Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
Factors involved in the plasminogen activation system in human breast tumours.
Fermented goat milk consumption improves cardiovascular health during anemia recovery.
Fibrin and Fibrinolysis in Cancer.
Fibrinogen and tumor cell metastasis.
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Fibrinolytic abnormalities associated with progression of pediatric solid tumors.
Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
From plasminogen to plasmin: role of plasminogen receptors in human cancer.
Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.
Functional evaluation of plasmin formation in primary breast cancer.
Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells.
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Gender affects skin wound healing in plasminogen deficient mice.
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype.
Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells.
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia.
Hemostatic function in cancer patients.
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation.
Hormonal regulation of plasminogen activator in rat hepatoma cells.
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines.
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Human and canine mammary tumors: A role for urokinase plasminogen activator?
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance.
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract.
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Immunologic detection of the cellular receptor for urokinase plasminogen activator.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Immunological analysis of plasminogen activators from normal and transformed hamster cells. Evidence that the plasminogen activators produced by SV40 virus-transformed hamster embryo cells and normal hamster lung cells are antigenically identical.
Impact of apolipoprotein(a) on in vitro angiogenesis.
Importance of viability and attachment to an ascites tumor in the release of plasminogen activator.
In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis.
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Increased expression of alpha-enolase in c-jun transformed rat fibroblasts without increased activation of plasminogen.
Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Increased plasminogen activator inhibition levels in malignancy.
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma.
Influence of Stromal Components on Lung Cancer Carcinogenesis.
Influence of urokinase on cell proliferation and invasion.
Inhibition by bovine endothelial cells of degradation by HT-1080 fibrosarcoma cells of extracellular matrix proteins.
Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.
Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking.
Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5.
Inhibition of plasminogen activators and the growth of cultured human tumour cells.
Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis.
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.
Inhibition of tumor growth by plasminogen-related protein-B.
Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells.
Inhibition of tumor implantation at sites of trauma by plasminogen activators.
Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin).
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Inhibitors of proteases as anticancer drugs.
Inhibitors of the protease domain of urokinase-type plasminogen activator.
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.
Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent.
Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.
Interaction of tissue plasminogen activator inhibitor with cell surface guanidinobenzoatase and urokinase plasminogen activator.
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis.
Investigation of serum proteome alterations in human glioblastoma multiforme.
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Kinin-generating cascade in advanced cancer patients and in vitro study.
Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.
Lactoferrin is a natural inhibitor of plasminogen activation.
Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators.
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities.
Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Limited proteolysis of tumor cells increases their plasmin-binding ability.
Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis.
Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response.
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Maspin inhibits cell migration in the absence of protease inhibitory activity.
Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation.
Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions.
Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors.
Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.
Matrix metalloproteinase-9, -10, and -12, MDM2 and p53 expression in mouse liver during dimethylnitrosamine-induced oxidative stress and genomic injury.
Matrix metalloproteinases generate angiostatin: effects on neovascularization.
Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator.
Mechanisms and pathobiology of ovulation.
Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo.
Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo.
Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment.
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.
Metalloproteinases in tumor progression: the contribution of MMP-9.
Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Micro RNA 146a gene variant / TNF-? / IL-6 / IL-1 ?; A cross-link axis inbetween oxidative stress, endothelial dysfunction and neuro-inflammation in acute ischemic stroke and chronic schizophrenic patients.
Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate.
Microglial cells prevent nitric oxide-induced neuronal apoptosis in vitro.
Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Modulation of Ion Channels and Receptors by p11 (S100A10).
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Modulation of tumor cell motility by plasmin.
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Molecular mechanisms of protease-mediated tumor invasiveness.
Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Mortality and major complications after emergency laparotomy: A pilot study of risk prediction model development by preoperative blood-based immune parameters.
Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
Natural and engineered plasmin inhibitors: applications and design strategies.
New concepts in fibrinolysis and angiogenesis.
New Insight on the Role of Plasminogen Receptor in Cancer Progression.
No association between the 4g/5G polymorphism of the plasminogen activator inhibitor-1 gene promoter and autistic disorder.
Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study.
Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
On the changes of plasmin activity caused by radiation treatment in cancer patients and effects of antiplasmin (ipsilon) administration.
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
On the regulation of the plasminogen activator inhibitor-1 gene expression.
Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management.
Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
p22 is a novel plasminogen fragment with antiangiogenic activity.
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck.
PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Pathways of coagulation/fibrinolysis activation in malignancy.
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo.
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
Physiological mechanisms for metalloproteinase activation.
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors.
Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.
Plasmin cleaves tumor necrosis factor alpha exodomain from sheep follicular endothelium: implication in the ovulatory process.
Plasmin in pericellular proteolysis and cellular invasion.
Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment.
Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion.
Plasmin reduction by phosphoglycerate kinase is a thiol-independent process.
Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX.
Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation.
Plasmin-tumour necrosis factor interaction in the ovulatory process.
Plasmin: Its Role in the Extracellular Processing of Progalanin in Tumor Tissue.
Plasminogen activation and cancer.
Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Plasminogen activation in human acute leukaemias.
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Plasminogen activation in melanocytic neoplasia.
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Plasminogen activation on tumor cell surface and its involvement in human leukemia.
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Plasminogen activation transforms the morphology of quiescent 3T3 cell monolayers and initiates growth.
Plasminogen activation: biochemistry, physiology, and therapeutics.
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH.
Plasminogen activator and plasmin-like activities in experimental rat tumours.
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance.
Plasminogen activator inhibitors in endometrial adenocarcinoma.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium.
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Plasminogen activators (urokinase) mediate neovascularization: possible role in tumor angiogenesis.
Plasminogen activators and cancer.
Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses.
Plasminogen activators and plasmin in lung cancer.
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy.
Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy.
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Plasminogen activators and tiaprofenic acid in inflammation. A preliminary study.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Plasminogen activators as markers of tumor colonization potential.
Plasminogen activators in (pre)malignant conditions of the colorectum.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Plasminogen activators in human colorectal neoplasia: Authors' reply.
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators in ovarian tumours.
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Plasminogen activators, tissue degradation, and cancer.
Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma.
PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS.
Plasminogen and plasminogen proactivator in liver diseases.
Plasminogen binding and cancer: promises and pitfalls.
Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer.
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Plasminogen is a master regulator and a potential drug candidate for the healing of radiation wounds.
Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein.
Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways.
Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78.
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites.
Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development.
Plasminogen receptors: the sine qua non of cell surface plasminogen activation.
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia.
Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
PO-17 - Identification of IgG bound to plasminogen in oncologic diseases.
Polymeric prodrug for release of an antitumoral agent by specific enzymes.
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system.
Posttranscriptional regulation of PAI-1 gene expression.
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.
Preoperative radiotherapy and extracellular matrix remodeling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Pro-invasive stimuli and the interacting protein Hsp70 favour the route of alpha-enolase to the cell surface.
Production of plasminogen activator and plasminogen activator inhibitor by bovine lymphatic endothelial cells: modulation by TNF-alpha.
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Profibrinolytic properties characterize a stably transformed human endothelial cell line.
Prognostic molecular markers in early breast cancer.
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Prognostic role of tumor-associated proteases in colorectal cancer.
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Proteases as prognostic markers in cancer.
Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
Proteases in human tumors.
Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).
Proteolysis of CCN1 by plasmin: functional implications.
Proteolytic and cellular death mechanisms in ovulatory ovarian rupture.
Proteolytic and metastatic activities of clones derived from a methylcholanthrene-induced murine fibrosarcoma.
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.
Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function.
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Purification and identification of a novel and four known serine proteinase inhibitors secreted by human glioblastoma cells.
Purification of the plasmin receptor from human carcinoma cells and comparison to alpha-enolase.
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
Quantification of autoantibodies to plasminogen in plasma of patients with cancer.
Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study.
Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.
Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator.
Receptor for plasmin on human carcinoma cells.
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Regional differences in protein production by human adipose tissue.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance.
Regulation of collagenolysis and cell death by plasmin within the formative stigma of preovulatory ovine follicles.
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.
Regulation of fibrinolysis by S100A10 in vivo.
Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells.
Regulation of matrix metalloproteinases: an overview.
Regulation of plasminogen receptors.
Regulation of S100A10 Gene Expression.
Regulation of the synthesis and secretion of plasminogen activators by endothelial cells.
Regulation of tumor dormancy and role of microenvironment: a mathematical model.
Relationship between circulating plasminogen activators and tumor development in mice.
Relationship between expression of NM23 protein and clinical morphological factors and content of plasminogen activation system components in tumors of patients with gastric cancer.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Release of various molecular forms of plasminogen activators during culture of human ovarian tumours.
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
Revisiting the role of fat mass in the life extension induced by caloric restriction.
Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours.
RhGM-CSF in bone marrow transplantation: experience in pediatric patients.
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
Role of annexin II tetramer in plasminogen activation.
Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix.
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Role of integrins in invasion of endometrial cancer cell lines.
Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo.
Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression.
Role of plasminogen activator-plasmin system in tumor angiogenesis.
Role of plasminogen in matrix breakdown by neoplastic cells.
Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization.
Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
S100A10 Has a Critical Regulatory Function in Mammary Tumor Growth and Metastasis: Insights Using MMTV-PyMT Oncomice and Clinical Patient Sample Analysis.
S100A10 regulates plasminogen-dependent macrophage invasion.
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.
S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor.
Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation.
Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases.
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Sequential dynamics of inflammatory cytokine, angiogenesis inducing factor and matrix degrading enzymes during spontaneous resorption of the herniated disc.
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Serpins shield tumor cells from antimetastatic brain defenses.
Serum amyloid A - A prime candidate for identification of neonatal sepsis.
Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients.
Serum proteomics for gastric cancer.
Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Significance of coagulation and fibrinolysis markers for benign and malignant soft tissue tumors.
Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer.
Simultaneous three color and electronic cell volume analysis with a single UV excitation source.
Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential.
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.
STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.
Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Stromal cell involvement in cancer.
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Studies on the fibrinolysis in tumor bearing mice. IV. Mechanism of ascites retention with special reference to plasmin activity of tumor cell origin.
Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.
Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway.
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion.
Surgical treatment of tumor metastases: general considerations and results.
Synergism among oxidants, proteinases, phospholipases, microbial hemolysins, cationic proteins, and cytokines.
Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.
Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Synthetic urokinase inhibitors as potential antitumor drugs.
Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
Targeting of the ?6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity.
Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer.
TGF-?-mediated regulation of plasminogen activators is human telomerase reverse transcriptase dependent in cancer cells.
The 9E3/CEF4 cytokine: kinetics of secretion, processing by plasmin, and interaction with extracellular matrix.
The accumulation of angiostatin-like fragments in human prostate carcinoma.
The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
The chicken Chemotactic and Angiogenic Factor (cCAF), a CXC chemokine.
The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
The elastase-mediated pathway of fibrinolysis.
The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF.
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.
The fibrinolytic system in experimental prostate tumor.
The fibrinolytic system in human ascites.
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
The Function of ?2-glycoprotein I in Angiogenesis and Its in Vivo Distribution in Tumor Xenografts.
The hemostatic system and angiogenesis in malignancy.
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
The molecular biology of colorectal cancer development and the associated genetic events.
The Multifaceted Role of Plasminogen in Cancer.
The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.
The plasmin system in human colonic tumors: an immunofluorescence study.
The plasminogen activation system and its role in lung cancer. A review.
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
The plasminogen activation system in tumor growth, invasion, and metastasis.
The plasminogen activation system in tumour invasion and metastasis.
The plasminogen activator inhibitor "paradox" in cancer.
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
The plasminogen activator system and cancer.
The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
The plasminogen-activation system in ovarian tumors.
The plasminogen-plasmin system in malignancy.
The procoagulant state of the VX-2 tumor in rabbit lung in vivo--relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor.
The prognostic value of S100A10 expression in cancer.
The protease inhibitor bikunin, a novel anti-metastatic agent.
The relationship of plasminogen activators and oncogenes to tumour invasion.
The relevance of plasminogen activators to neoplastic growth. A review of recent literature.
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
The role of lysosomes in cancer chemotherapy. 3. Influence of plasmin on the lysosomes of tumor cells and on the cytocidal effect of mitomycin-C.
The role of plasminogen in cell-mediated collagen degradation.
The role of plasminogen-plasmin system in cancer.
The role of the fibrinolytic system in corneal angiogenesis.
The role of the plasminogen activation system in cancer.
The secretion of fibrinolysin by cultured rat ovarian tumor cells.
The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
The urokinase plasminogen activator system: a target for anti-cancer therapy.
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
The urokinase receptor as a potential target in cancer therapy.
The urokinase receptor as an entertainer of signal transduction.
The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system.
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
The urokinase-type plasminogen activator system in cancer metastasis: a review.
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Three are better than one: plasminogen receptors as cancer theranostic targets.
Three receptor genes for plasminogen related growth factors in the genome of the puffer fish Fugu rubripes.
Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors.
Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.
Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.
Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate.
Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro.
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors.
Transformation of immortal, non-tumorigenic osteoblast-like human osteosarcoma cells to the tumorigenic phenotype by nickel sulfate.
Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Treatment of cancer patients with infusions of plasmin.
Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis.
Treatment of malignancy by activation of the plasminogen system.
Tumor associated proteases -- prognostic markers of colorectal cancer.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice.
Tumor Necrosis Factor Alpha Modulates the Dynamics of the Plasminogen-Mediated Early Interaction between Bifidobacterium animalis subsp. lactis and Human Enterocytes.
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Tumorigenicity of EJ-ras oncogene transformed NIH 3T3 cells and expression of plasminogen activators.
Tumorigenicity of herpesvirus-transformed cells correlates with production of plasminogen activator.
Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Type-1 plasminogen activator inhibitor in human breast carcinomas.
u-PA expression in benign, borderline and malignant ovarian tumors.
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor.
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
uPAR: a versatile signalling orchestrator.
Update on tumor cell procoagulant factors.
Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha.
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Urokinase and macrophages in tumour angiogenesis.
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors.
Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix.
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes.
Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth.
Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Urokinase-dependent cell surface proteolysis and cancer.
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis.
Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA.
Visualization of the plasmin receptor on sections of human mammary carcinoma cells.
Vitronectin in human breast carcinomas.
Volume 223, Number 2 (1996), in the article "Upregulation of Cell-Surface-Associated Plasminogen Activation in Cultured Keratinocytes by Interleukin-1beta and Tumor Necrosis Factor-alpha," by Michael J. Bechtel, Jeannette Reinartz, Jutta M. Rox, Stefan Inndorf, Birgit M. Schaefer, and Michael D. Kramer, pages 395-404: On page 398
[A plasminogen regulation system in brain tumors].
[Adipose tissue as an endocrine organ].
[Advance in the biology of pancreatic of cancer].
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
[Assessment of variables relative to prethrombotic state after operation in patients with gynecological malignancies]
[Blood coagulation system in oncological patients treated with rubomycin, adriamycin and carminomycin]
[Cell interactions in the extracellular matrix in tumoral invasion in mammary pathology]
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
[Change in endogeous hydrogen sulfide in patients with acute pancreatitis and its relationship to coagulation function].
[Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
[Clinical and etiopathogenetic role of plasminogen and metaloproteinase systems in the tumor growth. Pericellular proteolysis of extracellular matrix and tumor growth].
[Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]
[Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
[Determination of plasminogen activator of the head and neck tumor tissue]
[Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers]
[Effect of large fibrinolysin doses on the degree of hematogenous metastasizing of experimental tumors]
[Endothelial cell proteases and their modulation by platelets]
[Experimental and clinical studies on cancer chemotherapy--enhancement of the cytocidal effect of Mitomycin-C by one of lysosome labilizer, plasmin]
[Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy]
[Hematological disorders in patients with gastric cancer]
[Hemostatic indices of oncological patients with different forms of jaundice]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Laser hyperthermia of tumors with the use of golden nanoparticles under the control of optical coherent tomography and acoustothermometry].
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
[Mechanism of formation of blocking factors and method of antiblocking immunotherapy in malignant tumors]
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]
[Modern prospects for molecular-biochemical methods for evaluating biological "behavior" of breast neoplasms]
[Molecular pathways of pancreatic carcinogenesis]
[New molecular targets in pancreatic cancer]
[New prognostic and predictive factors in advanced colorectal cancer]
[On the changes of plasmin activity caused by radiation treatment in cancer patients and effects of antiplasmin (Ipsilon) administration.]
[Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer]
[Plasminogen activators in malignant tissues and lungs of mice during metastatic spreading and administration of various pharmacological agents]
[Plasminogen activators in tumor tissue]
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
[Preparation and functional study of an adenovirus vector expressing human plasminogen kringle 5 gene]
[Prognostic and predictive factors in breast cancer]
[Protease activities in gastric and colon cancer tissues]
[Proteases and breast carcinoma]
[Regulation of microglial cell function by ATP]
[Role of PAI-1 in gynaecological malignancies]
[Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis]
[Role of plasminogen activator inhibitor type 1 in tumor angiogenesis]
[Role of plasminogen activators in cancer dissemination. Clinical perspectives]
[Role of plasminogen activators in the development of tumors and the process of their metastasis]
[Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases]
[Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor]
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
[Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--inducer of plasminogen activator (IPA) in malignant ascites tumor]
[Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis]
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
[The influence of plasmin on the metastasizing of implanted tumors in the rat]
[The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)]
[The location of components of fibrinolytic system in laryngeal cancer]
[The role of proteases in the growth, invasion and spread of cancer cells]
[The role of proteolytic enzymes in skin neoplasm progression and development of metastasis]
[The role of urokinase type plasminogen activator in invasion of bile duct carcinoma]
[The urokinase-type plasminogen activator system and its role in tumor progression].
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
[Tumor plasminogen activators and their clinical significance]
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
[Urokinase plasminogen activation system and its role in cancer progression]
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Neoplasms, Germ Cell and Embryonal
Evidence for the clinical use of tumour markers.
Nephritis
Identification of an extracellular plasmin binding protein from nephritogenic streptococci.
IgA nephritis associated with plasminogen abnormalities.
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.
Opposing effects of interleukin-1 and transforming growth factor-beta on the regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 expression by human mesangial cells.
Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis.
The occurrence of nephritis plasmin binding protein (SPEB) in the extracellular products of group C nephritogenic Streptococcus zooepidemicus.
Nephrosis
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Nephrotic Syndrome
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.
Association of Plasminuria with Overhydration in Patients with CKD.
Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.
Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome.
Inhibition of fibrinolysis by lipoprotein(a).
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Mechanisms of renal NaCl retention in proteinuric disease.
Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog.
Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
Over- or underfill: not all nephrotic states are created equal.
Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Plasmin and sodium retention in nephrotic syndrome.
Plasmin in nephrotic urine activates the epithelial sodium channel.
Plasminogen activator in nephrotic syndrome.
Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria.
Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome.
Proteinuric diseases with sodium retention: Is plasmin the link?
Regulation of sodium transport by ENaC in the kidney.
Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Use of noninvasive laboratory testing in the prediction of thrombosis in the nephrotic syndrome.
[A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer]
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Nervous System Diseases
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity.
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Nervous System Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neuralgia
Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Neurilemmoma
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Neuritis
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Neuritis, Autoimmune, Experimental
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Neuroblastoma
A multimolecular signaling complex including PrPC and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator.
Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.
Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro.
Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions.
Degradation of fibrin-? amyloid co-aggregate: A novel function attributed to ubiquitin.
Modulation of the proteolytic balance plasminogen activator/plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein.
Regulation of neuronal migration and neuritogenesis by distinct surface proteases. Relative contribution of plasmin and a thrombin-like protease.
Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-beta and retinoic acid.
[Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture]
[Effects of plasminogen, streptokinase and their equimolar complexes with pyruvate kinase on the human neuroblastoma IMR-32 cells]
Neurodegenerative Diseases
An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease.
Beta-amyloidolysis and glutathione in Alzheimer's disease.
Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.
Neuroendocrine Tumors
Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion.
Neurofibroma
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Neurofibromatoses
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiency.
Neuroinflammatory Diseases
Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin.
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.
Hemorrhagic transformation after ischemic stroke in animals and humans.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
The plasminogen activation system in neuroinflammation.
Using antifibrinolytics to tackle neuroinflammation.
Nevus
TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells.
[Histochemical studies of transepidermal elimination of nevus cells in nevus cell nevi of the corium]
[Indicators of plasminogen activation system and growth factors in the tissue of nevi and skin melanoma].
Noonan Syndrome
Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Obesity
Assessing Plasmin Generation in Health and Disease.
Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
In vivo plasminogen deficiency reduces fat accumulation.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.
Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6?months after obesity surgery.
Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model.
Risk Factors for Thrombosis Development in Mexican Patients.
Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity.
Strain- and tissue-dependent induction of plasminogen activator inhibitor-1 gene expression in fasted mice.
The effect of BMI on haemostasis: Implications for thrombosis in women's health.
[Chronic recurrent pulmonary thromboembolism associated with sedentary work]
[Hemostasis profiles in thrombotic disease]
Obesity, Abdominal
Cardiovascular issues in hypogonadism and testosterone therapy.
[The markers of dysfunction of endothelium and cytokine profile in patients with metabolic syndrome and abdominal obesity.]
Obstetric Labor, Premature
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review.
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Oral Manifestations
Hypoplasminogenaemia, gingival swelling and ulceration.
Osteoarthritis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Fibrin dissolution in synovial fluid.
Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis.
Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients.
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis.
Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor.
Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: regulation by dehydroepiandrosterone.
[Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)]
Osteonecrosis
Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor.
Osteoporosis
Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis.
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Osteoporosis, Postmenopausal
??-Antiplasmin is involved in bone loss induced by ovariectomy in mice.
Osteosarcoma
Binding and activation of plasminogen on the surface of osteosarcoma cells.
Humoral hypercalcemia of malignancy.
Induction of morphological transformation, anchorage-independent growth and plasminogen activators in non-tumorigenic human osteosarcoma cells by lead chromate.
Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells.
Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex.
Localization of plasmin activity on osteosarcoma cells: cell surface proteolysis of insulin-like growth factor binding proteins.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine.
The course of fibrinolytic proteins in children with malignant bone tumours.
Otitis Media
Fibrinolytic activity of middle ear fluid in otitis media with effusion.
Spontaneous development of otitis media in plasminogen-deficient mice.
The fibrinolysin system in otitis media with effusion.
Otitis Media with Effusion
Antifibrinolytic activity in middle ear effusion.
Fibrinolytic activity of middle ear fluid in otitis media with effusion.
Plasmin and fibronectin degradation in chronic secretory otitis media.
The fibrinolysin system in otitis media with effusion.
Out-of-Hospital Cardiac Arrest
Relationship Between Severity of Fibrinolysis Based on Rotational Thromboelastometry and Conventional Fibrinolysis Markers.
Ovarian Cysts
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Ovarian Neoplasms
Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer.
Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells.
Evidence for the clinical use of tumour markers.
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
The role of annexin A2 in tumorigenesis and cancer progression.
Overweight
Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Hemostatic status and fibrinolytic response potential at different phases of the menstrual cycle.
Pancreatic Diseases
Plasminogen in pancreatic disease and in pancreatic secretion.
Pancreatic Neoplasms
Generation of multiple angiogenesis inhibitors by human pancreatic cancer.
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Molecular pattern of ductal pancreatic cancer.
Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.
S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.
[Effects of human plasminogen Kringle 5 gene therapy on pancreatic cancer]
Pancreatitis
Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis.
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence.
Experimental pancreatitis and fibrinolysin.
Indirect strong inhibition by acid-stable trypsin-plasmin inhibitor (ASTPI) of the activations of elastase and plasma fibrinolysis in a dog model of acute pancreatitis.
Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis.
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
[Changes in some of the kallikrein-kinin system indices in patients with acute pancreatitis]
[Hemostatic indices of oncological patients with different forms of jaundice]
Pancreatitis, Acute Hemorrhagic
Prevention of hemorrhagic pancreatitis with fibrinolysin or heparin.
Pancreatitis, Acute Necrotizing
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis, Chronic
Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis.
Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer.
Paralysis
Pathogenesis of venous thromboembolism: when the cup runneth over.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Paraproteinemias
Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease.
Parasitemia
A new method for factor VII deficient substrate preparation and coagulation studies in malaria.
Hematological and coagulation studies in malaria.
Parasitic Diseases
Complete Molecular and Immunoprotective Characterization of Babesia microti Enolase.
Parkinson Disease
Proteolytic cleavage of extracellular ?-synuclein by plasmin: implications for Parkinson disease.
Pemphigoid Gestationis
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Pemphigoid, Bullous
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Collagen XVII Processing and Blistering Skin Diseases.
Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid.
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid.
Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
[The autoimmune dermatosis bullous pemphigoid: deposition and activation of plasminogen in affected epidermis]
Pemphigus
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Complement fixation by pemphigus antibody. II. Complement enhanced detachment of epidermal cells.
Complement fixation by pemphigus antibody. III. Altered epidermal cell membrane integrity mediated by pemphigus antibody and complement.
Complement fixation by pemphigus antibody. IV. Enhanced epidermal cell detachment in the absence of human plasminogen.
Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes.
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis.
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Plasmin induces acantholysis in skin organ cultures.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Pemphigus, Benign Familial
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies.
Plasmin induces acantholysis in skin organ cultures.
Peptic Ulcer
Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874.
Peri-Implantitis
A controlled, cross-sectional exploratory study on markers for the plasminogen system and inflammation in crevicular fluid samples from healthy, mucositis and peri-implantitis sites.
Discriminating Microbial Community Structure Between Peri-Implantitis and Periodontitis With Integrated Metagenomic, Metatranscriptomic, and Network Analysis.
Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties.
Pericarditis
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Perinatal Death
Syphilis-associated perinatal and infant mortality in rural Malawi.
Periodontal Diseases
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Destructive membranous periodontal disease (ligneous periodontitis): a case report and 3 years follow-up.
Gingival crevicular fluid plasmin activity in different clinical conditions and after periodontal treatment.
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Ligneous periodontitis and gingival antioxidant status: report of two cases.
Ligneous periodontitis in a child with plasminogen deficiency.
Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature.
Periodontitis associated with plasminogen deficiency: a case report.
Plasmin is essential in preventing periodontitis in mice.
Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets.
Plasminogen activation by fibroblasts from periodontal ligament and gingiva is not directly affected by chemokines in vitro.
Plasminogen activator in human periodontal health and disease.
Periodontal Pocket
Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets.
Periodontitis
A ligneous periodontitis and conjunctival lesions in a patient with plasminogen deficiency.
Acquisition of plasmin activity by Fusobacterium nucleatum subsp. nucleatum and potential contribution to tissue destruction during periodontitis.
Altered functional activity patterns of fibroblasts related to periodontitis by systemic plasminogen deficiency (ligneous periodontitis).
Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples.
Cellular source, activation and inhibition of dental plaque collagenase.
Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis.
Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy.
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level.
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Ligneous periodontitis and Ehlers-Danlos syndrome.
Ligneous periodontitis and gingival antioxidant status: report of two cases.
Ligneous periodontitis in a child with plasminogen deficiency.
Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature.
Pathogenic potential of Tannerella forsythia enolase.
Periodontitis associated with plasminogen deficiency: a case report.
Plasmin is essential in preventing periodontitis in mice.
Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties.
Salivary collagenase. Origin, characteristics and relationship to periodontal health.
The plasminogen activation system in periodontal tissue (Review).
Peripheral Arterial Disease
Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
Hypercoagulability Markers in Patients With Peripheral Arterial Disease: Association to Ankle-brachial Index.
Translational initiatives in thrombolytic therapy.
Peripheral Nerve Injuries
Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury.
Peripheral Vascular Diseases
Inhibition of human plasmin activity using humic acids with arsenic.
[Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension]
Peritonitis
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1.
Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.
Persistent Infection
Glycoproteomic analysis of serum from patients with gastric precancerous lesions.
Plasmin in Parasitic Chronic Infections: Friend or Foe?
The plasminogen activation system in periodontal tissue (Review).
Pharyngitis
Streptococcal fibrinolysin; a study of this substance and its antibody in group A hemolytic streptococcus sore throat.
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Pheochromocytoma
Increased vascular plasminogen activity in patients with pheochromocytoma.
Pituitary ACTH Hypersecretion
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Plague
A Yersinia pestis-specific DNA fragment encodes temperature-dependent coagulase and fibrinolysin-associated phenotypes.
Deletion of Braun lipoprotein and plasminogen activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.
Dissociation of Tissue Destruction and Bacterial Expansion during Bubonic Plague.
Fibrin and fibrinolysis in infection and host defense.
Impact of the Pla protease substrate ?2-antiplasmin on the progression of primary pneumonic plague.
Lack of O-antigen is essential for plasminogen activation by Yersinia pestis and Salmonella enterica.
Mutation in the pla gene of Yersinia pestis alters the course of the plague bacillus-flea (Siphonaptera: Ceratophyllidae) interaction.
Polyphosphate and omptins: novel bacterial procoagulant agents.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins.
Temperature-Induced Changes in the Lipopolysaccharide of Yersinia pestis Affect Plasminogen Activation by the Pla Surface Protease.
[Detection and characterization of the plasmids of the plague microbe which determine the synthesis of pesticin I, fraction I antigen and "mouse" toxin exotoxin]
[Extracellular resistance of Yersinia pestis to phagocytosis]
plasmin deficiency
A functional overlap of plasminogen and MMPs regulates vascularization during placental development.
A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia.
A large deletion in the Plasminogen gene is associated with ligneous membranitis in a Maltese dog.
A lethal phenotype associated with tissue plasminogen deficiency in humans.
A ligneous periodontitis and conjunctival lesions in a patient with plasminogen deficiency.
A novel combined treatment for plasminogen deficiency with lung involvement.
A novel missense mutation in two families with congenital plasminogen deficiency: identification of an Ala675 to Thr675 substitution.
A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension.
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution.
Altered functional activity patterns of fibroblasts related to periodontitis by systemic plasminogen deficiency (ligneous periodontitis).
An international registry of patients with plasminogen deficiency (HISTORY).
Anterior Segment Surgeries Under Topical Fresh Frozen Plasma Treatment in Ligneous Conjunctivitis.
Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
Asymptomatic coinheritance of heterozygous plasminogen deficiency and the factor VLeiden mutation.
Atypical Microglandular Hyperplasia of Endocervix as the Presenting Feature of Plasminogen Deficiency.
Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases.
Calciphylaxis: A Disease of Pannicular Thrombosis.
Causes of venous thrombosis in fifty Chinese patients.
Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report.
Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia.
Cerebral venous thrombosis with plasminogen deficiency.
Characterization of plasminogen variants in healthy subjects and plasminogen mutants in patients with inherited plasminogen deficiency by isoelectric focusing gel electrophoresis.
Clinical disorders of fibrinolysis: a critical review.
Clinical manifestations due to severe plasminogen deficiency: a case report.
Clinical, histopathological, and genetic aspects in one case of ligneous conjunctivitis.
Coagulation disorders in young adults with acute cerebral ischaemia.
Coagulopathies and arterial stroke.
Combined Ala601-Thr-type dysplasminogenaemia and antiphospholipid antibody syndrome in a patient with recurrent thrombosis.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis.
Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome.
Congenital deficiency of plasminogen and its relationship to venous thrombosis.
Congenital heterozygous plasminogen deficiency associated with a severe thrombotic tendency.
Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency.
Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol.
Congenital plasminogen deficiency caused by a Ser572 to Pro mutation.
Congenital plasminogen deficiency with long standing pseudomembranous conjunctival and genital lesions.
Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis.
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models.
Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review.
Destructive membranous periodontal disease (ligneous periodontitis): a case report and 3 years follow-up.
Development and application of global assays of hyper- and hypofibrinolysis.
Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency.
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Dysfunctional fibrinolysis and cerebral venous thrombosis.
Effective treatment of ligneous conjunctivitis with topical plasminogen.
Endoluminal arterial injury in plasminogen-deficient mice.
Extensive fibrin accumulation and accompanying epithelial changes in the pathogenesis of ligneous mucosal disease (ligneous periodontitis).
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks.
Familial occurrence of membranous obstruction of the inferior vena cava: arguments in favor of a congenital etiology.
Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog.
Fibrinase deficiency.
Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice.
Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW- and LMW'-fibrinogen.
Fibrinolysis and the risk of venous and arterial thrombosis.
First Treatment for Plasminogen Deficiency Is Approved.
Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous Conjunctivitis.
Functional overlap between two classes of matrix-degrading proteases in wound healing.
Gender affects skin wound healing in plasminogen deficient mice.
Growth and behavioral development in plasminogen gene-targeted mice.
Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature.
Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds.
Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis.
Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis.
Homozygous type I plasminogen deficiency.
Human homozygous type I plasminogen deficiency and ligneous conjunctivitis.
HUS and atypical HUS.
Hypercoagulable states and lower limb ischemia in young adults.
Hypercoagulable states.
Hypoplasminogenaemia, gingival swelling and ulceration.
Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity.
IgA nephritis associated with plasminogen abnormalities.
Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva.
In vivo plasminogen deficiency reduces fat accumulation.
Increased neurite development and plasminogen activator expression by exposure of human neuroblastoma cells to plasminogen-deficient growth medium.
Induction of bilateral ligneous conjunctivitis with the use of a prosthetic eye.
Inflammatory bowel disease promotes venous thrombosis earlier in life.
Inflammatory Bowel Disease: A Gastrointestinal Presentation of Congenital Plasminogen Deficiency.
Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice.
Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.
Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members.
Isolated familial plasminogen deficiency may not be a risk factor for thrombosis.
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
Laryngeal obstruction in congenital plasminogen deficiency.
Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency.
Ligneous alveolar gingivitis in the absence of plasminogen deficiency.
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
Ligneous Cervicitis in a Woman With Plasminogen Deficiency Associated With an Atypical Form of Microglandular Hyperplasia: A Case Report and Review of Literature.
Ligneous conjunctivitis associated with type I plasminogen deficiency: A rare case.
Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report.
Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency.
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
Ligneous conjunctivitis in plasminogen-deficient mice.
Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog.
Ligneous conjunctivitis with plasminogen deficiency.
Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency.
Ligneous conjunctivitis.
Ligneous conjunctivitis: a local manifestation of a systemic disorder?
Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis.
Ligneous gingivitis secondary to plasminogen deficiency: a multidisciplinary diagnostic challenge.
Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report.
Ligneous periodontitis and Ehlers-Danlos syndrome.
Ligneous periodontitis and gingival antioxidant status: report of two cases.
Ligneous periodontitis in a child with plasminogen deficiency.
Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature.
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Lupus-like anticoagulants and lower extremity arterial occlusive disease.
Management of hydrocephalus in children with plasminogen deficiency.
Management of ligneous conjunctivitis in a child with plasminogen deficiency.
Minor Role of Plasminogen in Complement Activation on Cell Surfaces.
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients.
Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.
Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.
Molecular pathogenesis of type I congenital plasminogen deficiency: expression of recombinant human mutant plasminogens in mammalian cells.
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
Nonsynonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles.
Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review.
Novel plasminogen gene mutations in Turkish patients with type I plasminogen deficiency.
Novel preclinical murine model of trauma-induced elbow stiffness.
Oral and Maxillofacial Pathology Case of the Month. Plasminogen Deficiency (Ligneous Periodontitis).
Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia).
Orthomolecular nutritional therapy for plasminogen deficiency: report of a case that showed positive results.
Otolaryngological manifestations of ligneous conjunctivitis.
Pathophysiology of the plasminogen/plasmin system.
Periodontitis associated with plasminogen deficiency: a case report.
Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Plasma values for u-PA in children.
Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice.
Plasmin deficiency in Alzheimer's disease brains: causal or casual?
Plasmin Deficiency Leads to Fibrin Accumulation and a Compromised Inflammatory Response in the Mouse Brain.
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure.
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis.
Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy.
Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis.
Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.
Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice.
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice.
Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome.
PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE.
Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity.
Plasminogen deficiency leads to impaired lobular reorganization and matrix accumulation after chronic liver injury.
Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver.
Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury.
Plasminogen deficiency.
Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation?
Plasminogen directs the pleiotropic effects of uPA in liver injury and repair.
Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency.
Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis.
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus.
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
Prevention of ligneous conjunctivitis by topical and subconjunctival fresh frozen plasma.
Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.
Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan.
Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice.
Pseudomembranous disease (ligneous inflammation) of the female genital tract, peritoneum, gingiva, and paranasal sinuses associated with plasminogen deficiency.
Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency.
Recurrence of superficial vein thrombosis in patients with varicose veins.
Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report.
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Replacement Therapy with Glu-Plasminogen for the Treatment of Severe Respiratory and Auditory Complications of Congenital Plasminogen Deficiency.
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
Root dentin anomaly and a PLG mutation.
Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis.
Serine proteases, inhibitors and receptors in renal fibrosis.
Severe thrombotic tendency associated with a type I plasminogen deficiency.
Spontaneous versus secondary thrombosis in congenital heterozygous plasminogen deficiency.
Successful treatment of ligneous conjunctivitis with topical fresh frozen plasma in an infant.
Successful treatment of ligneous gingivitis with warfarin.
Symptomatic versus asymptomatic patients in congenital hypoplasminogenemia: a statistical analysis.
Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis.
The fibrinolytic system and thrombotic tendency.
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
The search for new approaches to treating type 1 plasminogen deficiency.
The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice.
The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease.
The ventriculocholecystic shunt: two case reports and a review of the literature.
Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency.
Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency.
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.
Thrombophilia found in patients with moyamoya disease.
Thrombotic manifestations in plasminogen deficiency and in plasminogen abnormalities.
Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds.
Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis.
Transient ischaemic attacks in two sisters with plasminogen deficiency and factor V Leiden.
Treatment of hereditary and acquired thrombophilic disorders.
Treatment of ligneous conjunctivitis with fresh frozen plasm in twin babies.
Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen.
Treatment of plasminogen deficiency patients with fresh frozen plasma.
Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation.
Type I congenital plasminogen deficiency is not a risk factor for thrombosis.
Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type I.
Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiency.
[Clinical diagnosis of thrombosis and blood coagulation tests]
[Congenital plasminogen deficiency in a Japanese family]
[Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature]
[Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)]
[Ligneous conjunctivitis].
[Molecular abnormalities in recurrent thromboembolic disease]
[Molecular biological approach for congenital abnormality of blood coagulation]
[On the demonstration of plasmin deficiency in retracted clots of full blood and on its significance in the lysis with streptokinase]
[Pharmaceutical supply of human plasminogen replacement therapy for the treatment of ligneous conjunctivitis: Logistics for a university hospital].
[Plasminogen deficiencies in 2 Spanish families. Response to the administration of DDAVP]
[Protein-S deficiency in young patients with thrombotic brain infarction]
[Recurrent arterial thromboembolism in hereditary hypoplasminogenaemia]
Pleural Effusion
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.
Fibrinolytic and inflammatory processes in pleural effusions.
The dynamics and clinical significance of alpha 2 plasmin inhibitor-plasmin complex and thrombin-antithrombin complex in postoperative pleural effusion following a pulmonary lobectomy.
Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.
[Assessment of the activity of plasminogen activators in the differential diagnosis of pleural effusion]
[The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion]
Pleurisy
Effect of invertebrate serine proteinase inhibitors on carrageenan-induced pleural exudation and bradykinin release.
Pneumoconiosis
[Blood coagulating system in miners and the effectiveness of the therapeutic use of fibrinolysin with heparin in pneumoconiosis]
Pneumonia
An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
The development of granulomatous pulmonary inflammation in rabbits by aerosol challenge. I. Release of plasminogen activator by alveolar macrophages.
The plasminogen activation system: new targets in lung inflammation and remodeling.
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
[Comparative evaluation of the efficacy of electrophoresis of heparin and heparin combined with fibrinolysin in protracted pneumonias]
[Evaluation of haemostasis and endothelial dysfunction characteristics in patient with community-acquired pneumonia].
Pneumonia, Ventilator-Associated
Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients.
Pneumonia, Viral
[The vascular wall and fibrinolysis--pathologic aspects]
Poliomyelitis
Activator of plasminogen and protease from various cell cultures and present in poliomyelitis vaccine.
Polycystic Ovary Syndrome
Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state.
Polymicrogyria
Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR.
Porphyria, Variegate
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Postpartum Hemorrhage
PATHOPHYSIOLOGY OF PLASMIN SYSTEM. V. PLASMIN SYSTEM AND POSTPARTUM HEMORRHAGE.
TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol.
Postthrombotic Syndrome
[The vascular wall and fibrinolysis--pathologic aspects]
Prader-Willi Syndrome
Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus.
Pre-Eclampsia
Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy.
Coagulation/fibrinolysis disorder in patients with severe preeclampsia.
Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia.
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia.
Influence of pre-eclampsia on concentrations of haemostatic factors in mothers and infants.
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.
Mechanisms of renal NaCl retention in proteinuric disease.
Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
The imbalance of plasminogen activators and inhibitor in preeclampsia.
Urinary fibrinolysis in toxemia of pregnancy.
Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia.
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.
[Plasminogen activator in leukemic cell homogenate]
Pregnancy, Ectopic
Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies.
Pressure Ulcer
Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta1.
Involvement of proteolytic enzymes--plasminogen activators and matrix metalloproteinases--in the pathophysiology of pressure ulcers.
Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers.
Prospective randomized double-blind study of the wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers.
Priapism
FIBRINOLYSIN THERAPY FOR THROMBOSIS OF PRIAPISM.
Priapism: surgical or medical treatment?
Primary Myelofibrosis
Enhanced expression of urokinase activity on U 937 cell line by 1,25-dihydroxyvitamin D3 induction.
Prion Diseases
A novel real-time ultrasonic method for prion protein detection using plasminogen as a capture molecule.
Cellular mechanisms regulating non-haemostatic plasmin generation.
Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner.
The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion.
Progeria
Reduction of unscheduled DNA synthesis and plasminogen activator activity in Hutchinson-Gilford fibroblasts during passaging in vitro: partial correction by interferon-beta.
Prostatic Hyperplasia
Autoantibodies to plasminogen and their role in tumor diseases.
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
[Histochemical studies on the content of plasmin in the normal and hyperplastic prostate (author's transl)]
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor]
Prostatic Neoplasms
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures.
Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer.
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Autoantibodies to plasminogen and their role in tumor diseases.
Bioassay of prostate-specific antigen (PSA) using microcantilevers.
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells.
Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts.
Increased Blood Concentration of IgG Degradation Products in Prostate Cancer.
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.
New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
New circulating biomarkers for prostate cancer.
Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
Prostate Cancer Cell Surface-Associated Keratin 8 and Its Implications for Enhanced Plasmin Activity.
Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate.
Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer.
Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis.
Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Role of coagulation and fibrinolytic system in prostate cancer.
Separation and study of the range of plasminogen isoforms in patients with prostate cancer.
Specific isoforms of plasminogen in patients with prostate cancer.
The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
The fibrinolytic system in experimental prostate tumor.
The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs.
Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells.
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer.
Protein C Deficiency
Causes of venous thrombosis in fifty Chinese patients.
Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb.
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male.
Hypercoagulable states and lower limb ischemia in young adults.
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
Lupus-like anticoagulants and lower extremity arterial occlusive disease.
Prothrombotic risk factors in childhood stroke and venous thrombosis.
[Protein-S deficiency in young patients with thrombotic brain infarction]
Protein Deficiency
Massive acute pulmonary embolism in protein S deficiency--a case report.
[Analyses on activation and regulation of blood coagulation]
[Proteasome degradation of protein C and plasmin inhibitor mutants: molecular mechanism of congenital protein deficiency]
Protein S Deficiency
Causes of venous thrombosis in fifty Chinese patients.
Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb.
Coagulation disorders in young adults with acute cerebral ischaemia.
Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan.
Hypercoagulable states.
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
Lupus-like anticoagulants and lower extremity arterial occlusive disease.
Prothrombotic states in young people with idiopathic stroke. A prospective study.
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.
The surgical implications of primary hypercoagulable states.
Treatment of hereditary and acquired thrombophilic disorders.
[Protein-S deficiency in young patients with thrombotic brain infarction]
protein-glutamine gamma-glutamyltransferase deficiency
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Proteinuria
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients.
Association of Plasminuria with Overhydration in Patients with CKD.
Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
Elevated lipoprotein (a) levels in primary nephrotic syndrome.
Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients.
Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up.
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Over- or underfill: not all nephrotic states are created equal.
Physiology and pathophysiology of the plasminogen system in the kidney.
Plasmin activates epithelial Na+ channels by cleaving the gamma subunit.
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress.
Salt-Sensitive Hypertension in Chronic Kidney Disease: Distal Tubular Mechanisms.
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria.
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Pseudorabies
Expression of three recombinant proteins using baculovirus vectors in 23 insect cell lines.
Psoriasis
A further study on the mechanism of deposition of plasma protein in psoriasis scale.
Composition and mechanism of deposition of the intercellular substance in parakeratotic psoriatic epidermis.
Concepts in psoriasis: psoriasis and the extracellular matrix.
Expression of plasminogen activator enzymes in psoriatic epidermis.
Human skin proteases. Fractionation of psoriasis scale proteases and separation of a plasminogen activator and a histone hydrolysing protease.
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice.
Plasminogen activation in psoriasis.
Reduction in tissue plasmin: a new mechanism of action of narrowband ultraviolet B in psoriasis.
Pulmonary Disease, Chronic Obstructive
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease.
Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.
Moraxella catarrhalis Binds Plasminogen To Evade Host Innate Immunity.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
The plasminogen activation system: new targets in lung inflammation and remodeling.
Pulmonary Edema
Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?
Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report.
Pulmonary Embolism
Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
Clot penetration and retention by plasminogen activators promote fibrinolysis.
COMBINED FIBRINOLYSIN AND ANTICOAGULANT THERAPY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM.
Comparative tolerability profiles of thrombolytic agents. A review.
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis.
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism.
Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila.
Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism.
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).
One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism.
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.
Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded pressure stockings.
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats.
Subacute massive pulmonary embolism treated with plasminogen and streptokinase.
Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature.
The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
The treatment of pulmonary embolism with fibrinolysin.
Thrombin-antithrombin III complexes as an additional diagnostic aid in pulmonary embolism.
THROMBOLYSIN TREATMENT OF PULMONARY EMBOLISM FOLLOWING SURGERY. A REPORT OF TWO CASES.
Thrombolytic agents--an overview.
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Tissue-type plasminogen activator: a historical perspective and personal account.
[Abnormal plasminogen accompanying pulmonary embolism]
[Experimental pulmonary embolisms treated with fibrinolysin and epsilon-aminocaproic acid]
[Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations]
[Fibrinolytic treatment of thrombus of the right atrium causing severe pulmonary embolism]
[Level of tissue plasminogen activator protein in pulmonary artery in acute pulmonary thromboembolism in rabbit]
[Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism]
[Pulmonary thromboembolism accompanied by abnormal plasminogen]
[SUCCESSFUL USE OF FIBRINOLYSIN IN PULMONARY THROMBOEMBOLISM.]
[Thrombolysis in massive pulmonary embolism with moderate doses of plasminogen tissue activator in 2 octagenarians]
[Treatment of pulmonary embolism by fibrinolysin. Experimental research.]
Pulmonary Fibrosis
A novel mechanism of plasmin-induced mitogenesis in fibroblasts.
A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia.
Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis.
The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.
Pulmonary Heart Disease
Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
Pulpitis
Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties.
Purpura
Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis.
Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
Painful purpura: an adverse effect to a thrombolysin.
Rash after treatment with anistreplase.
Purpura, Thrombotic Thrombocytopenic
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa.
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Radicular Cyst
Fibrinolytic activity in cystic lesions of jaw bones.
Immunohistochemical localization of tissue-type plasminogen activator and type I plasminogen activator inhibitor in radicular cysts.
Radiodermatitis
Plasminogen activation is required for the development of radiation-induced dermatitis.
Rectal Neoplasms
[Changes in markers of proliferation, neoangiogenesis and plasminogen activation system in rectal cancer tissue].
Rectal Prolapse
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
Relapsing Fever
Dual binding specificity of a Borrelia hermsii-associated complement regulator-acquiring surface protein for factor H and plasminogen discloses a putative virulence factor of relapsing fever spirochetes.
Endogenous and Borrowed Proteolytic Activity in the Borrelia.
Identification of an antiparallel coiled-coil/loop domain required for ligand binding by the Borrelia hermsii FhbA protein: additional evidence for the role of FhbA in the host-pathogen interaction.
The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.
Renal Insufficiency
Alteration in insulin-like growth factor-binding proteins (IGFBPs) and IGFBP-3 protease activity in serum and urine from acute and chronic renal failure.
Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure.
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
[Effect of hemodialysis on the concentration of beta 2-microglobulin and acute phase proteins in the serum of patients with chronic renal failure]
Renal Insufficiency, Chronic
Impaired fibrinolysis and protein C increase after cadaver kidney transplantation.
Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis.
Reperfusion Injury
Direct induction of complement activation by pharmacologic activation of plasminogen.
Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia-reperfusion injury.
Reduction of post-ischemic lung reperfusion injury by fibrinolytic activity suppression.
Tissue plasminogen activator and plasmin independently decrease human neutrophil activation.
Tissue plasminogen activator-induced reperfusion injury after stroke revisited.
Respiratory Distress Syndrome
Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals.
Fibrinolysis inhibition in acute respiratory distress syndrome.
Plasma plasminogen levels in early respiratory distress syndrome.
Plasminogen did not affect lung function in surfactant-treated preterm lambs.
Serum plasminogen and lung surfactant in the respiratory distress syndrome.
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen.
The fibrinolysin system and its relationship to disease in the newborn.
THE USE OF FIBRINOLYSIN IN THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME.
Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak.
[Fibrinolysis in respiratory distress syndrome. Plasminogen levels in the plasma of premature infants]
Respiratory Insufficiency
[Serum plasminogen and alpha-2-antiplasmin levels in chronic bronchopneumopathology with respiratory insufficiency]
Respiratory Tract Infections
Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen.
Retinal Arterial Macroaneurysm
Management of submacular hemorrhage associated with retinal arterial macroaneurysms.
Retinal Artery Occlusion
Central retinal artery occlusion successfully treated with plasmin.
Retinal Detachment
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
High osmolarity effect of intravitreal plasmin enzyme on rabbit retina.
Secretion of plasminogen activators by cells cultured from subretinal fluid.
Tissue-type plasminogen activator in subretinal fluid.
[Coagulation factors and fibrinolytic system in subretinal liquid in patients with rheumatogenous retinal detachment]
Retinal Diseases
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach.
Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Plasminogen activators promote excitotoxicity-induced retinal damage.
Retinal Neovascularization
Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway.
Inhibition of Pathological Retinal Neovascularization by a Small Peptide Derived from Human Tissue-Type Plasminogen Kringle 2.
Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats.
Retinal Perforations
A new approach to stage 3 macular holes.
Autolytic degradation of ocriplasmin: a complex mechanism unraveled by mutational analysis.
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
Efficacy of autologous plasmin for idiopathic macular hole surgery.
Ocriplasmin for pharmacologic vitreolysis.
Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy.
Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes.
Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
Retinal Vein Occlusion
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
An unusual case of central retinal vein occlusion, treated successfully with intravenous fibrinolysin.
Experimental retinal vein occlusion and treatment with fibrinolysin.
Fibrinolytic treatment of retinal vein thrombosis. The use of Fibrinolysin Human Lyovac (Merck).
Intravitreal functional plasminogen in eyes with branch retinal vein occlusion.
Intravitreal functional plasminogen is elevated in central retinal vein occlusion.
Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated with Branch Retinal Vein Occlusion.
Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion.
Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion.
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion.
The successful treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin.
Therapy of retinal vein occlusion. Use of fibrinolysin and anticoagulants.
[Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina]
[Fibrinolysin (Merck) treatment of retinal vein thrombosis.]
Retinopathy of Prematurity
Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial.
Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity.
Retinoschisis
Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system.
Rhabdomyosarcoma
Serine enzymes released by cultured neoplastic cells.
Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.
Rheumatic Diseases
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions.
Serum inhibitors of elastase, trypsin, and plasmin in chronic rheumatic diseases.
The urokinase-type plasminogen activator system and inflammatory joint diseases.
[BLOOD LEVEL OF PLASMINOGEN IN CHRONIC PROTOTYPIC RHEUMATISM.]
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
Rheumatic Fever
Fibrin dissolution in synovial fluid.
Quantitative studies on the total plasmin and the trypsin inhibitor of human blood serum; variations in the blood concentration of total plasmin and of trypsin inhibitor in streptococcal diseases with special reference to rheumatic fever.
[ON FIBRINOLYSIS IN THE FIELD OF ORTHOPEDIC SURGERY. (2) ON CHANGES IN PLASMIN IN CHRONIC RHEUMATIC FEVER.]
Rubella
Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation.
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Sarcoma
Acetylcholine receptor: effects of proteolysis on receptor metabolism.
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity.
High-level secretion of the four salivary plasminogen activators from the vampire bat Desmodus rotundus by stably transfected baby hamster kidney cells.
Horse v-fes feline sarcoma viral oncogene homologue; pyruvate kinase, muscle type 2; plasminogen; beta spectrin, non-erythrocytic 1; thymidylate synthetase; and microsatellite LEX078 map to 1q14-q15, 1q21, 31q12-q14, 15q22, 8q12-q14, and 14q27, respectively.
Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract.
Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine.
[Studies on the cytolytic action of plasmin on Yoshida ascites sarcoma]
Sarcoma, Avian
An inhibitor of plasminogen activator in rabbit endothelial cells.
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
Plasminogen-independent fibrinolysis by proteases produced by transformed chick embryo fibroblasts.
Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.
The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants.
Sarcoma, Ewing
The course of fibrinolytic proteins in children with malignant bone tumours.
Sarcoma, Yoshida
The cytotoxic effect of plasmin on Yoshida sarcoma cells.
[The cytotoxic effect of plasmin on yoshida sarcoma cells]
Schistosomiasis
A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
Scleroderma, Diffuse
Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS).
Scleroderma, Systemic
Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
Decrease in matrix metalloproteinase?3 activity in systemic sclerosis fibroblasts causes ?2?antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.
Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis.
Scrapie
A novel real-time ultrasonic method for prion protein detection using plasminogen as a capture molecule.
Plasminogen stimulates propagation of protease-resistant prion protein in vitro.
Role of plasminogen in propagation of scrapie.
Seizures
Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis.
Incidence of early poststroke seizures during reperfusion therapies in patients with acute ischemic stroke: An observational prospective study: (TESI study: "Trombolisi/Trombectomia e crisi Epilettiche precoci nello Stroke Ischemico").
Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis.
Plasmin-mediated processing of protein tyrosine phosphatase receptor type Z in the mouse brain.
Propofol treatment modulates neurite extension regulated by immunologically challenged rat primary astrocytes: a possible role of PAI-1.
Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Sepsis
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Actin accelerates plasmin generation by tissue plasminogen activator.
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Binding to carboxypeptidase M mediates protective effects of fibrinopeptide B?15-42.
Changes in fibrinolysis in the intensive care patient.
Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis.
Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis.
Comparison of immunological and functional assays for measurement of soluble fibrin.
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.
Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test.
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.
Evaluation of severity and prognosis in early stages of septicemia by means of chromogenic peptide substrate assays.
Fibrinolysis in disseminated intravascular coagulation.
Fibrinolysis inhibition in acute respiratory distress syndrome.
Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Klebsiella pneumoniae enolase-like membrane protein interacts with human plasminogen.
Management of Pleural Infection.
Mini-plasminogen like molecule in septic patients.
Modulators of coagulation. A critical appraisal of their role in sepsis.
Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Plasminogen activators in inflammation and sepsis.
Plasminogen: an important hemostatic parameter in septic patients.
Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.
Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia): biochemical, pathophysiological and therapeutic aspects.
The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays.
[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
[Approbation of a new test system determining the activity of a plasmin inhibitor in patients with sepsis]
[Effect on hemostasis and thrombogenesis by septic processes especially in childhood]
[Usefulness of plasminogen activating factor in meningococcal sepsis]
Severe Acute Respiratory Syndrome
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Severe Dengue
Peptide Bbeta(15-42) preserves endothelial barrier function in shock.
Sexually Transmitted Diseases
Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies?
Lues maligna.
Syphilis-associated perinatal and infant mortality in rural Malawi.
Shock, Cardiogenic
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy.
Successful surgical management of left ventricular free wall rupture in the course of myocardial infarction.
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
Shock, Septic
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Alterations of plasmin activity, plasminogen levels and activity of antiplasmins during endotoxin shock in dogs.
Changes in plasminogen levels, plasmin activity and activity of antiplasmins during endotoxin shock in dogs.
Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals.
Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.
DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma.
Endotoxin shock in the New Zealand white rabbit. An evaluation of fibrinolysin therapy.
INTRAVASCULAR COAGULATION AND FIBRINOLYSIN THERAPY IN ENDOTOXIN SHOCK.
Neutrophil elastase, thrombin and plasmin in septic shock.
Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
[Characteristics of hemostatic disorders in septic shock in children]
Silicosis
[Changes in the activity of the phagocytosis stimulating centers in the hypothalamus and fibrinolysin in silicosis]
Sinus Thrombosis, Intracranial
Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase.
Sinusitis
Studies on proactivator from the paranasal mucous membrane in chronic sinusitis.
Skin Diseases
Expression and ultrastructural localization of plasmin(ogen) in the terminally differentiated layers of normal human epidermis.
Expression of plasminogen activator enzymes in psoriatic epidermis.
Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97.
Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.
The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
[The autoimmune dermatosis bullous pemphigoid: deposition and activation of plasminogen in affected epidermis]
Skin Neoplasms
Gender affects skin wound healing in plasminogen deficient mice.
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Sleep Apnea, Obstructive
Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism.
The Plasminogen System and Transforming Growth Factor-? in Subjects With Obstructive Sleep Apnea Syndrome: Effects of CPAP Treatment.
Sleep Deprivation
Negative Influence of Insufficient Sleep on Endothelial Vasodilator and Fibrinolytic Function in Hypertensive Adults.
Small Cell Lung Carcinoma
Abnormal haemostasis in small cell lung cancer.
Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis.
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Soft Tissue Injuries
Novel preclinical murine model of trauma-induced elbow stiffness.
Spasm
Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm.
Spinal Cord Injuries
Plasminogen activator promotes recovery following spinal cord injury.
Role of plasminogen activator in spinal cord remodeling after spinal cord injury.
The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-D-aspartate Receptors.
Tissue-type plasminogen activator-primed human iPSC-derived neural progenitor cells promote motor recovery after severe spinal cord injury.
tPA-mediated generation of plasmin is catalyzed by the proteoglycan NG2.
Spondylarthropathies
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Squamous Cell Carcinoma of Head and Neck
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Proteolytic patterns of head and neck squamous cell carcinoma.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
ST Elevation Myocardial Infarction
An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma.
Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Recombinant tissue-type plasminogen activators: "time matters".
Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial.
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Staphylococcal Infections
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Stevens-Johnson Syndrome
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Stillbirth
Syphilis-associated perinatal and infant mortality in rural Malawi.
Stomach Neoplasms
Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology.
Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer.
Immunological analysis of plasminogen activators from cultured human cancer cells.
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78.
Relationship between expression of NM23 protein and clinical morphological factors and content of plasminogen activation system components in tumors of patients with gastric cancer.
The plasminogen activation system and its role in lung cancer. A review.
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
[Protease activities in gastric and colon cancer tissues]
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
[Wound healing, blood coagulation and fibrinolysis during operations involving gastric cancer surgery]
Stomach Ulcer
Gastric fibrinolysis.
Stomatitis
[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]
Strabismus
Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant.
Streptococcal Infections
Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity.
Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis.
In Vivo Tracking of Streptococcal Infections of Subcutaneous Origin in a Murine Model.
Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.
Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.
Stroke
"Hesitating and Puzzling": The Experiences and Decision Process of Acute Ischemic Stroke Patients with Prehospital Delay after the Onset of Symptoms.
16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke.
4.5 Hours. The New Time Window for Tissue Plasminogen Activator in Stroke.
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity.
A step toward understanding the mechanism of action of audit and feedback: a qualitative study of implementation strategies.
Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
Acute endovascular recanalization: lessons from randomized controlled trials.
Advances in ischemic stroke treatment: neuroprotective and combination therapies.
Alpha 1-Antitrypsin Therapy Mitigated Ischemic Stroke Damage in Rats.
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis.
Antithrombotic and thrombolytic therapy for ischemic stroke.
Antithrombotic therapy of acute stroke: thrombolytic agents.
Benefits of stroke treatment delivered using a mobile stroke unit trial.
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Calculated Decisions: tPA (Tissue Plasminogen Activator) Dosing for Stroke Calculator
Can Quality-Adjusted Life-Years and Subgroups Help Us Decide Whether to Treat Late-Arriving Stroke Patients With Tissue Plasminogen Activator?
Catheter-Directed Thrombectomy for Pulmonary Embolism in the Setting of Acute Stroke.
Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions.
Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation.
Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease.
Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats.
Comparison of outcomes of patients with inpatient or outpatient onset ischemic stroke.
Coronary artery disease, myocardial infarction, and brain embolism.
Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Cuprizone-induced demyelination under physiological and post-stroke condition leads to decreased neurogenesis response in adult mouse brain.
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Development of thrombolytic therapy for stroke: a perspective.
Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques.
Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes.
Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke: A Matched-Pairs Analysis.
Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register.
Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke.
Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes: Analysis From the SELECT Study.
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury.
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment.
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.
Emergent Management of Tandem Lesions in Acute Ischemic Stroke.
Enhanced Detection of Edema in Malignant Anterior Circulation Stroke (EDEMA) Score: A Risk Prediction Tool.
Ethnic Differences in 90-Day Poststroke Medication Adherence.
Extracellular proteolytic pathophysiology in the neurovascular unit after stroke.
Fn-EDA (Fibronectin Containing Extra Domain A) in the Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation.
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity.
Functional Outcome Measures of Recombinant Tissue Plasminogen Activator-Treated Stroke Patients in the Telestroke Technology.
Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society.
HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients.
Hemostatic disturbances in acute ischemic stroke: a study of 86 patients.
Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
Human placenta mesenchymal stem cell protection in ischemic stroke is angiotensin converting enzyme-2 and masR receptor-dependent.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator-Treated Patients.
Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial.
Impact of Initial Imaging Protocol on Likelihood of Endovascular Stroke Therapy.
Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time.
Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke.
Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis.
Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis.
Increased Access to and Use of Endovascular Therapy Following Implementation of a 2-Tiered Regional Stroke System.
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators.
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Intraarterial Thrombolysis as Rescue Therapy for Large Vessel Occlusions.
Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow.
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Lack of association between pretreatment neurology consultation and subsequent protocol deviation in tissue plasminogen activator-treated patients with stroke.
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Letter by Katsanos and Tsivgoulis Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Letter by Tan and Xu Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.
Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings.
Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.
Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator).
Medical therapy for ischemic stroke.
Mesenchymal stem cells in the treatment of ischemic stroke: progress and possibilities.
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage and Blood Brain Barrier Disruption After Experimental Stroke.
Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke: editorial commentary on tang et Al., 2013.
Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes.
Molecule of the Month. PDGFR-alpha antagonist Gleevec reduces blood vessel leakage and increases the therapeutic window associated with tissue plasminogen activator stroke treatment.
Mouse model of in situ thromboembolic stroke and reperfusion.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome: External Validation on Safe Implementation of Thrombolysis in Stroke-Monitoring Study Data.
National Practice Patterns of Obtaining Informed Consent for Stroke Thrombolysis.
New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty.
Nurse-Initiated Acute Stroke Care in Emergency Departments.
On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity.
One-Year Home-Time and Mortality After Thrombolysis Compared With Nontreated Patients in a Propensity-Matched Analysis.
Organ damage in shock, disseminated intravascular coagulation, and stroke.
Oxidative stress after thrombolysis-induced reperfusion in human stroke.
Paradoxically accelerated fatal brain herniation following thrombolytic therapy in acute ischemic stroke.
Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples.
Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4.
Plasminogen activation and thrombolysis for ischemic stroke.
Plasminogen and stroke: more is better.
Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice.
Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice.
Poststroke Sonic Hedgehog Agonist Treatment Improves Functional Recovery by Enhancing Neurogenesis and Angiogenesis.
Potentially Missed Diagnosis of Ischemic Stroke in the Emergency Department in the Greater Cincinnati/Northern Kentucky Stroke Study.
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients With Proximal Intracranial Occlusions.
Production and purification of urokinase: a comprehensive review.
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat.
Prothrombotic disorders and ischemic stroke in children.
Puerperium Stroke and Subsequent Tissue-Type Plasminogen Activator-Induced Hemorrhage: A Case Report.
Rates, Characteristics, and Outcomes of Patients Transferred to Specialized Stroke Centers for Advanced Care.
Real-World Treatment Trends in Endovascular Stroke Therapy.
Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Regional Learning Collaboratives Produce Rapid and Sustainable Improvements in Stroke Thrombolysis Times.
Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children.
Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Response by Flint et al to Letter Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia.
Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment.
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Role of fibrinolytic markers in acute stroke.
Role of transcranial Doppler ultrasonography in evaluation of patients with cerebrovascular disease.
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts.
Sequential combination of two intravenous thrombolytics (recombinant tissue plasminogen activator/tenecteplase) in a patient with stroke and cardioembolic basilar artery occlusion.
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Simplified modified Rankin Scale questionnaire correlates with stroke severity.
Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression Is Stroke Mimic.
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
Stroke in a young adult with familial plasminogen disorder.
Strokes and their relationship to hypertension.
Systemic inflammation affects reperfusion following transient cerebral ischaemia.
Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation.
Telemedicine versus face-to-face evaluation in the delivery of thrombolysis for acute ischaemic stroke: a single centre experience.
The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
The Combination of Clinical Features, Transcranial Doppler, and Alberta Stroke Program Early Computed Tomography Score (Computed Tomography Angiography) in Predicting Outcome in Intravenous Recombinant Tissue Plasminogen Activator-Treated Patients.
The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke.
The emerging role of mechanical and topographical factors in the development and treatment of nervous system disorders: dark and light sides of the force.
The evaluation of intracranial pressure evaluation by optic nerve sheath diameter measurement on bedside ultrasonography after ischemic stroke.
The impact of a statewide stroke quality improvement program: Colorado Stroke Alliance and Colorado Stroke Registry.
The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
The Protective Role of Immunomodulators on Tissue-Type Plasminogen Activator-Induced Hemorrhagic Transformation in Experimental Stroke: A Systematic Review and Meta-Analysis.
The role of plasminogen activators in stroke treatment: fibrinolysis and beyond.
Thrombi of different pathologies: implications for diagnosis and treatment.
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Thrombolysis with plasmin: implications for stroke treatment.
Thrombolytic properties of leukocytes from peripheral blood in healthy subjects and in patients with acute cerebral ischemia.
Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients.
Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit.
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.
Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Tissue plasminogen activator-induced reperfusion injury after stroke revisited.
Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke.
Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.
Tissue-type plasminogen activator: characteristics, applications and production technology.
Ultrasound in the treatment of ischaemic stroke.
Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
Update on stroke.
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
Using the behavioral flexibility operant task to detect long-term deficits in rats following middle cerebral artery occlusion.
Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage.
[Blood-brain barrier pathophysiology and ischaemic brain oedema]
[Endovascular thrombectomy for ischemic stroke].
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
[Revising the principles and improving the methods of differential therapy of ischemic stroke]
Stroke, Lacunar
Hemostatic Factors and Subclinical Brain Infarction in a Community-Based Sample: The ARIC Study.
Subarachnoid Hemorrhage
Effect of tissue plasminogen activator on intimal platelet accumulation in cerebral arteries after subarachnoid hemorrhage in cats.
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Modification of experimental post-subarachnoid hemorrhage vasculopathy with intracisternal plasmin.
Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage.
Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems.
Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery.
Using antifibrinolytics to tackle neuroinflammation.
[Correlations among FPB beta 15-42, PAC and D-dimer]
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Superior Vena Cava Syndrome
[Iatrogenic superior vena cava syndrome. Successful thrombolysis with recombinant tissue plasminogen activator (r-tPA)]
Suppuration
[Several components of plasma hemostasis in patients with suppurative processes in the abdominal cavity]
Surgical Wound Infection
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Plasmin, Immunity, and Surgical Site Infection.
Syncope
A Rare Case of Acute Pulmonary Embolism after Coronary Angiography due to Sand Bag Compression.
Synovitis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Collagenase in synovitis of rheumatoid arthritis.
Syphilis
Don't Forget What You Can't See: A Case of Ocular Syphilis.
Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury.
Integration of antenatal syphilis screening in an urban HIV clinic: a feasibility study.
Single Mothers and Female Sex Workers in Zambia Have Similar Risk Profiles.
Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.
Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response.
Syphilis-associated perinatal and infant mortality in rural Malawi.
The Number of Interviews Needed to Yield New Syphilis and Human Immunodeficiency Virus Cases Among Partners of People Diagnosed With Syphilis, North Carolina, 2015.
The resurgence of congenital syphilis: a cocaine-related problem.
Utility of rapid plasmin reagin titres in assessing treatment response and re-infection for infectious syphilis.
Syphilis, Congenital
The resurgence of congenital syphilis: a cocaine-related problem.
t-plasminogen activator deficiency
Blood protein defects associated with thrombosis. Laboratory assessment.
Haematologic disorders and cerebral venous thrombosis.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
Syndromes of hypercoagulability and thrombosis: a review.
The surgical implications of primary hypercoagulable states.
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior.
[Thrombophilic states]
Takotsubo Cardiomyopathy
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Telangiectasis
[A case of Osler-Rendu disease with simultaneous thrombopenia and a factor VIII inhibitor]
Temporomandibular Joint Disorders
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Tetanus
Effect of fragmentation of tetanus immune globulin (human) on neutralization of tetanus toxin.
Possible involvement of plasmin in long-term potentiation of rat hippocampal slices.
Thrombasthenia
Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation.
Plasminogen interacts with human platelets through two distinct mechanisms.
Thromboangiitis Obliterans
Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Thrombocytopenia
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Haemostatic changes during open heart surgery with extracorporeal circulation and deep hypothermia in children.
Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants.
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Occurrence of disseminated intravascular coagulation (DIC) in obstructive jaundice and its relation to biliary tract infection.
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Urokinase receptor (uPAR, CD87) is a platelet receptor important for kinetics and TNF-induced endothelial adhesion in mice.
[A case of Osler-Rendu disease with simultaneous thrombopenia and a factor VIII inhibitor]
[Disorders of hemostasis in dysthyroidism]
[Thrombocyte function and plasma coagulation following poisoning with organophosphates]
Thrombocytosis
POEMS syndrome with vascular lesions and renal carcinoma - possible role of cytokines.
Thromboembolism
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Acute femoral arterial thromboembolism. Successful treatment with fibrinolysin.
Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism.
Congenital deficiency of plasminogen and its relationship to venous thrombosis.
FIBRINOLYSIN TREATMENT OF THROMBOEMBOLISM.
LYSIS OF INTRACEREBRAL THROMBOEMBOLISM WITH FIBRINOLYSIN. REPORT OF A CASE.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Perfusion with fibrinolysin in experimental iliofemoral thromboembolism.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation.
THERAPEUTIC THROMBOLYSIS IN CEREBRAL THROMBOEMBOLISM. DOUBLE-BLIND EVALUATION OF INTRAVENOUS PLASMIN THERAPY IN CAROTID AND MIDDLE CEREBRAL ARTERIAL OCCLUSION.
Thrombolysis with fibrinolysin (plasmin)-new therapeutic approach to thromboembolism.
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
[Fibrinolysin therapy of thromboembolism of the major vessles]
[Healing of a patient with thromboembolism of the bifurcation of the aorta with a mixture of fibrinolysin and heparin]
[Problems of the early diagnosis and treatment of thromboembolism of the pulmonary artery. Results of the use of fibrinolysin]
[Pulmonary thromboembolism accompanied by abnormal plasminogen]
[Treatment of thromboembolism of the aortic bifurcation with fibrinolysin and heparin]
Thrombophilia
"TEG talk": expanding clinical roles for thromboelastography and rotational thromboelastometry.
A case of acute pulmonary embolism associated with dysplasminogenemia.
A protein C and plasminogen compound heterozygous mutation and a compound heterozygote of protein C in two related Chinese families.
Abnormal plasminogen: a genetically determined cause of hypercoagulability.
Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Arterial thrombosis in homozygous antithrombin deficiency.
Blood coagulation studies in domestic pigs (Hanover breed) and minipigs (Goettingen breed).
Calciphylaxis: A Disease of Pannicular Thrombosis.
Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia.
Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia.
Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma.
Disturbances of the coagulating equilibrium of blood in diabetes mellitus.
Effect of endotoxin on clotting mechanism. III. On the relationship between hypercoagulability, plasminogen activator activity, and antithrombin activity.
Enzymatic Functional Assays of Coagulation Using Small Sample Volumes.
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis.
Hemostasis in Overt and Subclinical Hyperthyroidism.
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
Hypercoagulability and thrombosis.
Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery?
Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?
Laboratory screening of inherited thrombotic syndromes.
Late changes in hemostatic parameters following open-heart surgery.
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation.
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group.
Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis.
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan.
Protocol and preliminary results of a clinical study for comparison of solvent/detergent-inactivated plasma VIP versus FFP with special consideration of the balance of hemostasis.
Risk Factors for Thrombosis Development in Mexican Patients.
Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia.
The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome".
Thrombophilia found in patients with moyamoya disease.
Trimester-specific reference intervals of TAT, TM, tPAI-C and PIC for healthy Chinese pregnant women.
[A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer]
[A method for determining plasminogen with a Russian chromogenic substrate and its diagnostic significance]
[Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis]
[Diagnosis and treatment of coagulation disorders]
[Etiological analysis of thrombophilia]
[Evaluating the origin of thrombophilia: indications and implementation]
[Genetic polymorphism and risk of thromboses]
[Immunoradiometric determination of blood/tissue plasminogen activators in thrombophilia]
[Pregnancy and thrombophilia in women with congenital deficit of antithrombin III, protein C, protein S or plasminogen: analysis of 39 cases]
Thrombophlebitis
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Fibrinolysin (plasmin) therapy in acute deep thrombophlebitis. A controlled study.
Fibrinolysin therapy of thrombophlebitis and pulmonary embolism--a double-blind study.
Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism.
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
[Acute thrombophlebitis and its treatment with fibrinolysin and anticoagulants]
[The influence of the intra-tissue electrical phonophoresis on the hemostasis system in the treatment of acute thrombophlebitis and phlebothrombosis]
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
Thrombosis
"Plasminogen steal" and clot lysis.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
99mTc-plasmin test in deep vein thrombosis of the leg.
A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.
A clinical approach in regression of glomerulosclerosis.
A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.
A lethal phenotype associated with tissue plasminogen deficiency in humans.
A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma.
A multi-modal approach to the management of bypass graft failure.
A new treatment for traumatic shock and ARDS.
A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.
A plasminogen-related gene is expressed in cancer cells.
A potential basis for the thrombotic risks associated with lipoprotein(a).
A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators.
A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis.
A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.
Abnormal plasminogen, a case of recurrent thrombosis.
Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis.
Abnormal plasminogen: a genetically determined cause of hypercoagulability.
Abnormalities of the fibrinolytic system as a cause of upper extremity ischemia: a preliminary report.
Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase.
Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Activity of coagulation and fibrinolytic system components in the vein thrombus.
Acute arterial thrombosis associated with inadvertent high dose of tranexamic acid.
Acute deep vein thrombosis treated with porcine plasmin. A double blind trial.
Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis.
Alfimeprase: a novel recombinant direct-acting fibrinolytic.
Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal.
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia.
An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm.
Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Annexin A2 autoantibodies in thrombosis and autoimmune diseases.
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Antithrombotic effects of odorless garlic powder both in vitro and in vivo.
Antithrombotic therapy of acute stroke: thrombolytic agents.
Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen.
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review.
Arterial expression of the plasminogen activator system early after cardiac transplantation.
Assembly of plasmin-generating proteins on the surface of human endothelial cells.
Assessment of antithrombotic properties of sodium ibuprofen.
Association of inherited dysfibrinogenaemia and protein C deficiency in two unrelated families.
Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
Bafibrinase: A non-toxic, non-hemorrhagic, direct-acting fibrinolytic serine protease from Bacillus sp. strain AS-S20-I exhibits in vivo anticoagulant activity and thrombolytic potency.
Biological control of tissue plasminogen activator-mediated fibrinolysis.
Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface.
Capturing host plasmin(ogen): a common mechanism for invasive pathogens?
Causes of venous thrombosis in fifty Chinese patients.
Central venous line thrombosis in premature infants: a case management and literature review.
Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study.
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.
Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors.
Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation.
Clinical disorders of fibrinolysis: a critical review.
Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series.
Clone, expression and plasminogen binding property of three fructose-1,6-bisphosphate aldolases from Clonorchis sinensis.
Cloning and characterization of a plasminogen-binding surface-associated enolase from Schistosoma bovis.
Clot accumulation characteristics of plasminogen-bearing liposomes in a flow-system. Groningen Utrecht Institute for Drug Exploration.
Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.
Coagulative and fibrinolytic activity in parietal thrombus of aortic aneurysm.
Coagulopathies and arterial stroke.
Coevolutionary patterns in plasminogen activation.
Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
Combined Ala601-Thr-type dysplasminogenaemia and antiphospholipid antibody syndrome in a patient with recurrent thrombosis.
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli.
Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis.
Comparative anticoagulant effects of coumadin, heparin, and fibrinolysin on direct-current thrombosis of rat mesoappendix vessels.
Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison between 99Tcm-porcine plasmin and 99Tcm-labelled erythrocytes in diagnosis of deep vein thrombosis.
Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.
Comparison of plasma total plasmin activities in male and female hypertensive rats.
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age.
Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity.
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Construction and biological activities of human tPA eukaryotic expression plasmid.
Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Coronary arterial and other intravascular thromboses treated with fibrinolysin. Experimental and clinical results.
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.
Current concepts in coronary thrombolysis.
Current Trends on Glomerulosclerosis Regression.
Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Delivery system for targeted thrombolysis without the risk of hemorrhage.
Demonstration of 99mTc-labelled plasmin on the surface of ex vivo thrombi.
Design of novel thrombolytic agents via domain modifications.
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
Detection and treatment of intravascular thrombi with magnetofluorescent nanoparticles.
Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis.
Determinants of fibrin formation, structure, and function.
Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis.
Development of an immunoaffinity method for purification of streptokinase.
Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion.
Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots.
Dimerized plasmin fragment D as a potential biomarker to predict successful catheter-directed thrombolysis therapy in acute deep vein thrombosis.
Disequilibrium of Blood Coagulation and Fibrinolytic System in Patients With Coronary Artery Ectasia.
Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery.
Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Drug treatment of acute ischemic stroke.
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction.
Echocardiographic assessment of right atrial thrombus related to the implanted port device in patient receiving chemotherapy for non-Hodgkin's lymphoma.
Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.
Effect of anti plasminogen monoclonal antibodies on whole blood clot lysis.
Effect of mutalysin II on vascular recanalization after thrombosis induction in the ear of the hairless mice model.
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo.
Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis.
Effect of volume expanders on the lysability of ex vivo thrombi in the rabbit.
Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease.
Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.
Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis.
Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.
Effects of heparin, plasmin, dextran and low-molecular-weight dextran on electrically induced thromboses.
Effects of heparin, plasmin, dextran, and low molecular dextran on bioelectrically induced thromboses.
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Effects of lipids on thrombotic mechanisms in atherosclerosis.
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Effects of lipoprotein(a) on thrombolysis.
Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Effects of plasmin on rabbit platelets.
Effects of statins in reducing thrombotic risk and modulating plaque vulnerability.
Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Electron microscopic study on the outer membrane of chronic subdural hematoma.
Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina.
Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.
Endothelial cell injury induced by plasmin in vitro.
Engineered Micro- and Nanoparticles for Fibrinolysis.
Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.
Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors.
Enhanced spontaneous thrombolysis: a new therapeutic challenge.
Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Enolase, a plasminogen receptor isolated from salivary gland transcriptome of the ixodid tick Haemaphysalis flava.
Epsilon amino caproic acid inhibits streptokinase-plasminogen activator complex formation and substrate binding through kringle-dependent mechanisms.
Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model.
Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke.
Evaluation of intravenous human fibrinolysin as a treatment for recent intravascular thrombosis.
Experimental study of biosoluble drugs. Thrombus lysis with biosoluble immobilized fibrinolysin in experiment.
Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation.
Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila.
Factors Affecting Clot Lysis Rates in Patients With Spontaneous Intraventricular Hemorrhage.
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Familial dysplasminogenemia with central retinal vein and cilioretinal artery occlusion.
Feedback regulation of endothelial cell surface plasmin generation by PKC dependent phosphorylation of annexin A2.
Fibrin formation and dissolution in women receiving oral contraceptive drugs.
Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis.
Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease.
Fibrinogen anomalies and disease. A clinical update.
Fibrinogen counteracts the antiadhesive effect of fibrin-bound plasminogen by preventing its activation by adherent U937 monocytic cells.
Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA.
Fibrinolysin for thrombosis.
FIBRINOLYSIN THERAPY FOR THROMBOSIS OF PRIAPISM.
Fibrinolysis and the risk of venous and arterial thrombosis.
Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate.
Fibrinolysis: from blood to the brain.
Fibrinolytic treatment of retinal vein thrombosis. The use of Fibrinolysin Human Lyovac (Merck).
From Cerius(2) based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors.
Functionalized carriers for the improved delivery of plasminogen activators.
Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom.
Further studies on an inhibitor of plasminogen activation in human serum. Release of the inhibitor during coagulation and thrombus formation.
Gender affects skin wound healing in plasminogen deficient mice.
Generation and role of angiostatin in human platelets.
Generation of fibrinolytic activity by infusion of activated protein C into dogs.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Glucose Concentration Affects Fibrin Clot Structure and Morphology as Evidenced by Fluorescence Imaging and Molecular Simulations.
Haemostasis.
Haemostatic changes in patients with deep vein thrombosis.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds.
High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris.
Homocysteine-Enhanced Proteolytic and Fibrinolytic Processes in Thin Intraluminal Thrombus and Adjacent Wall of Abdominal Aortic Aneurysm: Study In Vitro.
Human fibrinogen.
Human plasminogen catalytic domain undergoes an unusual conformational change upon activation.
Hypercoagulability and thrombosis.
Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin.
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis.
Immobilization of bioactive plasmin reduces the thrombogenicity of metal surfaces.
Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model.
Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke.
In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography.
In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay.
In Vivo Anticoagulant and Thrombolytic Activities of a Fibrinolytic Serine Protease (Brevithrombolase) With the k-Carrageenan-Induced Rat Tail Thrombosis Model.
In vivo behaviour of vesicular urokinase.
Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.
Increased production of thromboxane A2 by coronary arteries after thrombolysis.
Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study).
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.
Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes.
Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro.
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Inhibition of vascular endothelial cell prostacyclin synthesis by plasmin.
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Insertion of fibrin peptides into urokinase enhances fibrin affinity.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis.
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
International collaborative study for the establishment of the second International Reference Preparation of plasmin.
Intracoronary thrombolysis in acute myocardial infarction: experimental background and clinical experience.
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Intravascular fibrinolysis of small-vessel thrombosis.
Intravenous Fibrinolysin in the Treatment of Intravascular Thrombosis.
Intravenous Human Fibrinolysin in the Treatment of Intravascular Thrombosis.
Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis.
Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms.
Isolated familial plasminogen deficiency may not be a risk factor for thrombosis.
Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis.
Kallikrein inhibition and C1-esterase inhibitor levels in patients with the lupus inhibitor.
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.
Lipoprotein (a): an emerging risk factor for atherosclerosis.
Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.
Lipoprotein(a) and ischemic heart disease-A causal association? A review.
Lipoprotein(a) as a risk factor for coronary artery disease.
Lipoprotein(a), atherosclerosis and thrombosis.
Lipoprotein(a): an emerging cardiovascular risk factor.
Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis.
Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Lonomia genus caterpillar envenomation: clinical and biological aspects.
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis?
Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs.
LYS-plasminogen shortens the duration of local thrombolytic treatment of peripheral arterial occlusions--a randomized controlled trial.
Lysis of intravascular blood clots. Fibrinolysin therapy. Indications, contraindications, and results.
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Management of hydrocephalus in children with plasminogen deficiency.
Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Mechanism of formation of vascular thrombosis and its treatment with fibrinolysin.
Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
Microfluidic Modeling of Thrombolysis.
Modelling fibrinolysis: a 3D stochastic multiscale model.
Modification of fibrin structure as a possible cause of thrombolytic resistance.
Molecular analysis of blood vessel formation and disease.
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues.
Monolithic peptidyl sorbents for comparison of affinity properties of plasminogen activators.
Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis.
Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates.
Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
New developments in thrombolytic therapy.
New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.
Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis.
NMR secondary structure of the plasminogen activator protein staphylokinase.
Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin.
Nonfibrinolytic functions of plasminogen.
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Novel and emerging therapies: thrombus-targeted fibrinolysis.
Novel Pheretima guillelmi-derived antithrombotic protein DPf3: Identification, characterization, in vitro evaluation and antithrombotic mechanisms investigation.
One year in review 2017: Behçet's syndrome.
Our fibrinolytic potential.
Outcome of Acute Deep Venous Thrombosis Using Standard Treatment versus Thrombolytics: A Literature Review.
PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.
Pathophysiology of thrombophilic states.
Penetration of macromolecules into contracted blood clot.
Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans.
PGE1 accelerates thrombolysis by tissue plasminogen activator.
Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME.
Pharmacology of cyclooxygenase-2 inhibitors and preemptive analgesia in acute pain management.
Pharmacology of fibrinolysis.
Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion.
Photonic activation of plasminogen induced by low dose UVB.
Physical determinants of fibrinolysis in single fibrin fibers.
Physiologic regulation and pathologic disorders of fibrinolysis.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
Physiological role of alpha 2-plasmin inhibitor in rats.
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
Plasma D-dimer for the diagnosis of thromboembolic disorders in dogs.
Plasma Lipoprotein(a) and its relationship with disease activity in patients with Behçet's disease.
Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice.
Plasmin inactivation in plasma.
Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner.
Plasminflammation-An Emerging Pathway to Bradykinin Production.
Plasminogen acceleration of urokinase thrombolysis.
Plasminogen activation and lysis of blood clots induced by cells in vitro.
Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches.
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients.
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Plasminogen activator inhibitor-1 in vascular thrombosis.
Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis.
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
Plasminogen deficiency.
Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation?
Plasminogen in cerebrospinal fluid originates from circulating blood.
Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.
Plasminogen Paris I: congenital abnormal plasminogen and its incidence in thrombosis.
Plasminogen San Antonio: an abnormal plasminogen with a more cathodic migration, decreased activation and associated thrombosis.
Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.
Platelets: connecting clotting and lysis.
Pneumococcal phosphoglycerate kinase interacts with plasminogen and its tissue activator.
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state.
Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile.
Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
Prediction of the three-dimensional structure of the enzymatic domain of t-PA.
Prevention of arterial thrombosis following experimental endarterectomy with plasmin (fibrinolysin).
Prevention of femoral vein occlusion by local injection of Thrombolysin in the rat.
Prevention of microvascular thrombosis with short-term infusion of human tissue-type plasminogen activator.
Prevention of thromboplastininduced thrombosis in rabbits by means of plasmin.
Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli.
Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.
Properties of molecular variants of tissue-type plasminogen activator.
Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.
Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.
Radioiodinated plasminogen: an imaging agent for pre-existing thrombi.
Radiological stenting provides effective palliation in malignant central venous obstruction.
Recanalization and flow regulate venous thrombus resolution and matrix metalloproteinase expression in vivo.
Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy.
Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates.
Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.
Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis.
Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin.
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Remaining perspectives of mutant and chimeric plasminogen activators.
Reminiscences of my contributions to Thrombosis and Haemostasis: urine tissue factor and plasma plasmin inhibitor.
Renal vein thrombosis in a newborn with prothrombotic genetic risk factors.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.
Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
Risk factors for chronic thromboembolic pulmonary hypertension.
Risk factors for thrombosis in lupus patients.
Role of neutrophil membrane proteases in fibrin degradation.
SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
Schistosoma mansoni glyceraldehyde-3-phosphate dehydrogenase enhances formation of the blood-clot lysis protein plasmin.
Schistosomes Enhance Plasminogen Activation: The Role of Tegumental Enolase.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Selective binding of plasmin in the presence of excess plasminogen by certain anionic polystyrene resins.
Seminars in thrombosis, thrombolysis and vascular biology. 4. Fibrinolysis.
Sequential treatment of arterial occlusions with porcine plasmin and low dose streptokinase.
Sequential treatment of deep leg vein thrombosis with porcine plasmin and low dose streptokinase.
Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy.
Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.
SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats.
Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli.
Soluble fibrin species in arterial thrombi.
Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures.
Spontaneous thrombolysis: a forgotten determinant of life or death.
Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases.
Spontaneous versus secondary thrombosis in congenital heterozygous plasminogen deficiency.
Statistical optimization of fibrinolytic enzyme production using agroresidues by Bacillus cereus IND1 and its thrombolytic activity in vitro.
Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms.
Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries.
Streptokinase@alumina nanoparticles as a promising thrombolytic colloid with prolonged action.
Structure and activity of plasmin and other direct thrombolytic agents.
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Studies on the synthesis and Antithrombosis Activity of the Analogue of Fibrin Decomposed Product-Related Peptide.
Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
Successful endovascular therapy for acute basilar thrombosis in an adolescent.
Successful treatment of central venous catheter induced superior vena cava syndrome with ultrasound accelerated catheter-directed thrombolysis.
Sulfenamide and Sulfonamide Derivatives of Metformin - A New Option to Improve Endothelial Function and Plasma Haemostasis.
Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain.
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
Symptomatic versus asymptomatic patients in congenital hypoplasminogenemia: a statistical analysis.
Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Textilinin-1, an alternative anti-bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss.
Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model.
The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility.
The annexin A2/S100A10 system in health and disease: emerging paradigms.
The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
The effect of fibrinolysin on the incidence of thrombosis in small-artery suturing.
The effect of fibrinolytic enzyme FII(a) from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits.
THE EXPERIMENTAL USE OF THROMBOLYSIN TO DISSOLVE A BLOOD CLOT PLACED WITHIN THE PLEURAL SPACE OF DOGS.
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015.
The fibrinolytic system in man.
The fibrinolytic system of the vascular wall.
The Fibrinolytic System-More Than Fibrinolysis?
The hemostatic system in children undergoing intensive plasma exchange.
The human plasma fibrinolytic system: regulation and control.
The inactivation of hemostatic factors by hematin.
The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
The Internal Dynamics of Fibrinogen and Its Implications for Coagulation and Adsorption.
The lipoprotein(a). Significance and relation to atherosclerosis.
The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
The physiopathology of lipoprotein (a).
The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.
The release of B beta 1-42 from fibrinogen and fibrin by plasmin.
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen.
The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen.
The role of lipoproteins and apolipoproteins in prediction of coronary heart disease risk.
The role of the annexin A2 heterotetramer in vascular fibrinolysis.
The role of the monocyte in the generation and dissolution of arterial and venous thrombi.
The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis.
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site.
The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1.
The successful treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin.
The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action.
The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus.
The tissue-type plasminogen activator story.
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease.
The use of fibrinolysin in the prevention of thrombus formation in small artery anastomoses.
The use of plasmin in the treatment of intravascular thromboses.
Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thromboembolic diseases in neonates and children.
Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
Thrombolysis for intravascular thrombosis in neonates and children.
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.
Thrombolysis of palmar and digital arterial thrombosis by intra-arterial Thrombolysin.
Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
Thrombolytic agents--an overview.
Thrombolytic Agents.
Thrombolytic Agents: Nanocarriers in Controlled Release.
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.
Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells.
Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Thrombolytic therapy in acute myocardial infarction: Part II--rt-PA.
Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available.
Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma.
Thrombolytic therapy.
Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Thrombomodulin is associated with increased mortality and organ failure in mechanically ventilated children with acute respiratory failure: biomarker analysis from a multicenter randomized controlled trial.
Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds.
Thromboxane antagonism in experimental canine carotid artery thrombosis.
Tissue plasminogen activator is a potent activator of PDGF-CC.
Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
Tissue-type plasminogen activator gene is on chromosome 8.
Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.
Tissue-type plasminogen activator: a historical perspective and personal account.
Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms.
Towards safer thrombolytic therapy.
tPA in the injured central nervous system: different scenarios starring the same actor?
Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro.
Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report.
Treatment of cerebrovascular thrombosis with plasmin and plasminogen activators.
Treatment of Recurrent Prosthetic Mitral Valve Thrombosis with Reteplase: A Report of Four Cases.
Treatment of thrombosis with fibrinolysin (plasmin).
Trends and future developments in the pharmacological treatment of acute ischaemic stroke.
Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis.
Type I congenital plasminogen deficiency is not a risk factor for thrombosis.
Ultrasound affects distribution of plasminogen and tissue-type plasminogen activator in whole blood clots in vitro.
Ultrasound-Enhanced Thrombolytic Effect of Tissue Plasminogen Activator-Loaded Echogenic Liposomes in an In Vivo Rabbit Aorta Thrombus Model.
Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type I.
Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis.
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Urokinase-immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles.
Use of fibrinolysin in experimental thrombosis.
Use of newly developed assays for protein C and plasminogen in horses with signs of colic.
Use of noninvasive laboratory testing in the prediction of thrombosis in the nephrotic syndrome.
Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.
Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Vascular functions of the plasminogen activation system.
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin.
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.
[A Japanese family with congenital abnormal plasminogen]
[A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement]
[Abnormal plasminogen and thrombosis]
[Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients]
[Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina]
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
[COMBINED FIBRINOLYSIN AND HEPARIN THERAPY OF VASCULAR THROMBOSIS.]
[Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis]
[Diagnosis and treatment of coagulation disorders]
[Diagnosis of thrombosis resulting from tension (Paget-Schroetter syndrome) and its treatment with fibrinolysin and heparin]
[Enzymatic debridement of wounds. Comparison of 2 commercial preparations]
[Etiological analysis of thrombophilia]
[EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.]
[Experimental substantiation of diagnosis of thrombosis by means of I-131-labeled fibrinolysin]
[Features of thrombophilia in nephrotic syndrome in children]
[Fibrinolysin (Merck) treatment of retinal vein thrombosis.]
[Fibrinolytic system and a central retinal vein thrombosis]
[Fibrinolytic treatment of thrombus of the right atrium causing severe pulmonary embolism]
[Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis].
[Formation of left ventricular thrombus in acute myocardial infarction: significance of the determination of fibrinogen, of products of fibrinogen degradation, and of plasminogen]
[Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events]
[Hemostasis system and inflammation acute-phase proteins in thrombogenic pathologies]
[Hemostatic changes in idiopathic venous thrombosis in childhood and adolescence]
[Hereditary deficiency of antithrombin III, protein C, protein S and factor XII in 121 patients with venous or arterial thrombosis]
[Hypercoagulable state in Duchenne muscular dystrophy]
[Increasing the local concentration of fibrinolysin and thrombolysis rate using magnetic fluid in a model of occlusive thrombosis]
[Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age].
[Inferior vena cava thrombosis after laparoscopy].
[Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method]
[Lipoprotein (a)--a further risk factor in arteriosclerosis?]
[Lipoprotein (a). An additional marker of atherosclerosis]
[Lipoprotein Lp(a) and CETP (cholesterol ester transfer protein): contribution of transgenic mice]
[Lipoprotein(a). Its importance as an additional atherosclerosis marker]
[Liver cirrhosis--procoagulant stasis].
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
[MEASURE OF PLASMA RESISTANCE TO LYSIS BY STREPTOKINASE. APPLICATION TO PATHOLOGIC THROMBOSIS. NEW TECHNIQUE FOR THE MEASUREMENT OF ACTIVATION OF PLASMINOGEN INHIBITORS.]
[Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA]
[Molecular defects of coagulation factors and of the fibrinolytic system associated with thromboembolism]
[New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?]
[Pathogenesis and laboratory diagnosis of venous thrombosis]
[Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs]
[Plasmin & therapy of thrombosis.]
[Plasminogen activation and regulation of fibrinolysis].
[Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value]
[Plasminogen depletion and incorporation in experimental venous thrombosis]
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
[Preliminary results of the treatment of thrombosis with domestic fibrinolysin.]
[PREVENTION OF EXPERIMENTAL THROMBOSIS IN SPLENECTOMIZED ANIMALS BY INTRAVENOUS ADMINISTRATION OF FIBRINOLYSIN WITH HEPARIN.]
[RESULTS OBTAINED BY FIBRINOLYSIN IN RECENT VENOUS AND ARTERIAL THROMBOSIS.]
[Staphylokinase--a specific plasminogen activator]
[Structure and functions of plasminogen/plasmin system].
[Studies on fibrinolysin activities in thrombosis.]
[Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis]
[Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.]
[t-PA in thrombolytic therapy of acute myocardial infarct]
[The application of fibrinolysin in thromboses and its effect on some indices of the blood coagulation system (preliminary report)]
[The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]
[The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis]
[The resolution of a mitral valve prosthesis thrombosis with low-dose plasminogen tissue activator and the role of Doppler echocardiographic monitoring]
[The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension].
[The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism]
[The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis]
[Thrombolytic properties of the heparin-tissue plasminogen activator complex and its effect on the fibrinolytic and coagulating systems of the blood in animals]
[Thrombosis and ischemia: experimental data]
[Thrombosis of ovarian veins in puerperium associated with heparin-induced thrombocytopenia type II]
[Thrombosis prophylaxis using plasmin and its combination with alpha-adrenoreceptor antagonists]
[Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)]
[Treatment of thrombosis and embolisms with human fibrinolysin.]
[Treatment of thrombosis as a result of stress (the Paget-Schroetter syndrome) in diabetes with fibrinolysin and anticoagulants]
[Use of fibrinolysin in experimental thrombosis.]
Thrombotic Microangiopathies
Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy.
Thrombotic Stroke
Activation of coagulation and fibrinolytic systems following stroke.
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Interventional use of plasminogen activators in central nervous system diseases.
Investigational use of tPA in acute stroke.
Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.
Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.
Thyroid Cancer, Papillary
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Thyroid Diseases
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Thyroid Neoplasms
Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Molecular regulation of thyroid gland function.
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions.
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Tonsillitis
Arthus tonsillitis in the rabbit. Histological findings and fibrinolytic activity in the blood.
Control of Arthus tonsillitis by the administration of an antiplasminic agent.
Fibrinolytic activity in patients with acute tonsillitis.
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
[Activity of fibrinase in patients with chronic tonsillitis]
Tooth Mobility
Periodontitis associated with plasminogen deficiency: a case report.
Toxemia
Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy.
Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy.
Studies on the purification and characterization of human urinary plasminogen and plasmin.
Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin.
Urinary fibrinolysis in toxemia of pregnancy.
[Blood coagulation and fibrinolytic studies in patients with toxemia of pregnancy]
Toxoplasmosis
Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection.
Tuberculosis
Binding and activation of human plasminogen by Mycobacterium tuberculosis.
Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes.
Enolase of Mycobacterium tuberculosis is a surface exposed plasminogen binding protein.
Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Interaction of mycobacteria with Plasmin(ogen) affects phagocytosis and granuloma development.
Tuberculosis, Meningeal
Bacterial Fibrinolysin, its Possible Therapeutic Application in Tuberculous Meningitis.
Bacterial fibrinolysin, its possible therapeutic application in tuberculous meningitis.
Tularemia
[Adjuvant immunotherapy for patients with cancer of corpus uteri]
Tympanic Membrane Perforation
A reply to the commentary on "Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice" by Wang AY, Shen Y, Wang JT, Eikelboom RH and Dilley RJ; Clin Translat Med, 2014; 3:5.
Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice.
Lack of plasminogen does not alter the early inflammatory response following a tympanic membrane perforation: a study in plasminogen-deficient mice.
u-plasminogen activator deficiency
Plasmin and matrix metalloproteinases in vascular remodeling.
Ureteral Obstruction
Serine proteases, inhibitors and receptors in renal fibrosis.
Urinary Bladder Neoplasms
Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Is interferon gamma one key of metastatic potential increase in human bladder carcinoma?
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
[The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)]
Urogenital Neoplasms
Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors.
Urologic Neoplasms
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Uterine Cervical Neoplasms
ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells.
[Studies on serum protein fractions of patients with uterine cervical cancer undergoing radiotherapy: relationship between changes in serum protein fractions and prognosis]
Uterine Cervicitis
Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency.
Ligneous Cervicitis in a Woman With Plasminogen Deficiency Associated With an Atypical Form of Microglandular Hyperplasia: A Case Report and Review of Literature.
Uterine Hemorrhage
[Changes in the hemostatic system in anomalous uterine hemorrhages and uterine myoma at perimenopause]
[The relation of fibrinolysin in uterine bleeding.]
Uveitis
Don't Forget What You Can't See: A Case of Ocular Syphilis.
Regulation of anterior chamber fibrinolysis.
Vaccinia
The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge region.
Vaginitis
Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature.
Varicose Ulcer
Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study.
Varicose Veins
Causes of venous thrombosis in fifty Chinese patients.
Fibrinolytic parameters during acute haematemesis in endemic hepatosplenomegaly.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins.
Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia.
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Superficial thrombophlebitis of the lower limbs in patients with varicose veins.
Vascular Diseases
Arterial expression of the plasminogen activator system early after cardiac transplantation.
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation.
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease.
Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5.
PARD: platelet aggregation as a risk factor in diabetics: results of a prospective study.
Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins.
Young women with advanced aortoiliac occlusive disease: new insights.
[Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina]
[Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease]
Vascular System Injuries
Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury.
Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen.
Lack of alpha 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice.
Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment.
Plasmin and matrix metalloproteinases in vascular remodeling.
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.
Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury.
Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process.
Thrombin-induced lung vascular injury. Roles of fibrinogen and fibrinolysis.
Vasculitis
Anti-Plasminogen Antibodies Compromise Fibrinolysis and Associate with Renal Histology in ANCA-Associated Vasculitis.
Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.
Coagulation abnormalities in rheumatoid disease.
Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis.
The role of inflammatory cells and their proteases in extravascular fibrinolysis.
Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
[A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy]
Vasculitis, Leukocytoclastic, Cutaneous
[Hypersensitivity vasculitis after thrombolytic therapy with APSAC (anisoylated plasminogen streptokinase activator complex). Presentation of a clinical case and review of the literature]
Vasospasm, Intracranial
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
The evidence for a role of vasospasm in the pathogenesis of cerebral malaria.
Venous Insufficiency
Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration.
Venous Thromboembolism
Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol.
High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma.
Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation.
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?
Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members.
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Massive acute pulmonary embolism in protein S deficiency--a case report.
Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under experimental thrombotic conditions.
Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
[Hemostatic changes in idiopathic venous thrombosis in childhood and adolescence]
Venous Thrombosis
99mTc plasmin in 394 consecutive patients with suspected deep venous thrombosis.
99mTc-plasmin test in deep vein thrombosis of the leg.
A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia.
A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis.
Acute deep vein thrombosis treated with porcine plasmin. A double blind trial.
Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.
Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Blood tests for the diagnosis of venous and arterial thrombosis.
Cerebral venous thrombosis with plasminogen deficiency.
Cervical Cancer Associated Biomarkers of Identify High Risk of Venous Thrombosis.
Clinical observations in the treatment of phlebothrombosis with fibrinolysin.
Coagulopathies and arterial stroke.
COMBINED FIBRINOLYSIN AND ANTICOAGULANT THERAPY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM.
Comparison between 99Tcm-porcine plasmin and 99Tcm-labelled erythrocytes in diagnosis of deep vein thrombosis.
COMPARISON OF A FIBRINOLYSIN AND HEPARIN ON INDUCED VENOUS THROMBOSIS AND THROMBOLYSIS.
Comparison of immunological and functional assays for measurement of soluble fibrin.
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.
Congenital deficiency of plasminogen and its relationship to venous thrombosis.
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.
Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis.
Diagnosis of deep venous thrombosis with 99mTc plasmin using the gamma camera.
Dimerized plasmin fragment D as a potential biomarker to predict successful catheter-directed thrombolysis therapy in acute deep vein thrombosis.
Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery.
Effect of exceptional valine replacement for highly conserved alanine-55 on the catalytic site structure of chymotrypsin-like serine protease.
Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Effects of porcine plasmin on the coagulation and fibrinolytic systems in humans.
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Fibrinolysin treatment of induced venous thrombosis in the dog.
Fibrinolysis. II. Evaluation of enzymatic thrombolysis: Experiments with plasmin preparations in arterial, venous thrombosis.
Haemostatic changes in patients with deep vein thrombosis.
Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male.
Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?
Inflammatory bowel disease promotes venous thrombosis earlier in life.
Inherited hypercoagulable states in children.
Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis.
Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia.
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis.
Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME.
Physiological role of alpha 2-plasmin inhibitor in rats.
Plasmin and matrix metalloproteinase system in deep venous thrombosis resolution.
Plasmin generation in dogs with venous thrombosis.
Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.
Plasminogen levels in healthy volunteers--influence of age, sex, smoking and oral contraceptives.
Platelet adhesiveness and fibrinolysis after recent cerebro-vascular accidents and their relationship with subsequent deep venous thrombosis of the legs.
Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study.
Prevention of fibrinolytic shut-down after major surgery by intramuscular stanozolol.
Prothrombotic risk factors in childhood stroke and venous thrombosis.
Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia.
Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality.
Some haemostatic parameters in patients with deep and superficial venous thrombosis.
The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
The molecular genetics of familial venous thrombosis.
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
Thrombin and plasmin activity and platelet activation in the development of venous thrombosis.
Thrombolysis for intravascular thrombosis in neonates and children.
Thrombolytic agents--an overview.
Thrombolytic therapy for deep vein thrombosis: potential application of plasmin.
Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients.
Tissue-type plasminogen activator: a historical perspective and personal account.
Translational initiatives in thrombolytic therapy.
Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion.
Use of plasminogen activators in venous thrombosis.
Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin.
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
[Congenital abnormalities related to coagulation and the fibrinolytic system in patients with vein thrombosis of the lower extremities]
[Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen]
[Etiological analysis of thrombophilia]
[Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution]
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
[Plasminogen depletion and incorporation in experimental venous thrombosis]
[Problems posed by etiologic research on thrombotic conditions]
[Quantitative determination of tissue-type plasminogen activator in varicose soleus veins]
[Results of surgical treatment of acute ileofemoral venous thrombosis with subsequent fibrinolysin and anticoagulant therapy]
[Role of plasminogen activators in the treatment of deep venous thrombosis]
[Scintigraphic studies with J123 miniplasmin in patients with suspected deep venous thrombosis of the leg: comparison of the diagnostic value of J123 miniplasmin scintigraphy and Tc99m plasmin test]
[Studies on thrombolytic therapy for venous thrombosis in the extremities--dynamics of plasmin inhibitor and FDP following administration of urokinase (author's transl)]
[The influence of the intra-tissue electrical phonophoresis on the hemostasis system in the treatment of acute thrombophlebitis and phlebothrombosis]
[Thrombolytic treatment of venous thrombi with combined use of streptokinase and human plasminogen (author's transl)]
[Use of fibrinolysin and anticoagulants in the treatment of venous thrombosis of the extremities]
Ventricular Premature Complexes
Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Vertigo
Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder.
Inhibitors of coagulation-fibrinolysis system and platelet function in patients with vertigo.
Virus Diseases
Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.
Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection.
Elevation of tear fluid plasmin in corneal disease.
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
Vitamin A Deficiency
Neutrophil cathepsin G is specifically decreased under vitamin A deficiency.
Vitreoretinopathy, Proliferative
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Plasmin in subretinal fluid.
Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
uPA, tPA and PAI-1 mRNA expression in periretinal membranes.
Vitreous Detachment
AUTOLOGOUS PLASMIN FOR PHARMACOLOGIC VITREOLYSIS PREPARED 1 HOUR BEFORE SURGERY.
Effect of intravitreal plasmin on vitreous removal through a 25-gauge cutting system in the rabbit in vivo.
Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy.
Efficacy of autologous plasmin for idiopathic macular hole surgery.
Enzymatic Vitrectomy and Pharmacologic Vitreodynamics.
Enzymatic vitreolysis.
In Vivo Retinal Vein Bypass Surgery in a Porcine Model.
Intrasurgical plasmin enzyme in diabetic macular edema.
Intravitreal functional plasminogen is elevated in central retinal vein occlusion.
Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous.
Nonclinical safety and pharmacokinetics of intravitreally administered human-derived plasmin in rabbits and minipigs.
Pharmacologic induction of posterior vitreous detachment in the rabbit.
Pharmacologic vitreodynamics and molecular flux.
Pharmacological Vitreolysis.
Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes.
Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous.
Posterior vitreous detachment with plasmin in the isolated human eye.
Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.
PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy.
Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis.
Successful closure of traumatic macular holes.
The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.
The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment.
Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.
[An experimental study on dissolving and detaching vitreoretinal interface with enzymes]
[Pharmacologic vitieolysis in diabetic rats]
[Preparation of high-purity and safe autologous plasmin and its clinical application]
[Relationship between vitrectomy and the morphology and function of the retina]
[Research update of ocriplasmin for symptomatic vitreomacular adhesion].
von Willebrand Disease, Type 2
Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.
[A case of combined abnormalities with plasminogen abnormality, type IIA von Willebrand disease, hypofibrinogenemia and hemolysis]
von Willebrand Disease, Type 3
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
von Willebrand Diseases
Absence of functional activity of tissue plasminogen activator in patients with severe forms of von Willebrand's disease.
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis.
Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.
Platelets modulate the proteolysis of factor VIII:C protein by plasmin.
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
[A case of combined abnormalities with plasminogen abnormality, type IIA von Willebrand disease, hypofibrinogenemia and hemolysis]
[Combined abnormalities of plasminogen abnormality, von Willebrand disease, hypofibrinogenemia and increased erythrocyte membrane fragility. A new hereditary syndrome?]
Warts
[Immunohistologic alterations of epidermal cytokeratins following cryotherapy]
Wasting Syndrome
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Whooping Cough
Characterization of Phospholipase A(2) Activation by Plasmin in Cultured Bovine Endothelial Cells.
Domain-dependent action of urokinase on smooth muscle cell responses.
Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells.
Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
Plasmin induces smooth muscle cell proliferation.
Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Yaws
Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study.